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Abstract 
Background 
An early objective biomarker to predict the severity of hypoxic ischaemic encephalopathy (HIE) 
and identify infants suitable for intervention remains elusive. Our knowledge of the full 
metabolic response to perinatal asphyxia, and its sequelae, HIE is also incomplete. The ability to 
identify metabolite alterations and perturbed biochemical pathways in HIE may identify early 
biomarkers of injury and suggest new treatment targets. Investigations have begun using 
metabolomics to study the compliment (metabolome) of low molecular weight biochemicals 
(metabolites), with early evidence suggesting extensive metabolic derangement post hypoxic 
ischaemic insult. However, these early studies have varied with regard to analytical method, 
biospecimen, animal model and study cohort. To date no study has reported validated findings. 
To progress a metabolomic biomarker toward clinical utility, discovery work must be followed 
by study and cohort validation in a well phenotyped cohort of infants with consistently 
biobanked samples, and ideally with long-term neurodevelopmental follow up. Furthermore, to 
translate to practical use it is imperative that potential biomarkers are robust to preanalytical 
variables.  
This thesis aims to progress our knowledge of metabolomic markers of HIE through a pipeline 
of biomarker development, completing the discovery and technical study validation phase by 
employing a novel untargeted mass spectrometry metabolomic method. Furthermore the 
potential of proposed metabolomic markers to predict neurodevelopmental outcome will be 
assessed. I have also aimed to improve technical validity by investigating the effect of 
haemolysis on cord blood metabolites.  
Methodology 
The primary study cohort was recruited between September 2009 and June 2011 in a single 
maternity hospital. Term infants with perinatal asphyxia were identified and all had umbilical 
cord blood (UCB) drawn and biobanked within three hours of birth. HIE was defined by a Sarnat 
score at 24hours and confirmed by continuous multichannel-EEG monitoring. Infant 
neurodevelopment was assessed at 36-42 months using the Bayley Scales of Infant and Toddler 
Development Ed. III (BSID-III). Simultaneously a matched control population of healthy term 
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infants, with identically biobanked UCB samples, was recruited over the same period as part of 
an ongoing birth cohort study.  
Untargeted metabolomic analysis of UCB from these infants was performed using direct 
injection FT-ICR mass spectrometry (DI FT-ICR MS). Both polar and non-polar (lipid) features 
were detected in positive and negative ion mode, to achieve global characterisation of the 
metabolome. For each reproducibly detected metabolic feature, mean fold differences were 
calculated between two study arms, HIE vs. matched controls (ΔHIE) and perinatal asphyxia vs. 
matched controls (ΔPA). Putative metabolite annotations and lipid classes were assigned and 
pathway analysis was performed.   
Retrospective metabolomic data from the perinatal asphyxia/HIE cohort was used to evaluate 
the potential ability of two previously proposed metabolite models to predict HIE, by 
correlating with three year neurodevelopmental outcome. The models were assessed for 
clinical utility and compared to standard biochemical and clinical tools currently in use.  
Retrospective data from the healthy control cohort enabled a preliminary investigation into the 
effect of visual haemolysis on metabolite concentrations. This was followed by an untargeted 
DI FT-ICR MS metabolomic analysis into the effect of haemolysis on the UCB metabolome. 
Similarly biobanked, paired infant UCB serum samples from healthy term infants, one 
haemolysed (in vitro) and one non-haemolysed were chosen. The same untargeted workflow to 
that used in the biomarker discovery study was employed, to enable a comparison between 
the studies.   
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Results 
Untargeted metabolomic analysis: Thirty enrolled infants were diagnosed with HIE, including 17 
mild, 8 moderate, and 5 severe cases. Forty enrolled infants were defined as perinatal asphyxia, 
having no neurological signs of HIE. 100 putatively annotated polar metabolic features were 
significantly different between the study groups (p<0.05), 29 remained significantly altered 
post false discovery correction. Pathway analysis revealed that ΔHIE was associated with a 50% 
and 75% perturbation of tryptophan and pyrimidine metabolism respectively, alongside 
alterations in amino acid pathways. Altered metabolites include; melatonin which increased 1.9 
fold (1.4, 2.8 95%CI) in HIE; leucine, kynurenine, urea, and methoxytyrosine which 
differentiated between infant groups (ΔPA vs. ΔHIE); and tryptophan, D-erythrose-phosphate, 
indolelactate and N-acetylneuraminate all significantly different across grades of HIE severity.  
Significant metabolite alterations were detected from six putatively identified lipid classes 
including fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids and prenol 
lipids. Fatty acyl compounds were predominantly altered (>1.5 mean fold change) in the ΔHIE 
comparison including fatty amide, fatty esters and polyunsaturated fatty acids compounds. 
Three metabolic features displayed a significant difference between comparison groups (ΔPA 
vs. ΔHIE), a glycerophospholipid (p=0.02), fatty acyl (p=0.05) and glycerolipid (p=0.05), while 
glycerophospholipids were significantly altered across severity grades of HIE.  
Outcome prediction:Thirty six (model A) and thirty one (model B) infants had both UCB 
metabolomic analysis and neurodevelopmental outcome at 36-42 months available. Both 
metabolite model scores significantly correlated with outcome R=0.429 p=0.009 (model A) and 
R=0.549 p=0.001 (model B) respectively. Model B demonstrates the potential to predict both 
severe outcome (AUROC of 0.915, p=0.004) and intact survival (AUROC of 0.800, p=0.006). 
Neither model score correlated with infant performance in the individual BSID-III subscales 
(cognitive, language or motor).   
The effect of haemolysis:The preliminarily investigation into the effect of visual haemolysis on 
cord metabolite concentrations identified 43 metabolites significantly altered including, lipid 
compounds (acylcarnitines, glycerophospholipids and sphingolipids) carbohydrates, 
tricarboxylic acid cycle intermediates and amino acids. Comprehensive untargeted assessment 
revealed on average 5% of polar and 1.5% of non-polar features were altered between paired 
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haemolysed and clean samples, including putatively annotated carbohydrates, amino acids, 
sterol and prenol lipids. However unsupervised multivariate analysis concluded that the 
preanalytical variability introduced by haemolysis was negligible compared with the inherent 
biological inter-individual variability. 
Conclusion 
This research has employed untargeted metabolomics to identify potential early cord blood 
biomarkers of HIE which may help direct treatment and has performed the technical validation 
of previously proposed metabolite markers. It has also detected early lipid alterations and 
perturbed metabolic pathways specific to HIE which could provide key insights into its 
pathogenesis. Furthermore, I have shown that metabolite models measured at birth can 
outperform other standard biochemical markers for the prediction of neurodevelopmental 
outcome at three years. Finally I report that the use of haemolysed samples in biomarker 
discovery is feasible, however haemolysis must be controlled for in the interpretation of 
results. This research has progressed metabolomic markers of HIE toward clinical utility.  Future 
work will focus on the validation of these findings in a larger independent neonatal cohort 
recruited as part of the overall BIHIVE study.   
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Chapter 1  
1 Introduction 
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1.1 Background to thesis 
Despite remarkable improvements in obstetric and neonatal care, hypoxic ischaemic 
encephalopathy (HIE) remains a persistent worldwide problem occurring in approximately 2 of 
the 20 per 1000 infants born with perinatal asphyxia. Surviving children are at risk of lifelong 
neurological impairment and represent a large global burden of disease (1). The recent 
introduction of therapeutic hypothermia has further improved survival rates and critically, 
reduced neurological disability and improved neurocognitive outcomes (2, 3). However, for 
hypothermia to be effective, clinicians must diagnose HIE and commence treatment within 6 
hours of birth. Yet, the biochemical and neurological assessment tools currently used to select 
infants suitable for therapy are lacking, resulting in some infants being missed. A diagnostic 
biomarker of HIE, which is rapid, robust, non-user dependent and can be measured at birth is 
urgently needed. 
The encephalopathy triggered by a hypoxic ischaemic insult is largely metabolic, though the 
underlying mechanisms are not fully understood. A biochemical cascade led by a switch to 
anaerobic metabolism occurs including mitochondrial impairment, generation of reactive 
oxygen species and the accumulation of Ca2+, glutamate and excitatory amino acids(4). To 
discover novel biomarkers of this early injury we need a greater understanding of the complex 
interactions of individual metabolic pathways. 
Metabolomics, the systematic study of low molecular weight biochemicals (metabolites), can 
provide a snapshot of human metabolism which reflects the body’s health at a point in time. 
Metabolomic studies in perinatal asphyxia and HIE have largely focused on the metabolic 
response to hypoxia in animal models, proposing alterations in tricarboxylic acid (TCA) cycle 
intermediates, branched chain amino acids and cell membrane constituents(5, 6). More 
recently, studies in neonatal cohorts have expanded upon these findings(7, 8), however their 
targeted analytical approach has limited the investigation to well-known metabolites perhaps 
missing subtle pathway differences. To date no study in this field has conducted an untargeted 
and comprehensive mass spectrometry analysis of the biochemical derangements caused by 
HIE and none have assessed the usefulness of proposed early markers to predict long-term 
outcome. Furthermore, to translate a metabolomic biomarker to the clinic, multifaceted 
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validation is required to eliminate false discoveries. Technical validation using alternate 
analytical techniques and validation in independent neonatal cohorts are required and finally, 
the effects of preanalytical variation on metabolomic biomarker alterations cannot be ignored.  
 
1.1.1 Aims and objectives 
Aim 1: Identify novel metabolomic markers of perinatal asphyxia and HIE through untargeted 
metabolomic analysis. 
 Apply an untargeted metabolomic workflow to analyse the cord blood metabolome of a 
human neonatal cohort.  
 Investigate the metabolic response to perinatal asphyxia and HIE through examination 
of metabolic pathways and lipid classes.  
 Identify novel metabolomic markers with the potential to predict HIE. 
Aim 2: Technical validation of previously identified cord blood metabolomic markers and their 
potential to predict long-term outcome. 
 Validate metabolite markers previously proposed in the neonatal cohort under 
investigation, using an alternate analytical method. 
 Correlate previously proposed metabolite models with three year neurodevelopmental 
outcome. 
 Compare the ability of these models to predict neurodevelopmental outcome with 
current standard biochemical and clinical markers. 
Aim 3: Examine the robustness of metabolite markers to haemolysis. 
 Conduct a preliminary study to assess whether haemolysis may interfere with cord 
blood metabolite measurements. 
 Apply an untargeted metabolomic workflow to examine global metabolic alteration to 
determine the feasibility of using haemolysed UCB as a biomarker discovery specimen. 
 Assess individual metabolite alterations caused by haemolysis to ensure biomarker 
validity.  
4 
 
 
1.1.2 Scope 
This focus of this thesis is to investigate the ability of metabolomic biomarkers detected in 
umbilical cord blood to predict HIE. This thesis is composed of eight chapters including an 
introductory chapter, background chapter, five results chapters and a concluding chapter.  
Chapter 1introduces the clinical problem of HIE under investigation and highlights the gap in 
knowledge in the area of metabolomic biomarkers of this injury. It also outlines the aims and 
scope of the thesis, including its contribution to the research field. 
Chapter 2 details all relevant background to the work described in this thesis. It provides an 
overview of HIE both clinically and biochemically outlining the current diagnostic assessment 
tools. It includes an introduction to metabolomics, the experimental strategies and most 
common analytical platforms available to use. A literature review of metabolomic studies in 
perinatal asphyxia and HIE outlines all animal and neonatal research conducted to date, as well 
as, the special considerations for conducting research in this field. Finally, the issue of 
preanalytical variation in metabolomic studies is presented focusing specifically on haemolysis. 
Chapter 3describes polar (hydrophillic) metabolite alterations in the cord blood metabolome of 
infants with perinatal asphyxia and HIE versus their respective matched healthy controls, using 
an untargeted metabolomic method. It illustrates alterations in both novel and previously 
identified compounds and provides a comprehensive analysis of potential metabolic pathway 
perturbations. 
Chapter 4 describes alterations in lipid (hydrophobic) metabolite classes for the same cohort 
using untargeted direct injection mass spectrometry. The extraction, analysis and annotation 
methods vary from chapter 3 due to the complexity of lipid analysis and high variability 
associated with human biological data. I identify potential lipid classes altered as a result of HIE, 
which warrant further investigation. 
Chapter 5 presents two metabolite models proposed previously by our group through targeted 
and semi-targeted metabolomic investigations. These models, composed of individual 
endogenous metabolites measured at birth have the potential to be early biomarkers of HIE. 
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This chapter examines their potential to predict long-term outcome of infants with HIE who 
have undergone neurodevelopmental assessment at three years of age, and compares them to 
current standard clinical measurements. 
Chapter 6is focused on the potential difficulties, which may arise in the metabolomic analysis of 
umbilical cord blood acquired from neonates at delivery, due to the physiologically high 
haematocrit and consequently increased rate of haemolysis. I examined the hypothesis that 
haemolysis will alter metabolite concentration levels measured in umbilical cord blood.  Using 
previous analysis of metabolomics and clinical data, I described those metabolites potentially 
affected by hemolysis. 
Chapter 7 undertakes a comprehensive analysis of how the umbilical cord metabolome is 
affected by haemolysis. I determined whether a haemolysed sample should be used in 
metabolomic biomarker discovery studies. This analysis provides detailed analytical 
information on all metabolic features altered by haemolysis and lists putatively annotated 
metabolites particularly vulnerable to interference, which may need to be excluded from 
practical use as a biomarker of disease.  
Chapter 8 presents a summary of the main finding arising from the thesis. It outlines the 
implications of these findings for the clinical research field, describes the strengths and 
limitations of the work, summarises the contribution this work makes and discusses future 
directions of this research. 
 
1.1.3 Contribution 
This thesis makes a significant contribution the area of metabolomic investigations in perinatal 
asphyxia and neonatal HIE, by progressing metabolomic markers of HIE through the pipeline of 
biomarker discovery and evaluating their longterm and practical utility. 
 
Publications arising from thesis; 
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Denihan NM, Boylan GB, Murray DM. Metabolomic Profiling in Perinatal Asphyxia: A Promising 
New Field.BioMed research international 2015, 9. 
Denihan NM, Walsh BH, Reinke SN, Sykes BD, Mandal R, Wishart DS, Broadhurst DI, Boylan GB, 
Murray DM.The effect of haemolysis on the metabolomic profile of umbilical cord blood. Clinical 
Biochemistry 2015 48: 534-537 
Denihan NM. Who is the cool kid? Biomarkers to help treat newborn brain injury. The Boolean, 
June 2014, 13-17. 
Denihan NM, Looney A, Boylan GB, Walsh BH, Murray DM. Normative levels of Interleukin 16 in 
umbilical cord blood. Clinical Biochemistry 2013 46: 1857-1859. 
 
For further information of the dissemination of this research see‎Appendix D 
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Figure ‎1.1Thesis overview containing the study aims and corresponding chapter..
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Chapter 2  
2 Background 
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2.1 Hypoxic ischaemic encephalopathy 
2.1.1 Overview 
Hypoxic ischaemic encephalopathy (HIE) is the most common cause of brain injury among full 
term neonates, with an incidence of 1.6 per 1000 term live births(1) and estimates as high as 26 
per 1000 in the developing world (9). HIE arises from perinatal asphyxia, a persistent worldwide 
problem occurring in 20 per 1000 deliveries, whereby placental gas exchange to the foetus is 
compromised with failure of the initiation of respiratory gas exchange at delivery(10). A range 
of maternal, obstetric and neonatal conditions predispose the foetus and newborn to asphyxia 
therefore the timing of the insult varies, occurring antenatally, intra-partum or post-partum(11, 
12).  
The diminished oxygen supply associated with perinatal asphyxia causes hypoxemia and 
hypercarbia of the blood which, alongside glucose deprivation results in a derangement of 
aerobic metabolism. Blood flow may also be interrupted causing ischaemia which ultimately 
compromises cardiac and vascular functions, impairing the removal of respiratory and 
metabolic by-products. Depressed myocardial function will further restrict blood flow and 
oxygen, worsening the hypoxic-ischemic effect. It is these two intertwining pathogenic 
mechanisms, hypoxia and ischaemia which deprive the perinatal brain of oxygen, causing 
newborn HIE.   
HIEis a complex dynamic injury and not a static one. Timing and duration of hypoxia-ischaemia 
influences injury severity, causing the injury to either evolve or in less severe cases, resolve. As 
a result neonates who develop HIE present with varying clinical signs. The severity of 
encephalopathy arising from hypoxia-ischaemia is generally classed as mild, moderate or 
severe and most commonly defined using the Sarnat scoring system (13), discussed in 
Section ‎2.3.2.  Clinically, infants with mild HIE typically demonstrate irritability and hypertonia 
after delivery, and the electroencephalogram (EEG) may be normal or show mild 
abnormalities(14), symptoms which resolve over the first days of life. On examination infants 
with moderate HIE are lethargic after delivery, with hypotonia and decreased or absent 
primitive reflexes and may require mechanical ventilator support. The initial EEG may be 
moderately or severely abnormal but has the potential to improve (15). Though symptoms may 
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improve, the neurological exam on discharge may be variable. In severe HIE the infant presents 
as stuporous after delivery, with diminished response to external stimuli, absent primitive 
reflexes and will most likely require mechanical ventilator support. Severe HIE increases the risk 
of multi-organ dysfunction, seizures and the likelihood of death being the outcome.  
Biochemically HIE is an evolving injury and the culmination of three distinct phases, (i) the 
primary hypoxic-ischaemic insult, (ii) a latent recovery phase and (iii) a secondary energy failure 
(see Figure ‎2.1).  A biochemical cascade is initiated by the hypoxic and/or ischemic insult which 
primarily causes a switch to anaerobic metabolism, excitotoxicity and the accumulation of 
reactive metabolites. All of which result in cellular energy depletion and necrosis. Following 
resuscitation of the infant reperfusion ensues and brings with it a transient or ‘latent’ phase 
recovery of oxidative metabolism however inflammation and apoptotic cascades take hold. 
This is followed approximately 6-48 hours later by a secondary deterioration and failure of 
oxidative metabolism. This ‘secondary’ phase is characterised by a depletion in ATP and 
phosphocreatine (16), the formation of free radicals and excitotoxins, and activation of 
proteases and caspases which lead ultimately to permanent neuronal cell death(17, 18). 
The outcome for infants with HIE is highly variable and depends upon the severity of 
encephalopathy. HIE can result in neonatal death while survivors are at risk of significant 
morbidities, discussed in Section ‎2.3.3. Infants with moderate to severe encephalopathy are 
more likely to develop disabling long-term morbidities such as cerebral palsy, visual 
impairment, hearing loss, severe cognitive and motor disabilities, or epilepsy(19).  Traditionally, 
infants who sustained a mild encephalopathy were thought to develop normally(20), however, 
recent studies suggest they are also at risk of mild yet permanent neurological morbidities such 
as memory deficits, or social and behavioural difficulties(21).   
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Figure ‎2.1 Schematic overview of the pathophysiological features of HIE, adapted from 
Douglas-Escobar and Weiss 2015 (22). 
 
2.1.2 Current state of the art 
Therapeutic hypothermia, whereby the infant’s core body temperature is lowered to between 
33-34 °C for up to 72 hours (17) is currently the only widely accepted treatment for neonatal 
HIE. The advent of theraputic hypothermia has for the first time, allowed us to intervene and 
alter the course of this disease with improved rates of mortality and intact survival (2, 23-25). It 
has arisen from the key insight that the primary hypoxic ischaemic insult precipitates a complex 
biochemical cascade, which makes a partial or latent recovery before leading to secondary 
neuronal damage, discussed in more detail in Section ‎2.2.2 and ‎2.2.3. It is during the latent 
phase that therapeutic hypothermia has the potential to intervene and alter the course of the 
biochemical cascade and attenuate the delayed energy failure. To date two methods, total 
body cooling and head cooling, have been trialled in large multicentre randomised controlled 
studies (26-29), and subsequent meta-analysis has deemed both modalities efficacious with 
significant improvement in neurodevelopmental outcome at 18-24 months in those with 
moderate and severe HIE (3, 30).  
Though the exact mechanism of action is poorly understood, hypothermia is thought to 
attenuate the inflammation and cell death cascade associated with secondary energy failure 
and resultant damage to the brain. The latent phase presents the optimal window of 
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opportunity to commence cooling, prior to the irreversible secondary deterioration (31).  
Therefore, to be effective hypothermia must be initiated within the first 6 hours of birth, 
before secondary energy failure has commenced (32). By studying the injury in foetal sheep, 
Gunn et al. have showed the effectiveness of therapeutic hypothermia decreases when 
initiation is delayed. For example, early commencement of head cooling prevented the 
secondary cytotoxic edema and improved electroencephalographic recovery (33). Only partial 
neuroprotection was evident when cooling was delayed to just before secondary injury and no 
protection was evident once secondary injury and seizures were established (34, 35). Inclusion 
criteria in the large randomised control trials stated that hypothermia must be initiated within 
6 hours of birth (23, 25, 26). Early cooling of asphyxiated newborns before 3 hours of age, has 
shown significantly improved motor outcomes(32). The consensus is now that ‘time is brain’, 
and cooling should be initiated as early as possible in eligible infants and maintained until 
resolution of the secondary phase of injury (32, 36). Unfortunately the timing of the primary 
insult is often difficult to estimate in asphyxiated neonates and some may have suffered a 
hypoxic ischaemic injury prior to delivery. This leaves a short window of opportunity available 
for treatment, making our ability to quickly and correctly diagnose HIE of paramount 
importance.  
Currently several assessment tools are used to diagnose HIE in the delivery room including; low 
Apgar scores, high cord blood lactate and low cord blood pH. However, these tools are only 
useful at extremes having a combined positive predictive value of 25% (37). Clinical assessment 
using the Sarnat Score (discussed in Section ‎2.3.2.)is the most accurate however it requires 
repeated assessments and is most accurate at 24 hours, missing the narrow 6 hour treatment 
window. These markers suffer from inherent deficiencies to detect all infants suitable for 
treatment. The degree of EEG abnormality is the most efficient and reliable tool available to 
diagnose HIE and predict its severity. The EEG evolution over the first 24 hours of life can also 
strongly predict long-term outcome (15, 38). However, EEG requires highly specialised and 
skilled interpreters round the clock, which is rarely available in the acute setting, drastically 
limiting its use.  
Over the past decade, the search for useful biomarkers to accurately diagnose perinatal 
asphyxia and HIE has become a growing area of interest. Many attempts have been made to 
identify reliable biochemical and haematological markers for identifying newborn infants at 
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risk. Previous markers such as S100B, IL-6, glial fibillary acidic protein (GFAP), neuron specific 
enolase (NSE), ubiquitin carboxy-terminal hydrolase L1 (UCHL-1), and phosphorylated axonal 
neurofilament subunit H (pNf-H) have shown some promise in small cohorts of infants with HIE 
(39-43). Despite the potential of many promising markers, few studies have been validated and 
none have led to clinical advances, or commercially viable bedside tests (44-46). 
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2.2 Biochemical pathophysiology of HIE 
2.2.1 Normal carbohydrate and energy metabolism 
Metabolism, derived from the word metabolē meaning ‘change’ describes the life-sustaining 
chemical reactions within the cells of a living organism. These enzyme mediated reactions are 
essential for human growth and reproduction, enabling cells to maintain their structure and 
respond to their environment. It also refers to the chemical reactions integral to digestion and 
the transport of substances between cells. At its core, metabolism involves the breakdown of 
organic matter to produce energy (catabolism) and construction of metabolites and other 
biochemicals (anabolism), for example cellular components. 
Oxygen and glucose are the principle driving forces of energy metabolism in the newborn brain. 
It is supported almost exclusively by mitochondrial oxidative metabolism which generates 
adenosine triphosphate (ATP), the cell’s primary energy modulator. ATP is the driving force for 
biochemical reactions and physiological processes in the cell and therefore its homeostasis is 
essential for neuronal viability. Under normal conditions a method of facilitated diffusion 
allows glucose to enter the brain. This diffusion is mediated by three glucose transport 
proteins; GLUT1 (55 kDA) allowing glucose to cross the blood brain barrier, GLUT2 (45k DA) 
allowing it to cross glial membranes and GLUT3 facilitating glucose transport across neuronal 
membranes.  Compared to the adult brain, the immature brain holds relatively low levels of 
these proteins, limiting glucose transport and the subsequent cerebral metabolic rate for 
glucose.  
Upon entering the brain, glucose is phosphorylated to the critical metabolite glucose-6-
phosphate, which will progress down one of three paths (see Figure ‎2.2); (i) glycolysis and 
energy production, (ii) glycogen synthesis which stores the carbohydrate or (iii) the pentose 
monophosphate shunt associated with the synthesis of lipids. Primarily glucose-6-phosphate 
enters the glycolytic pathway and is converted first to fructose-6-phosphate and then to 
fructose-1,6-diphosphate by the rate limiting enzyme phosphofructokinase. This enzyme’s 
activity is constrained by ATP, phosphocreatine (PCr) and low pH.  Pyruvate is the major 
product of glycolysis and under aerobic conditions it enters the mitochondrion and is converted 
to acetyl-CoA via the complex pyruvate dehydrogenase. This vital complex is regulated by the 
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ATP/ADP ratio, in other words an increase in the ratio (energy) inhibits activity of the complex 
and a decrease in the ratio promotes its activity.   
Mitochondrial acetyl-CoA then enters the tricarboxylic acid (TCA) cycle and is ultimately 
oxidised to carbon dioxide. The conversion of isocitrate to alpha-ketoglutarate is the primary 
rate limiting step in this cycle, regulated by the enzyme isocitrate dehydrogenase which is also 
governed by the ATP/ADP ratio and responds to the cells need for energy. The TCA cycle 
functions to produce electrons or reducing equivalents (NADH, FADH2), which are converted to 
energy via oxidative phosphorylation. These electron donors, NADH and FADH2, enter the 
electron transport chain where electron carrier proteins embedded in the inner mitochondrial 
membrane move electrons from a donor (via oxidation) to the terminal electron acceptor 
oxygen (reduced to water) via a series of redox reactions. These reactions release energy, 
creating a proton (H+) gradient in the intermembrane space. Through chemiosmosis protons 
then enter the ATP synthase channel where they are phosphorylated by ADP and Pi, releasing 
ATP into the mitochondrial matrix. 
The ATP generated by the TCA cycle and oxidative phosphorylation is transported from the 
mitochondria, by a specific carrier to be utilised in the developing brain. Here it has two vital 
functions; (i) the transport and regulation of ions and neurotransmitters for impulse 
transmission (e.g. cytosolic calcium and extracellular glutamate) and (ii) the synthetic 
production of structural and functional proteins, neurotransmitters and membrane lipids.   
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Figure ‎2.2 Features of carbohydrate and energy metabolism in the brain. Reproduced from 
Volpe 2001 (47).  
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2.2.2 Hypoxia-ischaemia – The energy deficit 
Hypoxia and ischaemia are the two major mechanisms which deprive the neonatal brain of 
oxygen and glucose, the principle driving forces of carbohydrate and energy metabolism. This 
energy deficit will in turn alter cellular homeostasis, with neuronal and glial cells being 
particularly vulnerable to ischaemia.  Current understanding of the injury indicates that 
hypoxia-ischaemia triggers a dynamic biochemical cascade of deleterious events (48).  
Working in tandem, hypoxia and ischaemia quickly diminish the supply of high energy 
phosphate metabolites such as ATP. Inadequacies in oxygen availability inhibit normal function 
of the TCA cycle and electron transport chain. This causes a shift from aerobic metabolism 
which produces 38 ATP to the less efficient anaerobic metabolism producing only 2 ATP per 
mol of glucose consumed. Cells are forced to rely on glycolysis as the sole source of energy 
production. As an initial adaptive response, cyclic adenosine monophospate (cAMP) levels 
increase, up to 13 fold several minutes after ischaemia, tostimulate glycolysis via the activation 
of phosphofructokinase (49). To meet the demand for glucose, cAMP enhances glycogenolysis 
by activating phosphorylase which converts brain glycogen stores back to glucose. The glucose 
transporters GLUT1 and GLUT3 become upregulated and the net uptake of glucose from the 
blood to the brain increases. Unfortunately the impaired cerebral blood flow limits glucose 
supply and its utilisation becomes greater than its influx.  
Lactate and its associated hydrogen ions (H+) begin to accumulate while stores of high energy 
phosphates in the form of phosphocreatine (PCr) decline in an effort to preserve ATP formation 
(50). Animal models of ischaemia, produced for example by bilateral carotid ligation, have 
depicted declining levels of high energy phosphates and pH after several minutes of 
ischaemia(16). While studies in newborn infants with a hypoxic-ischaemic injury detected 
similar decreases in high energy phosphates and elevations in lactate using proton 
(1H)magnetic resonance (MR) spectroscopy(31, 51). Tissue acidosis caused by the accumulation 
of lactate and H+, is worsened by the impaired cerebral circulation which hampers the 
clearance of metabolic and respiratory by-products, in particular NADH, FADH, lactate and 
pyruvate. It also diminishes the ability of the bicarbonate buffering system to restore pH 
balance. Progressive tissue acidosis leads directly to metabolic acidosis whereby cellular injury 
and necrosis ensues (52). 
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Despite compensatory mechanisms, energy demands cannot be met and ATP levels being to 
fall. Using MR spectroscopy, altered brain energy stores in the form of the PCr/Pi ratio (Pi, free 
inorganic phosphate) were demonstrated in the neonatal dog during severe hypoxemia (53). 
The deficit in ATP production leads to the disruption of closely interrelated mechanisms. A 
decrease of 50% in PCr/Pi occurs at a critical point whereby oxidative phosphorylation is 
inhibited, and relates to brain lipid peroxidation and Na+, K+and ATPase activity (54). The 
sodium/potassium (Na+/K+) ATP dependant ion pumps, which function to maintain cellular 
homeostasis, begin to fail, hampering the export of Na+ from the cell in exchange for K+. In turn, 
intracellular levels of K+begin to deplete while Na+ and chloride (Cl-) accumulate. Water can 
then enter the cell by osmosis causing cytotoxic edema or cell swelling(55), which may trigger 
cell death by necrosis.  
This disturbance of ionic homeostasis leads to membrane depolarisation, whereby the negative 
internal charge of the cell becomes positive. Voltage dependent Ca++ channels begin to open, 
and neurotransmitter activation of specific post-synaptic glutamate receptors(NMDA and 
AMPA), as well as the g-protein linked metabotropic glutamate receptors (mGluR) occurs, 
encouraging excessive Ca++entry(56). Since normal function of the ATP dependant 
sodium/calcium (Na+/Ca+) pump is disrupted there is also an accumulation of intracellular Ca++ 
by its impaired removal.  This increased Ca++ triggers a deluge of events including the formation 
of toxic free radicals and the activation of enzymes involved in cell cycle control (protein kinase, 
MAP kinase, ERK1 and ERK2)(57). Extracellular glutamate concentration begins to increase due 
to the impaired energy dependant reuptake and its exaggerated release caused by 
depolarisation. A cycle of toxic events ensues, hinged upon the overproduction of calcium ions, 
membrane depolarisation and neurotransmitter activation, combined with mitochondrial 
damage propagated by free radicals.  Though many neurons do not die during this primary 
phase of HI injury, a cascade of pathological processes is sparked which leads to further loss of 
neurons hours to days later (48). 
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2.2.3 Injury progression 
This primary insult is followed by restoration of blood flow and oxygen to the ischaemic tissues, 
termed reperfusion (see Figure ‎2.3). During reperfusion pH returns to normal and aerobic 
metabolism should commence re-oxygenating the cells(58). A ‘latent’ or early recovery phase 
ensues, characterised by the transient restoration of cerebral oxidative metabolism and high 
energy phosphate levels return to normal (31, 33). However, alterations that occur to energy 
metabolism in the brain during reperfusion are not clear and it may be responsible for 
additional postasphyxial damage to organs and cells. The cause is multifactorial involving 
inflammatory reactions, an imbalance between excitatory and inhibitory neurotransmitter 
systems and the release of reactive oxygen metabolites.  
 
Figure ‎2.3 Diagram illustrating the relationship between the phases of the hypoxic ischaemic 
injury. 
 
Both neonatal and animal studies have documented a secondary energy failure or neuronal 
damage that occurs several hours after the primary insult (16, 31, 51). Using phosphorous (31P) 
MR spectroscopy to examine the behaviour of oxidative phosphorylation metabolites, Lorek et 
al. demonstrated that between 6 - 48 hours post resuscitation a gradual decline in [PCr]/[Pi] 
and ATP occurred, without intracellular acidosis. Moreover the severity of this secondary 
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energy failure was directly related to that of the primary insult (16). A similar pattern of 
primary insult, latent phase recovery and secondary energy failure was seen post HI which 
closely correlated to the severity of neuronal injury evident in rat and foetal sheep models (59, 
60). The maintenance of systemic pH during the secondary phase, despite cerebral lactate 
increasing again, indicates alternate mitochondrial mechanisms to the primary insult. 
Potentially alternate methods of proton extrusion are at play or there is heterogeneous 
damage of mitochondria which is unable to disrupt pH (58).  
The exact mechanisms underlying the progression to secondary energy failure are unknown 
however it goes beyond glucose and energy metabolism. It is thought mechanisms of 
secondary injury are centred on the vulnerability of mitochondria to damage following the 
primary insult including; oxidative stress and free radical accumulation, inflammatory factors, 
primarily the cytotoxic action of delayed microglial cells; excitotoxicity, the extracellular build-
up of excitatory amino acids and glutamate; and ultimately cell death by apoptosis (61). Some 
of the biochemical effects of hypoxia and ischaemia, for example, ionic pump failure, 
neurotransmitter redistribution and membrane alterations can also predispose the brain to 
seizure activity. Seizures may in turn contribute to delayed neuronal loss (48). The severity of 
secondary energy failure correlates with neurological deficits and injury. Emerging targets for 
early intervention and neuroprotection have been focused on the inhibition of these 
potentially destructive molecular pathways.  
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2.3 Current assessment tools 
Infants who experience asphyxia severe enough to adversely affect brain homeostasis will 
exhibit signs and symptoms of neurological dysfunction in the neonatal period (10). This is the 
clinical entity of Hypoxic-Ischaemic Encephalopathy. We currently use a number of tools, each 
with varying degrees of accuracy and usefulness, to help diagnose or assess the severity of this 
state and to attempt to establish prognosis.  
2.3.1 Clinical and biochemical 
Apgar score 
The Apgar score was first proposed as a method to evaluate the newborn infant in 1953, by Dr 
Virginia Apgar then Professor of Anaesthesiology at Columbia University (62). The purpose of 
the Apgar score was ‘to establish a simple and clear classification of newborn infants which can 
be used to compare the results of obstetric practises, types of maternal pain relief and the 
results of resuscitations’ (63).  Dr Apgar proposed five clinical signs; heart rate, respiratory 
effort, reflex irritability, muscle tone and colour, all of which could be quickly and easily 
evaluated by staff in the delivery room. The score is the sum of the five aspects, whereby each 
is assigned a grading of 0, 1 or 2 depending on absence or presence, one minute after the 
infant’s birth.  
The Apgar score is now almost universally assigned in the delivery room however, more 
recently its use has come under scrutiny for going beyond the scope of its initial remit. Large 
cohort studies have demonstrated a strong correlation between the Apgar score at 5 min of 
age and neonatal mortality, yet its sensitivity and positive predictive value (PPV) for death and 
cerebral palsy in survivors is low (64, 65). Often felt to be useful at extremes, one in five infants 
with an Apgar score of 0 at 10 minutes will survive to school age without a moderate or severe 
disability (66). The Apgar score is also inherently subjective, with the exception of heart rate 
the clinical signs are all assessed by visual inspection of the infant. A study by O’Donnell et a l. 
found large inter-observer variability between scores (67).  
The Apgar score was never intended to be a measure of perinatal asphyxia or outcome, as 
Apgar herself noted, ‘while we believe the score is useful, it has many limitations... nor will it 
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predict neonatal death or survival in individual infants’ (68). A low Apgar score is nonspecific 
and may occur in the absence of global hypoxic-ischaemic brain injury, however a consensus 
statement from the American Congress of Obstetricians and Gynaecologists (ACOG) notes that 
in combination with biochemical, neuroimaging, physiological markers and timing, an Apgar 
score of < 5 at five and ten minutes can be useful in determining the likelihood that an acute 
peripartum or intrapartum event may have contributed to neonatal encephalopathy  (69). More 
recently, efforts have focused on creating an expanded or combined score by combining the 
conventional Apgar score with several resuscitation parameters (70). A low 5 minute combined 
Apgar score could diagnose perinatal asphyxia (sensitivity 97% and specificity 99%), and 
independently predict the occurrence of HIE, however it could not predict the severity of HIE or 
adverse neurological outcome (70).  
Acid-base balance 
Foetal asphyxia has been defined as ‘a condition of impaired blood gas exchange leading to 
progressive hypoxemia and hypercapnia with a significant metabolic acidosis’ (71). Foetal 
acidosis is the accumulation of acid in tissues leading to a low blood pH (acidaemia). It is 
commonly used as a marker of foetal oxygenation and distress. The oxygen deficit in foetal or 
perinatal asphyxia necessitates a switch from the metabolism of carbohydrates to anaerobic 
metabolism which produces lactic acid causing metabolic acidosis. Foetal asphyxia can also 
cause respiratory acidosis characterised by accumulating carbon dioxide, arising from 
compression of the cord, decreased foetal cardiac output or insufficient placental perfusion 
(72). 
After delivery, a segment of the umbilical cord is double clamped and blood from the section of 
the cord between the clamps can be sampled for acidosis, usually measured as pH or base 
deficit.  Mild acidosis occurs in most labours and is directly related to the length of labour (73), 
however,  more severe acidosis is associated with newborn morbidity (71, 74). However infants 
born with perinatal asphyxia may not always demonstrate acidaemia in umbilical artery blood 
at birth, and recent studies have shown that severe acidaemia is not a prerequisite for those 
who suffer a subsequent brain injury. Ruth and Raivio described umbilical artery metabolic 
acidosis as a poor predictor of perinatal brain damage, with a PPV of 8% (75). In a large 
prospective cohort study Dennis et al. did not find any statistically significant associations 
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between acidosis and developmental outcome. In fact, infants who were most severely acidotic 
at birth (pH less ≤ 7.04) were more likely to be disability free as children, and those with low 
Apgarscores but normal pH were found to be most at risk of impairment (76). Several 
retrospective studies have also reported that about half of all infants born asphyxiated with 
resultant encephalopathy were born without severe acidosis (77). More recently Murray et al. 
examined pH in a clearly defined population of infants with HIE and found that pH was unable 
to differentiate between those with mild and moderate 7.05 (6.95- 7.14) or severe 7.01 (6.83-
7.05) HIE (78).  
In response to the evidence that in the absence of metabolic acidosis the infant may be at 
greater risk of encephalopathy or impaired outcome, Hermansen has introduced the concept of 
‘beneficial acidaemia’  whereby the failure of an asphyxiated infant to establish acidaemia may 
place the infant at increased risk for brain injury (77). Both human and animal studies have 
illustrated the newborn infant’s ability to use lactic acid as an alternate fuel source for brain 
metabolism (79). Animal studies have also shown that lactic acidaemia may increase cerebral 
blood flow, potentially reducing the risk of cerebral ischaemia (80). Finally, the Bohr Effect 
promotes the shift of the oxygen dissociation curve in response to a falling pH. This decreases 
oxygen’s affinity for haemoglobin and promotes its beneficial unloading into the surrounding 
tissue.  
Similar to the Apgar score, foetal acidosis should not be used in isolation to diagnose perinatal 
asphyxia or subsequent HIE, but in combination with other clinical markers. A foetal umbilical 
artery pH of < 7.0 or base deficit ≥ 12 mmol/L can alert clinicians to a potentially damaging 
peripartum or intrapartum event (69). A pH or base deficit measurement cannot indicate the 
aetiology of injury by itself, only the degree of acidosis at that specific time point. More 
importantly, the absence of metabolic acidosis does not exclude a diagnosis of perinatal 
asphyxia or HIE. 
Lactate 
Lactic acid is the primary end product produced by the fermentation of pyruvate to yield 2 ATP 
during anaerobic metabolism.  Therefore, it is directly related to tissue hypoxia and the ensuing 
metabolic acidosis, and may be a more precise measurement of foetal acidosis than indirect 
measures like pH or base deficit. Studies have shown strong correlations between lactate and 
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pH/base deficit in UCB samples and postnatal infant samples (81-83). More recently, Bowler 
and Beckmann demonstrated that a foetal scalp lactate measurement has a high sensitivity but 
low specificity in predicting foetal umbilical blood pH (84). 
Much like pH and base deficit, there is varying evidence as to whether lactate can identify 
those with perinatal asphyxia or HIE. A lactate level of 8 mmol/L has been suggested to 
indicated intrapartum asphyxia, based solely on its correlation with a base deficit of 12 mmol/L 
(82). In asphyxiated neonates, da Silva et al. reported an association between plasma lactate 
concentrations of  >9 mmol/l and moderate or severe encephalopathy with a sensitivity of 84 % 
and specificity of 67 % (81). However the authors mention that between their established 
upper (>9 mmol/l) and lower thresholds (<5 mmol/l) ‘neonatal evolution was unpredictable as 
a number of infants tolerated severe asphyxia without central nervous system damage, while 
others developed serious cerebral injury’. A study by Kruger found that foetal scalp blood 
lactate was a superior predictor of moderate to severe HIE compared to pH, and suggested a 
lactate concentration of > 4.8 mmol/L as suitable cut-off limit to indicate foetal asphyxia (85).  
Though Murray et al. described a raised serum lactate in all infants with HIE, the degree of 
lactic acidosis in the first 30 minutes of life did not predict the severity of the ensuing 
encephalopathy. On the other hand, the prolonged time to normalisation of serum lactate was 
related in particular, to the electrographic seizure burden (78). This is in agreement with similar 
serial lactate measurements by Shah et al. (86). Proton magnetic resonance spectroscopy has 
also shown cerebral lactate to be persistently raised, up to one month after birth in infants with 
HIE and an abnormal neurodevelopmental outcome (87). They hypothesised that an 
abnormality in cerebral energy metabolism, perhaps due to by dysfunctional mitochondria, 
brought about the prolonged elevation of lactate. The raised lactate levels may also be 
attributed to delayed lactate clearance, which may indicate hepatic dysfunction, a systemic 
effect of severe HIE.  
The severity of lactacidaemia may reflect the degree of foetal hypoxic-ischaemia, but a single 
lactate measurement gives no definitive information regarding the duration of asphyxia, the 
foetal response to hypoxia, or risk of an ensuing encephalopathy. 
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2.3.2 Early neurological outcome measures 
The Sarnat Score 
The Sarnat score was developed in 1976 by Harvey and Margaret Sarnat, as a method of 
classifying neurological dysfunction in infants. The Sarnat scoring system classifies infants as 
having either mild (Sarnat I), moderate (Sarnat II) or severe (Sarnat III) encephalopathy, and is 
derived from original observations the authors made by recording clinical and EEG data from 21 
infants with HIE (13). The clinical neurological sequelae assessed by the Sarnat score are 
thought to be better predictors of outcome than Apgar scores and blood gases (88).  
Sarnat and Sarnat took account of the fact that HIE is an evolving encephalopathy, and that the 
neurological symptoms may worsen and/or recover over the first days of life. In practise the 
infant may shift from one stage to another illustrating the continuum of the injury. In their 
original investigation all 21 infants received neurological examinations at regular intervals, over 
the first 6 days of life, and subsequently on alternate days until death or discharge.  An EEG 
recording was performed at 24 hours and then every 3-5 days until discharge (13).  
Robertson and Finer suggested the prognostic values of the stage of encephalopathy is greatest 
when evaluated over a seven day period, and Amiel-Tison and Ellison found the evaluation of 
the infant on day 7 to be most useful (89).  This outlines the importance of assessing the infants 
repeatedly over the first few days, to ensure the injury severity is properly categorised.  
One drawback with the Sarnat score is that it requires access to EEG. To this day, in the 
majority of neonatal intensive care units, a neonatologist may not have ready access to multi-
channel EEG in the acute setting. To overcome this issue, the Sarnat score has been modified to 
exclude EEG and in some instances the score’s clinical parameters were also simplified (88, 90). 
Levene’s modified Sarnat score, Table ‎2.1, has been widely adopted by clinicians and 
researchers worldwide, and is now considered a robust tool for the grading of encephalopathy 
and indicating prognosis.  For example, Murray et al examined 51 neonates with HIE and found 
that Levene’s modification of the Sarnat score at 24 hours was strongly correlated to outcome 
(r=0.64, p=0.001) (91). Interestingly, they found of the infants graded moderate HIE, half had a 
normal outcome and half an abnormal outcome at 2 years, highlighting the difficulty in 
predicting outcome or accurately defining moderate encephalopathy.   
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In the absence of EEG, careful neurological assessment remains the best clinical method of 
assigning prognosis in neonatal HIE and is useful for directing clinical care pathways regarding 
long-term follow up. However, an accurate clinical grade of encephalopathy takes over 24 
hours to assign and this may be hampered by the use of sedatives or anti-epileptic medications, 
which make clinical assessment of HIE severity more difficult (14). Therefore the optimum time 
for utilising clinical assessment is beyond the window for the initiation of therapeutic 
hypothermia and may also be too late for alternate neuroprotective therapies. In addition 
therapeutic hypothermia in itself will reduce the reliability of clinical assessment (92). 
  
27 
 
Table ‎2.1 The Modified Levene Classification– distinguishing features of the three clinical 
stages of postanoxic encephalopathy in the full-term newborn infant. 
Grade 1 (mild) Grade 2 (moderate) Grade 3 (severe) 
 Irritable ‘Hyperalert’  Lethargic  Comatose 
 Mild hypotonia  Marked abnormalities of 
tone 
 Severe hypotonia 
 Poor Sucking  Requires tube feeding  Failure to maintain 
spontaneous respiration 
 
 
Electroencephalography (EEG) 
Electroencephalogram (EEG) is a method of physiological monitoring which measures the 
electrical activity in the brain. Brain cells communicate via electrical impulses which can be 
detected using electrodes attached to the scalp and amplified and displayed using an EEG 
machine.  
Continuous multichannel EEG is an important tool for the early assessment of HIE(93)and 
detection of electrical seizures(94). Previous studies have found a strong correlation between 
the grade of HIE as defined by EEG and infant outcome (13, 15, 95).Grading of HIE using 
multichannel EEG is based on visual analysis of the background activity. The background activity 
is usually classified by interpreting features such as amplitude and symmetry, continuity of the 
signal, frequency and seizures, transients and sleep-wake states (96, 97).  
Increasingly one or two channel amplitude integrated EEG (aEEG) is used in the NICU because it 
allows for quicker and easier application (two electrodes) and its perceived ease of 
interpretation. For said reasons, aEEG was used as an inclusion criteria measure for the TOBY 
randomised control trial for therapeutic hypothermia (23). Though very useful in the hands of 
experienced aEEG users(98, 99), an international survey of neonatologists has shown that many 
are not confident in their ability to interpret the aEEG (100).  
Unlike clinical evaluation, continuous EEG allows the user to monitor the early evolution of the 
encephalopathy, not just a specific time point. For example, Murray et al. have found the worst 
EEG grade of HIE to be apparent as early as six hours after birth (15).  This real time 
measurement of cerebral function is relatively easy to implement at the cot-side. Unfortunately 
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neonatal EEG is complex and difficult to interpret. It requires neurophysiologists with the 
required neonatal experience or a clinician with expertise in EEG to be available around the 
clock to interpret the recordings. This resource is scarce, meaning the application of EEG is 
restricted to a minority of neonatal units. Furthermore there is still no single standardised 
classification system available to grade neonatal HIE (97).  
Despite these drawbacks, EEG remains the gold standard for accurately determining HIE grade. 
The EEG background consistently correlates with the clinical grade of HIE and long-term 
outcome (15, 93, 101). A prerequisite being that the EEG must be recorded and analysed at 
multiple time points over the first 48 hours of life, and ideally in a continuous fashion. The 
classification system widely used by this research group is given in Table ‎2.2. It has been 
published and validated in a large cohort of neonatal HIE with long-term follow up, and found 
to be highly accurate (14, 15, 37, 102). 
 
Table ‎2.2 Classification of EEG Background Activity(15). 
Grade Description of features 
Normal Continuous background pattern with normal physiologic 
features such as anterior slow waves 
Normal/mild abnormality Continuous background pattern with slightly abnormal activity 
(e.g., mild asymmetry, mild voltage depression, or poorly 
defined SWC) 
Moderate abnormality Discontinuous activity with IBI of <10 s, no clear SWC, or clear 
asymmetry or asynchrony 
Major abnormality Major abnormalities Discontinuous activity with IBI of 10–60s, 
severe attenuation of background patterns, or no SWC 
Inactive EEG findings Background activity voltage of <10 μV or severe discontinuity 
with IBI of >60 s  
IBI: inter-burst interval; SWC: sleep wake cycle;  
2.3.3 Long-term outcome in HIE 
HIE can lead to significant lifelong morbidity which represents a large global burden of disease. 
An ideal biomarker measured at birth would provide prognostic clinical information not just for 
the immediate neonatal period, in terms of identifying and predicting severity of HIE, but also 
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for the longer term neuropathological and neurodevelopmental outcome of the child. A recent 
systematic review estimated that in 2010, 1.15 million babies suffered from HIE resulting in 
287,000 deaths, 233,000 infants surviving with moderate/severe disability and 181,000 living 
with mild impairment (1). Several long-term neurological morbidities are associated with HIE. 
For example approximately 10-13% of infants with moderate-severe encephalopathy develop 
cerebral palsy, with dyskinetic cerebral palsy and spastic quadriplegia being the most common 
subtypes (103).  HIE may also disrupt sensory functions causing visual impairment (104) or 
hearing loss (105), or result in long-term seizure disorders such as epilepsy (103). Learning 
difficulties may also be present with or without motor or sensory dysfunction. Long-term follow 
up of infants with an encephalopathy has revealed; reduced school readiness including a drop 
in attention scores and increased irritability at five years old (106), memory and executive 
function impairments at 7 years (107) and lower working memory, reading accuracy and 
comprehension scores between 8-11 years (108). Learning impairment, neuropsychological 
deficits and behavioural difficulties are seen in over 40% of surviving children at school age 
(109). 
A metabolic biomarker which could predict long-term outcome for infants post HIE would 
provide powerful clinical utility for guiding clinical management, informing parents and long-
term resource planning. It could determine response to treatment and allow early referral to 
medical, educational or support services to maximise each child’s potential.  For infants with a 
predicted severe neurological outcome such knowledge may guide implementation of 
experimental therapies or redirection of care.  
To accurately assess our ability to predict long-term outcome in infants with HIE standardised 
methods are required. Subtle deficits in learning and memory may not become apparent for 
many years, but provide a significant societal burden following neonatal HIE. Therefore, long 
years of recruitment need to be followed by years of careful follow up to progress this rapidly 
evolving field. Retaining participants for long-term follow up studies can be difficult and 
continued communication with parents is essential (110).  
There are many neurodevelopmental outcome measurement tools (107). One such tool widely 
used to assess cognitive function in high risk infants is The Bayley Scales of Infant and Toddler 
Development Edition III (BSID-III) (111). Composed of a series of administered tasks, it is a 
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standardised developmental test used primarily to assess the motor (fine and gross), language 
(receptive and expressive), and cognitive development of infants and toddlers ages 0-3 years. 
Raw scores of successfully completed tasks are converted to scaled and composite scores, to 
measure child's performance through comparison with normative values for their age. A mean 
(± standard deviation (SD)) score of 100±15 is deemed normal on the Cognitive, Language and 
Motor subscale composite scores, while scores less than 85 (1 SD below the mean) are an 
indicator of neurodevelopmental impairment. Large clinical trials of therapeutic hypothermia 
have used the BSID-III to assess infant outcome at approximately 18 months of age (23, 27). 
However, performance on developmental assessments can be influenced by general motor 
dysfunction. This can be formally evaluated in the toddler period by structured physical 
examination such as the Gross Motor Function Classification Score or Dubowitz score (112, 
113). 
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2.4 Metabolomics 
2.4.1 Metabolites, metabolomes and metabolomics 
Metabolomics can be defined as the comprehensive study of the metabolome, a collection of 
all low molecular weight biochemicals or ‘metabolites’ present in an organism(114). 
Metabolites are a direct signature of biochemical activity, serving as substrates, intermediates 
and products of enzyme mediated cellular metabolism and thus are closely correlated with 
phenotype (115). They represent the final end products of gene expression, yet are also the 
building blocks for all biological structures, for example, proteins (amino acids), genes and 
transcripts (nucleotides) and cell membranes. Metabolites have low molecular weights ranging 
from 1 (proton) to 2000 Da for lipids and though predominantly organic molecules (amino and 
fatty acids, carbohydrates, vitamins, and lipids), inorganic metabolites such as iron have an 
equally important role to play (116). The physiochemical properties including; molecular 
weight, hydrophobicity or hydrophilicity, pH and boiling point can differ between metabolic 
compounds. For example, hydrophilic metabolites are low molecular weight polar compounds 
such as amino acids, while hydrophobic metabolites are higher molecular weight non-polar 
compounds such as lipids. This diversity necessitates the need for several analytical strategies, 
including different analytical platforms, in order to analyse the complete complement of 
metabolites in a biological system. Yet, it also aids the classification of metabolites, which can 
be based upon polarity (polar or non-polar), molecular weight, chemical structure and presence 
in a metabolic pathway (117).  
The metabolome has been described as the quantitative complement of metabolites in a 
biological system(118). The seminal work of both Kacser and Burns, and Heinrich and Rapoport, 
recognised that metabolomes could not be understood in isolation and instead indeed to be 
treated as systems of interacting components (119, 120). The human metabolome consists of a 
network of interacting metabolites, which vary in size and complexity depending on the sample 
type analysed. Metabolomes are also interconnected providing ‘cross talk’, for example that of 
blood and urine. Currently it is estimated that several thousand metabolites comprise the 
human metabolome however this may be an under-estimate as many lipids, drug metabolites 
and pollutants go undefined(117, 121). Metabolites within the human metabolome are derived 
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from enzyme catalysed chemical reactions central to metabolism. These include catabolism, 
the breakdown of products to produce energy, and anabolism; the construction or production 
of chemicals. The metabolome offers the unique potential to examine the mechanistic 
biochemistry which relates to the cellular phenotype (115). 
The aim of metabolomics is to observe and quantify the full complement of metabolites in a 
cell or system, creating a biochemical profile (122). Developments in analytic platforms for 
example, mass spectrometry (MS) allow the rapid and simultaneously measurement of 
thousands of metabolites. Metabolomics is particularly powerful when used in combination 
with theory, bioinformatics and computational statistics, as a systems biology 
approach(123).However, many detected metabolites have yet to be included in metabolite 
databases and repositories, indicating the breath of cellular metabolism still unknown (124). 
The field of metabolomics is expanding rapidly, as too are its applications in for example 
toxicology testing, nutritional analysis, plant and microbial analysis and clinical metabolomics.  
Metabolomics enables the measurement and examination of endogenous compounds and with 
high-throughput capacity increasing the coverage. Regarding clinical utility, one important 
application of this is the identification and determination of ‘biomarkers’ or risk factors that 
change as an indicator of disease or injury. Another is the acquisition of a greater 
understanding into the pathophysiology of disease onset and progression. Metabolomics and 
the measurement of endogenous biochemicals have already been translated successfully to the 
clinical environment particularly in the field of paediatrics. For example, using mass 
spectrometry newborn babies are screened for inborn errors of metabolism related to defects 
in 30 enzymes that catalyse the metabolism of carbohydrates, amino acids, fatty acids, nucleic 
acids and the urea cycle (125-127).  
2.4.2 Experimental strategies 
In the investigation of metabolite markers two metabolomic approaches are usually taken, an 
untargeted hypothesis generating approach or a targeted analysis of a defined set of 
metabolites specific to a disease or mechanism, see Figure ‎2.4(122). Ultimately the 
experimental strategy with respect to sample preparation and analytical instrumentation 
depends upon the number and chemical composition of metabolites to be studied. 
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Untargeted metabolomics or ‘metabolite fingerprinting’ aims to simultaneously detect as many 
metabolites as possible (hundreds or thousands) in a given biological sample(128). This method 
is hypothesis generating and no a priori knowledge of the metabolites of interest is needed. It 
acts as a screening tool to investigate whether metabolite features can discriminate between 
samples of different biological status without bias. Metabolite fingerprinting requires highly 
sensitive analytical platforms capable of rapid and high throughput peak detection from 
biological samples. MS is one such platform, whereby peak can be referred to as either 
metabolite or mass feature and corresponds to a detected ion with a unique mass to charge 
ratio. Generally sample preparation is simple and chromatographic separation is absent to 
ensure the global analysis of metabolites is possible. Quantification and metabolic 
identification are generally not employed. Untargeted metabolomic analysis produces very 
large and complex datasets, it is impossible to inspect these manually therefore researchers 
rely on metabolomic software to refine the data.  Metabolite identification remains a challenge 
though can be achieved to some extent through in silico library and database searches. 
However untargeted metabolomics has wide applicability in answering biological questions, 
given its sensitivity, high throughput and minimal sample requirements, for example it has the 
potential to provide insight into biological mechanisms that change as a function of health and 
disease (124). In particular it has facilitated the characterisation of unknown pathways and 
been instrumental in the identification metabolomic pathways altered by disease that 
represent novel drug targets ‘therapeutic metabolomics’ (129). 
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Figure ‎2.4Summary of the different metabolomics-based strategies, adapted from Dunn and Ellis 2005 (130).
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Targeted metabolomics refers to the measurement of a specified number (usually < 20) of pre-
defined metabolites (131). This approach is hypothesis driven and usually focuses on the 
investigation of particular metabolic pathways. Sample preparation is more extensive and 
chromatographic separation is generally used to isolate the candidate markers prior to 
detection by sensitive tandem MS (MS/MS) or ultra violet (UV). Isotopic internal standards for 
the compounds of interest are needed for their absolute identification and quantification with 
high specificity, precision and accuracy.   
Semi-targeted methods have recently been developed to quantify or semi-quantify the 
concentration of a greater number of metabolites (≤400) with higher specificity, precision and 
accuracy then for untargeted studies(122). One such method is the Biocrates Absolute-IDQ 
targeted metabolomic technology (BIOCRATES, Life Science AG, Innsbruck, Austria)(131, 132). 
This validated assay incorporates metabolite standards to allow for the simultaneous detection 
and quantification of metabolites in a high-throughput manner. Metabolites from varying 
metabolic pathways and chemical classes are included to provide wide coverage of the 
metabolome. This strategy can rapidly apply chemical identities and concentration values 
which facilitates the translation of results to practical applications. 
Both untargeted and targeted metabolomics are useful methods in metabolic biomarker 
investigations which need to progress through a pipeline of (1) biomarker discovery, (2) study 
validation, and (3) cohort validation (122) before they can reach clinical utility (see Figure ‎2.5). 
Typically biomarker discovery might begin with metabolite fingerprinting (untargeted) to define 
unbiased pathway or mechanistic alterations between case-control groups. The large number 
of detected metabolites makes this method susceptible to reduced precision and accuracy, 
increasing the potential of random chance discovery even when statistical corrections are 
applied. Therefore, careful validation is needed to ensure findings are reproducible and the 
candidate markers can progress. Study validation or technical validation can be achieved 
through metabolite profiling (semi-targeted) whereby a select number(<100) of pre-defined 
metabolites are identified (128) or detected using an alternate metabolomics method. Finally, 
cohort validation (targeted), which focuses on a short list of valid and reproducible candidate 
markers is performed using a larger, independent patient cohort. A targeted metabolomic 
approach is employed for the qualitative and quantitative analysis of candidate markers.  
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Figure ‎2.5The journey of a metabolite biomarker discovery study. A pipeline of biomarker 
discovery, study/technical validation and cohort validation, before translation to the clinic. 
 
2.4.3 Analytical platforms 
Mass spectrometry (MS), often coupled to chromatography and Nuclear Magnetic Resonance 
(NMR) spectroscopy are the most widely applied analytical platforms in metabolomics today, 
with their range extending from metabolite profiling and target analysis to metabolic 
fingerprinting, see Figure ‎2.4(130).  Many analytical technologies exist therefore it is important 
to remember that each offers specific advantages depending on the research question. The 
diversity of metabolites in terms of concentration and physiochemical properties means that 
no individual platform is appropriate for all investigations. Furthermore, no single platform can 
offer precise, accurate identification and quantification of all metabolites of interest.  
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Figure ‎2.6 Schematic workflow of a mass spectrometer. 
 
Mass spectrometry 
A mass spectrometer is designed to separate gas phase ions according to their mass to charge 
ratio (m/z) value. Its four main components are the ion source, mass analyser, detector and 
data collection module (computer), see Figure ‎2.6, in addition to a vacuum system, tools to 
introduce the sample and tools to produce the gas phase.MS operates by forming ions (either 
positively or negatively charged) at the ion source from the sample of interest. The mass 
analyser then separates the ions based on their mass to charge state using an electrical or 
magnetic field. This operates under high vacuum, moving the ions along to the detector. 
Importantly, the high vacuum reduces the occurrence of ion-ion or ion-molecule collisions 
which impinge mass resolution, mass accuracy and instrument sensitivity. The data collection,  
module produces a spectrum of mass to charge ratio values and the corresponding intensity of 
the detected ion.  
MS is typically used in the analysis of gaseous or liquid biological samples therefore an 
important requirement is that the ionisation process must not destruct the biomolecules. For 
this purpose the soft ionisation techniques, Matric Assisted Laser Desorption Ionisation 
(MALDI) and Electrospray Ionisation (ESI) were developed, allowing biochemical ionisation at 
either high vacuum (MALDI) or atmospheric (ESI) pressure respectively.  
A mass spectrometer is set to scan mass ranges of 20 to 2000 Da; the typical range of interest 
for metabolomic researchers.  Its main advantage is its high sensitivity providing the ability to 
simultaneously detect hundreds to thousands of metabolites per sample. The resultant mass 
spectrum can be used for sample classification and if the instrument is of high mass accuracy 
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and resolution, chemical identification of metabolites is possible. However, automated 
identification of molecules remains difficult and the identification of all detected features is 
unattainable. 
 
Direct injection - mass spectrometry (DI-MS) 
The high complexity of metabolomes demands for MS techniques to produce high mass 
accuracy to ensure fit for purpose mass separation of the majority of metabolites detected, 
particularly in untargeted metabolite investigations. The sample is directly introduced into the 
mass spectrometer’s ionisation source, negating the need for chromatographic or 
electrophoretic separation prior to detection. DI-MS facilitates the analysis of a large number of 
samples as process times are generally <1 min, increasing inter-sample reproducibility.  
DI-MS generally utilises ESI to allow robust interfacing of the liquid sample and mass 
spectrometer. As an ionisation source, ESI uses electrical energy to create droplets of either 
positively or negatively charged ions which are subsequently evaporated, passed into the MS 
and mass analysed (133).Only compounds that can ionise by the addition (ESI(+)) or removal 
(ESI(-)) of a proton or ionic species can be detected. Wider metabolome coverage can be 
achieved when both polar and non-polar metabolites are ionised in both positive and negative 
mode. ESI will fail in the presence of high salt, acid or base concentrations therefore 
composition of the sample solution is important. Automated nano-ESI systems (Advion 
Biosciences Inc.), a chip containing an array of nano-electrospray nozzles, have been created to 
facilitate high throughput fingerprinting (134, 135).   
As mentioned, untargeted metabolomic investigations require high mass accuracy and 
resolution. Mass resolution defines the ability to distinguish two peaks with similar m/zvalues 
and is calculated by dividing the m/zvalue of the peak by the Full Width Height Maximum 
(FWHM), in other words the full width of the peak at half the maximum peak intensity. Higher 
mass resolutions produce narrower peak widths and hence the ability to separately detect 
metabolites of similar but not identical accurate mass. Mass accuracy defines the error of the 
determined mass of a metabolite compared to the theoretical mass, therefore high mass 
accuracy = low mass error. Mass error is the difference between the theoretical m/z and the 
observed m/zin a spectrum, normalised to the m/z. 
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Achieving high mass accuracy and resolution is challenging, particularly in the absence of prior 
chromatographic separation, as peaks with differences in monoiostopic masses <0.025 Da can 
overlap. To overcome this problem mass analysers such as Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) are used (136). Detector plates record the charge of proximal groups of 
ions as a function of time and Fourier Transform is used to deconvolute signals into frequencies 
which are proportional to the m/zvalue of the ions. Though expensive, FT-ICR offers very high 
mass resolution (>1,000,000) and currently, the highest available mass accuracy (<1ppm 
external calibration, <0.1 internal calibration) and low detection limits in the attomole to 
femtomole range (137). This allows all possible metabolite peaks to be resolved and their 
empirical formula to be accurately calculated, making DIFT-ICRMS a promising tool for 
metabolite fingerprinting investigations(138). 
As with all metabolomic platforms DI-MS has a number of limitations. Definitive metabolite 
identification is limited as chemical isomers, or metabolites with the same exact mass but 
different chemical structure, such as the sterioisomers glucose and fructose, cannot be 
distinguished and will be detected as a single m/z. Ion suppression is a concern when using ESI, 
as all sample components are introduced simultaneously into the ionisation source. Both signal 
suppression and enhancement can occur, affecting the sensitivity (micromolar limits of 
detection) and impeding any meaningful data analysis (128). As well, the sample physically 
interacts with the instrument therefore the response can change over a short to medium 
period of time. To avoid this drift, an identical quality control sample can be injected 
throughout each batch and using correction algorithms the inter- and intra- batch variation can 
be adjusted for (135).  
For the untargeted metabolomic analysis of the umbilical cord blood, it was important to 
choose an analytical platform which could achieve high coverage of the metabolome therefore 
high mass accuracy and high sensitivity was required. Therefore DI nESI FT-ICR MS was the 
instrument chosen to acquire data for this thesis. 
 
Other popular platforms used in metabolomic applications.  
Gas chromatography - mass spectrometry (GC-MS) 
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Gas chromatography (GC)is a mature analytical technique, being applied in combination with 
MS for over 50 years. Its two main advantages are its high sensitivity with typical detection 
limits in the pmol or nmol range, and high resolving power. Its main metabolomic applications 
are in studying plant, clinical and microbial metabolomes. Coverage of the metabolome 
depends on volatility of the sample components, as GC-MS operates by vaporising the sample 
into a gas before injecting it through a capillary column located in an oven (≤ 350°C). Therefore, 
metabolites suitable for GC-MS are volatile, low molecular weight compounds with low boiling 
points, to allow vaporisation. The sample is transported though a column whose inner walls are 
coated with the stationary phase via an inert carrier gas (mobile phase). High chromatographic 
resolution can be achieved by varying the polarity of columns, or increasing column 
temperature.  
Endogenous metabolites generally have low volatility and requires enhancement by chemical 
derivatisation to be detected. The resultant chromatograms are complex, containing peaks 
from hundreds of metabolites and multiple derivatisation products. Quantification is 
performed by either external calibration, which is labour intensive, or by examining the 
response ratio (peak area of metabolite/peak area of standard). Identification of metabolites 
can be achieved manually by inspecting the fragmentation pattern and ions, or by 
computationally matching the retention time and mass spectrum of the sample peak with 
those of a known pure compound. Unfortunately, these are not available for a large number of 
metabolites, even in commercially available repositories though the field is continually building 
its mass spectral libraries.  
 
Liquid chromatography - mass spectrometry (LC-MS) 
The advent of atmospheric pressure ionisation techniques such as ESI,have helped introduce 
liquid chromatography (LC) into routine use in metabolomics. LC separates the metabolites to 
be measured based on differential partitioning between a liquid mobile and solid (or liquid) 
stationary phase. The mobile phase (containing the sample) passes thorough a column packed 
with particles upon which the stationary phase is present. Traditionally LC produced wide peak 
widths and poor chromatographic resolution. It differs from GC-MS by having lower analysis 
temperatures therefore volatile samples are not required and sample preparation is simpler.  
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In 2004, ultra-performance liquid chromatography (UPLC) was introduced whose narrow peak 
widths could rival that of GC. UPLC achieved higher resolution and sensitivity by increasing flow 
rates, pressure and producing smaller diameter column packing, reverse phase C8 and 
C18columns being the most widely used. These columns operate using a solvent system of high 
polarity gradually incorporating an organic solvent, suitable for the separation of non-polar 
(lipids) molecules but biased against polar compounds (amino acids, sugars). To analyse polar 
molecules hydrophilic interaction chromatography (HILIC) has been employed, which uses a 
hydrated silica column and mixed organic/aqueous stationary phase. Whichever strategy used, 
hundreds of features can be detected.  
The metabolites separated by the LC are ionised by atmospheric pressure ionisation which 
allow robust interfacing of the liquid sample and mass spectrometer and  passed into the MS 
and mass analysed (133). Similar to GC-MS, quantification can be achieved by external 
calibration or comparing the response ratio.  The higher throughput the method, the less 
potential there is for quantification. Metabolite identification is difficult and time intensive. 
Unlike EI, ESI does not produce fragmented molecular ions and mass spectral libraries for 
comparison are limited. Generally an accurate mass measurements or tandem MS analysis 
(MS/MS) is needed. Applications of LC-MS currently extend to plant, food and microbial 
metabolomics while clinically it may be used a screening tool or in biomarker discovery. 
 
Nuclear magnetic resonance (NMR) spectroscopy  
For decades NMR spectroscopy has been the analytical tool used mostly by chemists and 
structural biologists. Its use has expanded into clinical based metabolomics coining the term 
metabonomics (139). 1H-NMR is most commonly used in clinical studies as most common 
metabolites contain hydrogen atoms.  NMR functions by applying a strong magnetic field and 
radio frequency pulses, so that nuclei of atoms absorb and re-emit electromagnetic radiation. 
Nuclei with an odd atomic number (1H) or odd mass number (13C) have ‘nuclear spin’ and will 
spin in the presence of a magnetic field.  The alignment of nuclear spins can ‘flip’ from a low 
energy, spin aligned state to a higher energy spin opposed state. The sample is positioned in 
the magnetic field and excited via pulsations of radio frequency. When the pulsation is relaxed 
the excited nuclei will emit its absorbed radiation (energy). This radiation is detected and is 
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used to output an NMR spectrum, which contains peaks at different frequencies or ppm values. 
The spectrum is based on a reference proton from a reference compound solution, for example 
tetramethylsilane (TMS) in solution set at 1ppm. The spectrum is measured in chemical shifts, 
which is the difference in ppm between the resonance frequency of the observed proton and 
the reference proton, and can vary in length, for example 0 – 10 ppm for 1H and 0 – 250 ppm 
for 13C. Each compound will produce a splitting pattern, which arises from spin coupling, and 
the chemical shift will depend on the shielding of other electrons orbiting the nucleus. As well 
as the chemical shift and splitting pattern, each peak will display different intensities, which 
depend on the number of identical nuclei. These intensities allow for compound quantification. 
NMR has several properties which lend it to applications in clinical and pharmaceutical 
metabolomics (139).  
 Non-destructive analysis: A single bio-fluid sample can endure several rounds of 
analysis.  
 Non-selective and non-biased: Metabolite extraction is universal and does not depend 
on the metabolites polarity, volatility or acidity, meaning it will detect any metabolite 
within the detection limit. 
 Rapid and high throughput: The introduction of higher magnetic fields and automated 
injection from 96 well plates has shortened analysis times.  
 Increased sensitivity: Modern cryogenic probes increase sensitivity and allow smaller 
sample volumes (approx. 2 μl) to be analysed (140, 141). This is particularly important 
for paediatric studies where bio-fluid volume is limited.  
The limitations of NMR include its low sensitivity, compared to mass spectrometry techniques 
(130). Furthermore NMR can only quantify high concentration metabolites due to its detection 
limits.   
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2.4.4 Untargeted metabolomic workflow 
Figure ‎2.7shows a typical methodological pipeline of an untargeted metabolomic study, similar 
to that used in this thesis. The workflow starts with generation and processing of spectral data 
to generate sample metabolic information (i.e. metabolic features). These features are 
processed to obtain a final set of robust and reproducible features.  Finally bioinformatics can 
be applied, enabling the statistical and biochemical analysis of the data to ultimately extract 
meaningful biological knowledge from the analytical data. A brief overview of each step in the 
workflow applied in this thesis will be described herein, more detailed information is provided 
in the Methodology sections ‎3.3, ‎4.3 and ‎7.3 and ‎Appendix G. 
 
 
Figure ‎2.7 Analysisworkflow in an untargeted metabolomic study, modified from Dunn 
2011(122). 
Sample preparation and data acquisition 
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Sample preparation is extremely important to ensure metabolic activity remains quenched and 
that the profile measured is representative of the metabolome at the time of sampling. 
Typically metabolites need to be extracted from the sample, a process which separates 
metabolites from matrix species into a solvent suitable for analysis. Extraction methods are 
dependent on sample type, experimental strategy and analytical instrument to be used. 
Biofluids require an initial protein precipitation (removal) step to ensure only small molecules 
are isolated from the sample with maximum recovery. If both polar and non-polar (lipid) 
metabolites are of interest a bi-phasic solvent extraction system (142), which uses organic and 
aqueous solvents to extract hydrophobic and hydrophilic compounds respectively, is the most 
appropriate extraction method. Analysis throughput largely dependent on the analytical 
platform and its automation, DI nESI FT-ICR MS was the instrument chosen to acquire data for 
this thesis, see Appendix ‎G.3. 
Data Processing  
Metabolomic data acquired on analytical instruments or ‘raw data’ is complex, therefore pre-
processing is needed to reduce file size and ensure that individual metabolites or features are 
identified consistently, as the same metabolites or features in all samples analysed.  Pre-
processing aims to accurately identify features from the mass spectrum, until a final set of 
robust and reproducible features is obtained. Spectral processing generally includes baseline 
correction, noise filtering, feature detection, feature alignment, normalisation and 
deconvolution (143), but depends on the analytical instrument used. Pre-processed data is 
considered ‘clean data’ and arranged in a feature intensity matrix (for DI-MS) suitable for 
subsequent analysis.  
Prior to statistical analysis of clean data further data processing is required including; data 
normalisation, scaling or transformation(144), the imputation of missing values (145) and the 
detection and removal of outliers. Signal correction may also be performed to reduce the 
effects of bias in the dataset, for example instrument drift (135).   
Data analysis  
Bioinformatics is a management information system for molecular biology, defined as 
‘conceptualising biology in terms of molecules and applying “informatics techniques", derived 
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from disciplines such as applied maths, computer science and statistics, to understand and 
organise the information associated with these molecules on a large scale’(146). It allows for 
high-throughput analysis and interpretation of metabolomic data, including statistical analysis, 
metabolite identification and pathway visualisation.  
Statistical analysis 
Once robust and reproducible metabolic features are obtained univariate and multivariate 
statistical methods can be applied, to examine the structure of the metabolomic dataset and, 
the relationship between metabolic features and phenotypic data associated with the samples. 
The choice of univariate method will depend on the statistical properties of the feature 
distribution (147). Large datasets, particularly from untargeted mass spectrometry studies, are 
susceptible to a large number of erroneous significantly changing peaks, or high false discovery 
rate. A popular false discovery correction method applied to metabolomic data is the 
Benjamini-Hochberg correction, which creates an adjusted p-value based on the number of 
calculations to minimise the false discovery rate (148).  
To visualise large metabolomic datasets in a comprehensible manner, multivariate analysis 
methods are applied, which take into account all the metabolic features simultaneously. 
Multivariate analysis is either supervised or unsupervised; both are described as pattern 
recognition methods used to detect patterns that correlate with biological variables. 
Unsupervised methods detect patterns within the data without knowledge of sample class or 
phenotype, principal component analysis (PCA) being the most common technique in 
metabolomics (149), and is used throughout this thesis. PCA visualises the variation in a dataset 
by generating an axis of linearly uncorrelated variables (principal component) based on the 
linear transformation of metabolic features (143). The first principal component (PC1) contains 
the maximal variance and each subsequent component contains the maximal variance 
remaining.  
Supervised multivariate methods are used to identify features or metabolic patterns that are 
more associated with the phenotype of interest, while down weighting other sources of 
variance. Supervised methods are the basis for building classifiers or models that attempt to 
describe the observed data based on metabolomic features (144). The partial least squares 
(PLS) method is universally used in metabolomics, as either a regression analysis or a binary 
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classifier (150). The latter, partial least squares discriminate analysis (PLSDA) is used in this 
thesis.  PLS components maximise the covariance between the variable of interest and the 
metabolomic data, producing feature coefficients (loadings) which represent a measure of how 
much a feature contributes to the separation of different sample groups(150, 151).  
Metabolite identification and pathway analysis 
Identification of metabolites from metabolic features is essential in providing biological 
meaning to the data. Furthermore, metabolites interact via networks or ‘pathways’, a series of 
reactions which converts a set of substrates into a set of products (152). Biological databases 
for example the Human Metabolome Database (HMDB), the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database and Lipid Metabolites and Pathway Strategy (LIPID MAPS) database 
(117, 153, 154), contain vast amounts of detailed metabolite and metabolic pathway 
information.   
To determine the identity of an interesting feature and ascertain its biochemical pathway 
involvement, the accurate mass of the compound is searched for in extensive metabolite 
databases.  A database match presents only a putative ‘level 2’ identification as defined by The 
Metabolomics Standards Initiative (155, 156), therefore it must be confirmed by comparing 
retention time (chromatography) and MS/MS data of a pure compound to that from the 
feature of interest. Absolute identification represents a bottleneck in untargeted metabolomic 
studies; it is time consuming, expensive and highly labour intensive, with unknown features 
requiring de novo characterisation.  
2.5 Metabolomics in a neonatal HIE cohort 
2.5.1 Study population 
A major limitation in neonatal biomarker studies is the difficulty of recruiting a sufficient and 
appropriate study population.  Disease prevalence of HIE is low (0.3%) making it difficult to 
collect representative high quality samples in adequate numbers suitable for metabolomic 
biomarker discovery. Therefore, even in large maternity hospitals with 5-10,000 deliveries per 
year and with full recruitment, only 10-20 cases of moderate-severe HIE and 20 cases of mild 
HIE per annum would be expected. In a study that recruited 256 newborns from three separate 
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hospitals, only 11 were cases of severe asphyxia (8 HIE and 3 perinatal death) compared to 216 
healthy controls (16 excluded) (157).  Human neonatal biomarker studies clearly require 
standardised recruitment and clear case definition across multiple centres.  
To ensure a biomarker is in fact detecting hypoxic-ischaemic injury we must rule out the many 
other causes of a neurologically depressed neonate at birth. Infants with metabolic 
encephalopathies, sepsis, genetic abnormalities or neuronal migration disorders can all present 
with low Apgar scores and poor tone in the first days of life (158, 159). To progress biomarker 
research we need to surpass the “default diagnosis” of neonatal encephalopathy (158), and 
carefully define our population using clear recruitment criteria.  
Standardised recruitment poses its own challenges; firstly the clinical grading of HIE can vary 
between centres. To standardise the grade of HIE, EEG and amplitude integrated EEG 
monitoring as early as possible after birth has proved very useful (97, 160). A definitive 
diagnosis of HIE is often not available in the immediate postnatal period, and so the 
opportunity to collect early bio-samples may have passed. One solution is to collect samples 
from all infants “at risk” of HIE, using a study inclusion criteria encompassing broad signs of 
birth asphyxia. For example, ≥ 36 weeks gestational age, Apgar score ≤ 6 at 5 minutes, cord 
blood pH < 7.1 or, requiring intubation or CPR at birth (161). Inevitably infants with perinatal 
asphyxia but without HIE will be recruited, this must be favoured over omitting infants who 
progress to display more severe clinical signs later in the postnatal period.  
 
2.5.2 Sample and data collection 
The highly unpredictable nature of HIE requires a regimented and multidisciplinary approach to 
identify participants and collect samples 24 hours a day, 365 days of the year. The acute clinical 
setting demands the participation of medical, nursing, midwifery and research staff from both 
neonatal and maternity units. A biomarker suitable for early diagnosis of HIE must be 
detectable soon after birth, therefore the specimens used in the discovery phase should be 
collected, processed and biobanked from every ‘at risk’ infant, within 3 hours of birth. This 
short window may mean the reliance on labour ward staff to identify study candidates, draw a 
sample and notify the research team immediately after delivery. Informed parental consent 
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can be sought after delivery when clinically appropriate, due to the inability to identify cases 
prior to birth. Control infants can be simultaneously recruited by consenting antenatally.  
The demographic variability of the HIE population will itself account for metabolomic 
differences, for example, gestational age creates a distinct metabolomic profile (162), as does 
mode of delivery (163) and in utero growth (164). Other possible confounding factors include 
gender, ethnicity, maternal BMI and the length of time the blood sample has spent in the 
freezer. Matching cases 1:1 with controls is vital to achieve adequate power with smaller 
numbers (147), while incorporating demographic, physiological and lifestyle factors into a 
matched cohort will help to eliminate their potential discriminatory bias on the metabolomic 
model (165).  
As discussed, high quality bio-specimens are essential for metabolomic investigations to ensure 
the sample is a representative snapshot of the metabolome at the time of collection (122). 
Several different types of biological fluids and tissues can be analysed, each giving a unique 
snapshot of biochemical changes and complex interactions in a particular metabolome, 
depending on the physiological or environmental perturbation. In maternal-foetal metabolomic 
investigations a range of bio-specimens have already been employed including; plasma, urine, 
amniotic fluid, placental tissue, vaginal secretions and cord blood(166). It is important to note 
that no single specimen will reflect the total metabolomic disturbance of an organism; 
therefore one must be carefully chosen based on availability, suitability to achieve the study 
aims, and level of invasiveness.  
For infants with perinatal asphyxia and HIE, postnatal specimen collection is difficult and can 
easily be confounded by progression of disease, postnatal interventions or timing of collection. 
The average 3.5 kg infant will have only 280 ml of blood. Ethical guidelines limit research 
sampling to 1% of circulating blood volume per 24 hours, giving an upper limit of 3 ml for 
postnatal sampling, or approximately 1-1.3 ml of serum or plasma. This limited availability of 
blood for metabolomic analysis leaves little room for error. 
The metabolomic analysis of umbilical cord blood (UCB)provides a potent source of early 
metabolic information offering the unique potential to identify the severity of cellular hypoxia 
and resulting metabolic damage. The umbilical cord consist of the umbilical vein containing 
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blood directed from the placenta to the foetus and the umbilical arteries containing blood of 
the foetus returning to the placenta. A 1H-NMR based metabolic profiling study comparing 
blood from both reported no noticeable difference in the metabolomic profile of the two, 
however there were significant differences for some individual metabolites (167). 
Though UCB is not routinely stored, it is suited to biomarker discovery as large volumes (20 ml) 
can be non-invasively extracted allowing for whole blood, serum and plasma to be collected. A 
mixed arterial/venous cord sample simplifies collection and user friendly testing in the acute 
setting. Ideally, cord blood will be drawn from the placenta within 20 minutes of birth and 
immediately stored at 4°C before processing to quench enzymatic activity and ensure 
subsequent biological observations are accurate. To be suitable for metabolomic analysis, 
samples must be processed in a sterile environment; all work surfaces must be decontaminated 
and sterile consumables (e.g. pipette tips)  are recommended. Samples should be biobanked in 
microaliquot volumes that are sufficient for one metabolomic experiment, eliminating the need 
for freeze thaw cycles (122). Ideally biobank freezers should be housed in a facility containing 
temperature control, ventilation and generator backup power. Monitoring freezers 24 hours a 
day using internal temperature probes with the ability to produce log sheets and reports will 
verify -80°C is maintained, and hence no metabolic degradation has occurred.  
 
2.6 The emerging role of metabolomics in PA and HIE 
The metabolic response to hypoxia-ischaemia remains unclear, as does its role in alleviating or 
attenuating the injury sustained. Traditionally investigations have relied on a reductionist 
approach, which focused on small number or individual metabolites in isolation, when large 
scale disruption of multiple pathways is likely to occur. An integrative systems biology approach 
could help us understand the behaviour of all biological components in HIE, particularly their 
mechanistic interactions.  
Therapeutic hypothermia and the ongoing search for additional neuroprotective therapies has 
heightened the need for both early diagnosis of HIE and a better understanding of its initial 
pathophysiological mechanisms. Current markers used to assess the severity of the injury in 
routine clinical practice are unreliable and do not accurately predict long-term outcome (37). 
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There is an urgent need for a quick, reproducible, non-invasive and user independent biological 
marker to quantify HIE severity and likely prognosis (46).  
Metabolomics has the unique potential to elucidate disease mechanisms in perinatal asphyxia 
and neonatal HIE by describing qualitatively or quantitatively, the rapid alteration and 
interaction of metabolic pathways in response to the hypoxic environment and ultimately 
depict an infant’s phenotype (168). A unique metabolomic fingerprint of hypoxia-ischaemia or 
metabolic biomarkers could be used to indicate injury severity, predict response to treatment 
and potential neurodevelopmental outcome. 
 
2.6.1 Early work in the field 
Huang et al. (1999) began this search by examining the early urinary ratio of lactate to 
creatinine in asphyxiated neonates, using proton nuclear magnetic resonance (1H-NMR) 
spectroscopy. They defined a lactate to creatinine ratio value of 0.64 or higher, within 6 hours 
of birth, to be highly specific (100%) and sensitive (94%) for predicting the development of HIE 
(n=16). Furthermore, the mean ratio was significantly higher in infants who had an adverse 
outcome at one year of life (161). A urinary metabolomic profile of infants with clinical 
evidence of severe asphyxia has also been described using gas chromatography-mass 
spectrometry (GC-MS), which linked four energy and four oxidative stress metabolites to good 
and poor infant outcome respectively (157). While this initial work proved very promising, the 
severity of injury, timing of collection and outcome of the infants were poorly defined.  
 
2.6.2 Animal studies 
Several studies have employed animal models of asphyxia/hypoxia to study metabolomic 
alterations and a number of putative metabolomic fingerprints have been proposed. The 
accumulation and delayed recovery of TCA cycle intermediates (for example, fumarate, 
succinate, malate and alpha keto-glutarate) have been described in a range of models (5, 6, 
169, 170). These energy metabolites are a product of the shift toward anaerobic conditions, 
illustrated by the accumulation of lactate (87, 161, 171), and mitochondrial dysfunction (172) 
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leading to disturbance of the TCA cycle. Due to reduced ATP availability, these metabolites 
cannot enter the respiratory chain for energy production and have been suggested as possible 
cofactors in lactate formation (5). 
Altered amino acids profiles where shown in a number of animal studies (169, 173, 174). Amino 
acid ratios of alanine to branched-chain amino acids (BCAA) and of glycine to BCAA,in 
combination with the energy metabolites succinate and propionyl-L-carnitine, were shown to 
highly correlate (R2 =0.96) with the duration of hypoxia in a piglet model (5). BCAA act as 
alternate energy sources for the brain and muscles (174, 175). Their marked presence in 
metabolomic studies has been confirmed also in asphyxiated neonates (176) and may illustrate 
their mobilisation under condition of reduced ATP production. However valine a BCAA known 
to increase during excitotoxicity, has been described as contributing to hypoxia-ischaemia 
facilitating the return of nitrogen to astrocytes (177).  
Disturbance of the cell membrane, perhaps through the release of oxygen free radicals which 
cause membrane lipid perioxidation and membrane dysfunction, has been illustrated by the 
marked elevation of arachidonic acid, a constituent of the phospholipid bilayer (6). 
Metabolomic examination of neuronal tissue revealed three differentiating metabolites which 
participate in glycerophospholipid metabolism (CDP-choline, choline and acetylcholine) (178), 
also a component of cell membranes. Lastly, urinary metabolites, which are reflective of kidney 
function have displayed potential in predicting death in newborn piglets (172), reflecting the 
systemic organ failure caused by severe hypoxia. 
Animal models have made important contributions to the field of neonatal medicine. Most 
notably, translational research of this nature provided the evidence base to administer 
therapeutic hypothermia to neonates with HIE, which is now standard of care (179). Clinically a 
hypoxic-ischaemic insult is unpredictable, usually occurring in the perinatal period but the 
exact timing and duration is often difficult to estimate. Animal models provide the ability to 
control the timing of the injury, allowing for the timed detection of metabolite alteration and 
elucidation of disease mechanisms. Genetic and environmental variability can be tightly 
regulated ensuring the phenotype is representative of the injury, unlike the dynamic inter and 
intra individual variability in humans which demands large sample numbers to statistically 
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control (165). They also overcome ethical issues for example, using a non-treatment or 
normothermia control group.  
Despite these obvious advantages, animal models may not capture the complex organ 
interactions and multiple co-morbidities, especially neurodevelopmental, associated with HIE. 
The majority of studies in animal models have investigated the effect of a single insult (180). 
Many models exist but there is no consensus on which best mimic the pathophysiological and 
clinical condition (181). As a result, animal studies have varied in terms of species, outcome 
measures, method of asphyxial injury, bio-specimen sampled and metabolomic approach, 
presented in Table ‎2.3. 
Apart from Beckstrom et al. (6), animal models in this field have generally assessed neonatal 
but not the clinically occurring in utero or perinatal asphyxia. Newborn piglet models have 
induced systemic hypoxia by lowering the fraction of inspired oxygen (FiO2) to between 0.06 – 
0.13, however, this fails to inflict the clinically concurrent ischaemia associated with HIE. A 
rodent model by Vannucci has classically combined unilateral carotid artery ligation with 8% 
oxygen to mimic perinatal asphyxia (182). This model was used by Liu et al, to assess brain 
tissue metabolites in postnatal day 7 mice (177), which were originally considered to be 
equivalent to a 32-36 week gestation human infant (183). Choosing an optimal animal model 
whose brain is equivalent to that of a term newborn infant remains contentious (184).  
In the aforementioned studies, animals are usually sacrificed soon after recovery for 
histological examinations; no definitive diagnosis of HIE is provided and the extent of the brain 
injury is not assessed. Combining imaging and outcome studies with animal models is becoming 
increasingly important to assess the phenotype of newborn injury. Larger animals can be 
recovered post injury and their physiological and neurobehavioral responses assessed, for 
example, magnetic resonance imaging (MRI) and EEG can identify injury severity and seizure 
activity (185, 186). Yet, subtle long-term deficits in memory or processing speed remain difficult 
to measure.  
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Table ‎2.3 Summaryof metabolomic studies in animal models of hypoxia/asphyxia. 
Author, 
year 
Ref Studypopulation Specimen Analytical 
platform 
Metabolite alterations Key finding 
Fanos, 2014 (187) Newborn piglets 
(n=40) 
Urine 1H-NMR 15 metabolites  Resuscitation with 21% O2 
improves cellular recovery 
Arduini, 
2014 
(171) Piglets12-36 
hours old (n=10) 
Retinal & 
choroid 
tissue 
UPLC-MS/MS Lactate  ↓mitochondrial metabolites, 
anaerobic shift 
Murgia, 
2013 
(173) Newborn piglets 
(n=40) 
Urine 1H-NMR n-phenylacetylglycine, alanine, 
acetoacetate, dimethylamine 
methanol, glucose, sarcosine& 
succinate,  
 Re-oxygenation speed alters 
metabolite profile 
Solberg, 
2013 
(178) Piglets, 12-36 
hours old (n=10) 
Retinal tissue UPLC-QTOFMS 
UPLC-MS/MS 
CDP-choline, acetylcholine &  
choline  
 Phospholipid synthesis 
involvement and neuroprotective 
metabolites 
Skappak, 
2013 
(169) Piglets, 1-3 days 
old (n=32) 
Urine 1H-NMR 1-methylmicotinamide,amino acids, 
energy metabolites& betain 
 Urinary metabolites identify 
hypoxia 
Liu, 2013 (177) Mice, PN day 7 
(n=50) 
Brain tissue 1H-NMR Energy metabolites, ATP-ADP, 
glutamate, phosphocholine, lactate, 
glucose &valine 
 Hypothermia treatment alters 
metabolites 
Beckstrom, 
2011 
(6) Macaques 
(n=25) 
Plasma 2D GC/MS 10 metabolites  TCA cycle metabolites altered and 
cell membrane disturbance 
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Solberg, 
2010 
(5) Piglets, 12-36 
hours old (n=33) 
Plasma LC-
MS/MSFIA–
MS/MS 
Carnitines&Alanine/BCAA, 
glycine/BCAA (correlation R2 =0.96)  
 ↓ TCA cycle intermediates & 
delayed recovery with 100% O2 
resuscitation 
Atzori, 2010 (172) Piglets, 1-4 days 
(n=40) 
Urine 1H-NMR Creatinine, hydroxyisobutyric acid, 
methylguanidine,urea &malonate 
 Prediction of death 
Van 
Cappellen, 
2001 
(174) Foetal lambs 
(n=23) 
CSF 1H-NMR Amino acids, BCAA, lactic acid & 
hypoxanthine  
 Prolonged mild hypoxia leads to 
energy degradation 
Ref: reference; PN: postnatal;1H-NMR: proton nuclear magnetic resonance (1H-NMR) spectroscopy; UPLC-MS: ultra performance liquid chromatography – 
quadrupole time of flight mass spectrometry; UPLC-MS/MS: ultra performance liquid chromatography – tandem mass spectrometry; GC/MS: Two dimensional 
gas chromatography – mass spectrometry; LC-MS/MS: liquid chromatography – tandem mass spectrometry; FIA–MS/MS: Flow injection analysis – tandem mass 
spectrometry; BCAA: branched chain aminoacids; CSF: cerebrospinal fluid.(174)
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Metabolites generally reflect the genetic divergence between species. However, distinct 
concentration differences were evident when human metabolomes of the pre-frontal cortex, 
primary visual cortex, cerebellar cortex, kidney cortex and thigh skeletal muscle, were 
compared to those of chimpanzees, macaque monkeys and mice (188). This study reported 
that the metabolites of human pre frontal cortex undergo a fourfold divergence from their 
expected evolutionary lineage, indicating the advanced human metabolome may not be 
directly comparable to those of animals. 
Finally, ethical considerations in animal research to ‘replace, reduce and refine’ have resulted 
in study cohorts being relatively small making it difficult to extrapolate meaningful results. For 
example, Murgia et al. assessed the association between metabolite changes and recovery time 
post hypoxia in 10 piglet subjects but commented on the distinct basal inter-individual 
metabolomic differences among subjects (173).   
Though animal experiments are providing valuable information in this developing field, the 
varying cerebral maturation and metabolism of species mean that no one model reflects the 
human condition (189). Many early metabolomic investigations have failed to comply with the 
minimum reporting standards for metabolomic analysis which aim to enable the interrogation, 
replication and comparison of data (155). This is impinging the translation of animal findings to 
the human scenario.To progress metabolomic animal experimentation toward clinical benifit, 
parallel validation studies in cohorts of human neonates are essential (190).  
In summary, a number of putative metabolite fingerprints persist throughout the literature 
discussed. Metabolomic data thus far is consistent with the perturbation of energy metabolism 
and mitochondrial injury in hypoxia-ischaemia. In particular both human and animal work has 
described the alteration of TCA cycle metabolites (5-7, 157, 169, 170), amino acids (5, 7, 8, 169, 
173) and constituents of the cell membrane (6, 8, 178). These metabolic changes correlate with 
the previous understanding of injury mechanisms, evidence of strong biological plausibility.  
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2.6.3 Metabolomic profiling in neonates 
Despite these challenges, some progress in neonatal studies has been made, see Table ‎2.4. The 
biochemical derangement in UCB after a neonatal hypoxic-ischaemic injury has recently been 
reported. A quantitative DI-MS/MS and LC-MS/MS approach showed significant alterations 
between groups (HIE vs matched control, perinatal asphyxia vs matched control) in 29 serum 
metabolites from three distinct classes; amino acids, acylcarnitines and glycerophospholipids 
(8). Energy production depends on the conversion of amino acids to glucose and ketone bodies, 
or their role as precursor metabolites to the TCA cycle (175). Disruption of the TCA cycle has 
been shown to increase its intermediates (5), which may account for the elevated precursor 
amino acid concentrations. When functioning normally, acylcarnitines transport long chain 
fatty acids across the mitochondria via a carnitine shuttle. Acylcarnitine levels were increased 
in neonates with both perinatal asphyxia and HIE relative to matched controls, suggesting a 
defect in fatty acid oxidation, resulting in their accumulation and release into circulation (191). 
The metabolite profile of these infants could differentiate between HIE and controls with an 
AUC of 0.92 and demonstrated the potential to distinguish between injury severity. While a 
metabolite model combination of just five metabolites (decenoyl-L-carnitine, 3,5-
tetradecadiencarnitine, PC ae C38:0, phenylalanine and proline) could discriminate HIE from 
other outcomes.  
A 1D 1H-NMR spectroscopy method was used to specifically characterise primary energy 
metabolites, finding significant changes in 18 UCB metabolites from infants with either 
perinatal asphyxia or HIE (7). A metabolic profile of severe HIE was illustrated by the mean fold 
increase of succinate and glycerol and decrease of ketones; acetone and 3-hydroxybutyrate. 
Ketones act as an alternate energy source for the infant brain and in severe HIE, ketone 
depletion suggests that the magnitude or duration of hypoxia-ischaemia has depleted these 
stores and reduced critical ATP generation (192, 193). Mild hypoxia has previously shown no 
elevation in 3-hydroxybutyrate in contrast with severe hypoxia (174). The presence of 
acetoacetate and succinate post hypoxia has been previously reported in animals (173). 
Acetoacetate is integral to ketogenesis whereby it is decarboxylated to acetone or reduced to 
3-hydroxybutyrate, which in turn can be transformed to acetyl-CoA for energy production and 
hence the release of succinate. Many animal models have described the alteration of succinate 
but not its association with HIE severity.   Succinate was found to increase 8-fold in severe HIE 
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compared to 2-fold in mild/moderate HIE, suggesting it plays a more integral role in disease 
mechanisms. It potentially promotes a shift to anaerobic metabolism by stabilising hypoxia-
inducible factor 1α (HIF1 α), an important component in the hypoxic stress response.   
Finally Longini et al. reported alterations in urine metabolites from six infants with perinatal 
asphyxia compared to eight controls, also using 1H-NMR spectroscopy to measure metabolites 
(194). This study confirmed significant alterations in lactate and glucose, as well as reporting 
alterations in trimethylamine N-oxide (TMAO), threonine and 3-hydroxyisovalerate. Multivariate 
models built with the NMR data detected a metabolomic profile which could distinguish 
asphyxia from control infants however these results must be interpreted with caution due to 
the very low sample size. 
Whilst these early results are promising and are supported by animal data, they have yet to be 
validated in additional prospective neonatal cohorts. This is the next challenge in order to 
progress the field towards clinically useful metabolomic biomarkers.  
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Table ‎2.4 Summaryof metabolomic studies in human neonates with perinatal asphyxia and/or HIE. 
Author, 
year 
Ref. Study population Specimen Analytical 
platform 
Metabolite alteration Key finding 
Longini, 
2015 
(194) 6 PA vs. 8 control Urine 1H-NMR lactate, TMAO, glucose & 
threonine + 3-OH isovalerate  
 Urinary metabolite profile can 
differentiate asphyxia from controls  
Reinke, 
2013 
(7) 34 PA vs. matched 
control 
25 HIE vs.matched 
control 
UCB 1H-NMR Organic acids, amino acids, urea cycle 
metabolites, ketones & phospholipids 
 Severe HIE significantly alters 
ketones, succinate and glycerol 
 A four metabolite model classifies 
severe HIE with AUC of 0.95 
Walsh, 
2012 
(8) 40 PA vs.matched 
control 
31 HIE vs.matched 
control 
UCB DI-MS/MS 
LC-MS/MS 
Acylcarnitines, glycerophospholipids 
&amino acids 
 A five metabolite model classified 
HIE infants with AUC of 0.92 
Chu, 
2006 
(157) 13 good-outcome 
vs. control 
11 poor-outcome 
vs.control 
Urine GC-MS 3-OH-3-methylglutarate, 
2-OH-glutarate,  Glutarate, 
methylmalonate, 3-OH-butyrate & 
orotate, 2-oxo-glutarate ethylmalonate 
 Energy and oxidative stress 
metabolites associated with good 
and poor outcome respectively  
Huang, 
1999 
(161) 58 controlvs.26 PA 
vs. 16 HIE 
Urine 1H-NMR Ratio of lactate to creatinine  Ratio value ≥ 0.64 predicts HIE 
development with specificity (100%) 
and sensitivity (94%) 
Ref: reference; PN: postnatal;1H-NMR: proton nuclear magnetic resonance (1H-NMR) spectroscopy; GC/MS: Gas chromatography – mass spectrometry; LC-
MS/MS: liquid chromatography – tandem mass spectrometry; DI–MS/MS: Direct injection– tandem mass spectrometry; OH: hydroxy.
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2.7 Preanalytical variationin metabolomics 
High quality bio-specimens are essential for metabolomic investigations to ensure the sample is 
a representative snapshot of the metabolome at the time of collection (122). Metabolomes are 
highly dynamic, operating with high metabolic fluxes, measured in units of seconds, compared 
to minutes or hours for proteins and transcriptomes. This makes metabolites ideal biomarkers 
due to their immediate response to endogenous and exogenous perturbation however 
invariably they are more susceptible to preanalytical variation.Valid data is fundamental in 
metabolomics to enable its reliable interpretation and validation, particularly in biomarker 
discovery.  
This knowledge coupled with the potential applications for metabolomics has boosted recent 
interest into the effects of preanalytical variation on metabolites(195). Studies have begun to 
systematically examine the effects of collection, processing and storage variables on metabolite 
measurements, for example; blood collection tubes(196, 197), freeze thaw cycles(197, 198), 
temperature (before and during processing)(197-199), buffy layer contamination and clotting 
time (199), long and short term stability (time to processing and time in freezer)(197, 199, 200) 
and haemolysis(197, 199).  All of these studies report that preanalytical variations will impact 
upon metabolite measurements, and need to be controlled. However some variation is 
unavoidable therefore individual researchers need a thorough understanding of the effects of 
the most pertinent variation in their own investigations.  
To limit preanalytical variation prospective planning and the inclusion of quality assurance (QA) 
systems are necessary (199), particularly when large epidemiological biobanks are collected 
over long periods of time (201). QA measures or ‘planned process activities’ can be embedded 
into standard operating procedures (SOP), an invaluble tool for the metabolomic researcher 
which ensures that each sample is biobanked and analysed in an identical manner (202-204). 
This level of QA will minimise the variability introducedbetween staff and across sites. SOPs 
should provide step by step procedures for sample handling, processing and curation with 
adequate detail to ensure meticulous and consistent execution(122, 199).  
For the purposes of this thesis, samples were collected using standardised biobanking SOPs 
which detail collection times, temperature and consumables (‎E.3.1). Furthermore, samples 
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were stored in microaliquot volumes suitable for an individual metabolomic experiment, 
eliminating the need for freeze thaw cycles, and cases were matched with controls for length of 
time in freezer to limit variation unrelated to the subject of study. Despite these stringent 
measures, the sampling of umbilical cord blood was error prone due to the unpredictable time 
of birth, complications during delivery, physiologically high haemocrit levels (205) at birth, and 
variation in clinical staff collecting UCB samples.  As a result haemolysis is a common 
preanalytical error that occurs when umbilical cord blood is sampled in the delivery room. 
 
2.7.1 Haemolysis 
Haemolysis commonly occurs during the collection of blood products and describes the 
reputing of erythrocytes (red blood cells) and release of their contents into the surrounding 
fluid.It can occur in vivoas a clinical marker of disease, for example haemolytic anaemias, 
haemolytic uraemia, sickle cell anaemia and rhesus incompatibility, but more commonly in 
vitro due to specimen collection errors. Several in vitro errors have been documented for 
example, difficult collection or handling, incorrect needle size, unnecessary mixing, under fill of 
the sample tube and excessive force, can all result in the breakdown of red blood cells which 
contaminate the surrounding serum or plasma (206, 207).  
Haemolysis can influence and interfere with metabolites, through the release of erythrocyte 
contents, ultimately causing spurious analyte measurements (207). Depending on the ratio of 
analyte between the erythrocyte and serum/plasma dilution effects or false concentration 
increases can occur(208). The erythrocytes may also release enzymes which catalyse further 
metabolic reactions ex vivo,increasing metabolite consumption or production. Several studies 
have examined the influence of haemolysis on routine biochemical teststypically 20-30 analytes 
measured individually, and described the extent of chemical alterations (209-212).Guidelines 
advising when not to report a result based on haemoglobin concentration are routinely used in 
clinical laboratories to guide practice(213).In clinical laboratories, 3.3% of specimens reaching 
the laboratory are haemolysed, while haemolysis accounts for the highest percentage (60%) of 
rejected specimens (206, 214).  
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The advent of metabolomics has enabled the simultaneous detection of hundreds if not 
thousands of analytes in a given sample. For the majority of these metabolites, their response 
to haemolysis is unknown. Early investigative studies into the effect of haemolysis in 
metabolomics have begun. Only two previous papers have been published using varied 
analytical methods and specimen types. Kamalge et al. examined the effect of haemolysis on 
plasma metabolites using four mass spectrometry coupled analytical methods, gas 
chromatography (GC-MS), liquid chromatography (LC-MS/MS), solid phase extraction (SPE-LC-
MS/MS) and ultra-high performance liquid chromatography (UHPLC-MS/MS), and reported 
that up to 30% of metabolites were altered (199). Yin et al. also studied the response of plasma 
metabolites to haemolysis using UPLC-MS, and found alterations in 18% of detected metabolic 
features (197). Both of these studies recommended avoiding the use of haemolysed samples in 
metabolomic investigations.   
Due to the scarcity of literature, excluding haemolysed samples from metabolomic 
investigations may not be justified.  To date, no study has examined the effect of haemolysis on 
umbilical cord blood or serum metabolites, or used an untargeted direct injection (DI-MS) 
analytical approach.  
Though the prevalence of haemolysis in biobanked umbilical cord blood is unknown, 
anecdotally we believe it is higher than the 3% reaching clinical laboratories, due to 
physiologically high haematocrit levels found in fetal circulation at birth (haematocrit range 42-
65%, haemoglobin range 14-21.5 g/dL (at >37 weeks gestation)). Neonatal samples are 
expensive and difficult to collect, particularly those from infants with rare conditions.In 
addition the physical condition of the placenta and umbilical cord will affect the ease of sample 
extraction. Therefore those infants most of interest in perinatal research (preterm, growth 
restricted or chronic placental dysfunction) may be most at risk of haemolysis affecting their 
sample quality. Excluding all haemolysed samples will limit cohort diversity and potentially 
affect study feasibility.It is imperative to examine the effects of haemolysis on cord blood 
metabolites in more detail to; (i) Assess whether the metabolomic profile of cord blood serum 
is altered by haemolysis, (ii) Define a list of metabolic features which may be unreliable to 
measure in haemolysed cord blood and (iii) Ensure potential metabolic biomarkers are robust 
to haemolysis. We hope that thisnovel information will be an invaluable resource to the 
metabolomic community.  
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6.1 Abstract 
Background 
Metabolomics is defined as the comprehensive study of all low molecular weight biochemicals, 
(metabolites) present in an organism. Using a systems biology approach, metabolomics in 
umbilical cord blood (UCB) may offer insight into many perinatal disease processes by uniquely 
detecting rapid biochemical pathway alterations.  In vitro haemolysis is a common technical 
problem affecting UCB sampling in the delivery room, and can hamper metabolomic analysis. 
The extent of metabolomic alteration which occurs in haemolysed samples is unknown. 
Methodology 
Visual haemolysis was designated by the laboratory technician using a standardised haemolysis 
index colour chart. The metabolomic profile of haemolysed and non-haemolysed UCB serum 
samples from 69 healthy term infants was compared using both a 1H-NMR and targeted DI and 
LC -MS/MS approach.  
Results 
We identified 43 metabolites that are significantly altered in visually haemolysed UCB samples, 
acylcarnitines (n=2), glycerophospholipids (n=23), sphingolipids (n=7), sugars (n=3), amino acids 
(n=4) and TCA cycle intermediates (n=4).  
Conclusion 
This information will be useful for researchers in the field of neonatal metabolomics to avoid 
false findings in the presence of haemolysis, to ensure reproducible and credible results. 
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6.2 Introduction 
Interest in the effect of early life status on lifelong health is increasing. As a result, many 
predictive, diagnostic and prognostic biomarker discovery studies have begun to biobank and 
use umbilical cord blood (UCB) as their investigative specimen of choice (218). However, 
haemolysis is a common preanalytical problem that arises in UCB sampling in the delivery 
room. 
Haemolysis (or hemolysis) results when red blood cells are ruptured and their contents are 
released into the surrounding fluid, following damage to the cell membrane. Haemolysis of 
UCB can occur in vivo but more commonly  in vitro due to a combination of high haematocrit 
(205) and specimen collection errors. For example, difficult collection or handling, incorrect 
needle size, unnecessary mixing, under fill of the sample tube and excessive force, can all result 
in the breakdown of red blood cells which contaminate the surrounding serum or plasma (206).  
Metabolomics is the systematic study of temporal interactions between the compliment 
(metabolome) of low molecular weight biochemicals (metabolites) abundant within living 
organisms, tissues and cells. In UCB, metabolomics allows the measurement of rapid 
biochemical alterations and may offer early insight into many perinatal disease processes.  
Unfortunately haemolysis introduces high preanalytical variability, resulting in potentially 
unreliable results, and recommendations have been made to avoid using haemolysed samples 
in metabolomic experiments (197). However, neonatal samples for biomarker discovery are 
difficult and expensive to collect, and may be collected to examine rare or orphan diseases. 
Excluding all haemolysed samples is therefore not ideal, and may affect study feasibility.  
In the present study, retrospective data from two previous metabolomic investigations (7, 8), 
were combined to assess whether or not the visual haemolysis of UCB serum affects metabolite 
concentrations in a healthy control population. Metabolites must demonstrate robustness to 
haemolysis in order to translate to the clinical setting. Knowledge from this study will facilitate 
this translation by allowing researchers to avoid false results, and may enable correction for 
sample haemolysis.  
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6.3 Methodology 
6.3.1 Patient selection and sample collection 
Retrospective data from an ongoing birth cohort study, the Cork BASELINE Birth Cohort Study, 
recruited between June 2010 and July 2011 was analysed (218). Ethical approval was granted 
by the clinical research ethics committee of the Cork Teaching Hospitals, and written informed 
consent from all participants was obtained. Healthy control infants were selected based on the 
following criteria; Apgar scores ≥8 at 1min, ≥9 at 5min, duration of ruptured membrane <24 h, 
temperature in labour ≤37°C, gestational age ≥36 weeks, cord arterial pH ≥7.2 and birth weight 
centile ≥10%. This population had no underlying medical issues and normal neonatal exams.   
UCB was drawn in all infants using standardised operating procedures (SOPs). In brief, 6 ml was 
collected in a plain serum tube (BD Vacutainer no. 366431) within 20 min of placental delivery 
and allowed clot for 30 min at 4 °C, before centrifugation (2400 xg, 10 min, 4 °C). The serum 
was transferred to a second spin tube and centrifuged (3000 xg, 10 min, 4 °C) before being 
aliquoted into lithium heparin micro-tubes (VWR no. 89179-704) and stored at -80 °C until 
analysis. Total time from birth to samples being frozen at -80 °C was always under 3 hours.  
 
6.3.2 Haemolysis 
The haemolysis status was designated by laboratory technicians. In order to standardise visual 
assessment of the separated serum, a haemolysis index colour chart (Mayo Medical 
Laboratories, T 598) was used.  If a sample was dark orange – red in colour (corresponding 
haemoglobin ≥ 100 mg/dL), it was deemed haemolysed, see Figure ‎6.1.   
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Figure ‎6.1 Picture of four serum samples being thawed. Left hand side serum is clean (non-
haemolysed) and the others range in degree of haemolysis. Below the Mayo Medical 
Laboratories, haemolysis index colour chart (≥100 mg/dL = haemolysed). 
 
6.3.3 Metabolomic analysis 
Using both nuclear magnetic resonance (1H-NMR) spectroscopy and combined targeted direct 
infusion (DI-) and liquid chromatography (LC-)tandem mass spectrometry (MS/MS) assay 
(AbsolutIDQ p180 kit, Biocrates Life Sciences AG, Innsbruck, Austria), we have described the 
metabolomic profile of UCB from healthy term infants (7, 8)and evaluated the pre analytical 
effects of haemolysis to describe metabolite alterations. Quality control (QC) samples were 
employed to evaluate the precision and repeatability of the metabolite quantification. A 
detailed description of the metabolomic methods employed has been previously reported (7, 
8).  
 
6.3.4 Statistical Analysis 
Statistical analysis was performed using SPSS version 21.0. Metabolite data was normalised 
using log transformation for parametric tests and the antilog of the mean transformed data 
was reported; otherwise median and non-parametric tests were used. Statistical comparison 
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between haemolysis and clean serum groups was tested individually using Mann Whitney U 
test or using the Student’s t-test. 
No correction for multiple comparisons was performed, as the aim of this study was not to 
reduce the probability of false discovery, but to create a non-conservative “watch” list of 
haemolysis sensitive metabolites that could potentially confound any future biomarker studies.  
 
6.4 Results 
UCB serum samples (n = 69) were classified as being with (haemolysed, n = 13) or without 
(clean, n = 56) haemolysis upon visual inspection post centrifugation. All 69 samples underwent 
initial mass spectrometry metabolomic analysis using a combined targeted DI and LC -MS/MS 
approach. For 1H-NMR spectroscopy, ten samples were excluded due to insufficient sample 
volume, leaving 59 samples for the analysis. See Table ‎6.1for demographic details of the study 
cohort. 
Using the targeted method 148 metabolites were identified and quantified; 35 metabolites 
were significantly altered between groups, see Table 2. Separately, 37 were identified and 
quantified using 1H-NMR spectroscopy and eight unique metabolites were significantly altered 
between the clean (n = 48) and haemolysed (n = 11) groups,seeTable ‎6.2.  
Evident from the fold change values inTable ‎6.2, is the magnitude of metabolite concentration 
change with visual haemolysis. For example, acylcarnitines displayed an average fold change 
increase of 1.2 and glycerophospholipids an average fold change decrease of 1.3.  Metabolites 
closely associated with the tricarboxylic acid(TCA) cycle, acetate, formate and succinate, and 
the non-essential amino acid ornithine, all showed large fold increased concentrations of 1.5, 
1.8, 1.9 and 1.5 in haemolysed samples respectively. 
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Table ‎6.1Clinical and demographic details for the healthy control study populations of two 
separate metabolomic investigations. 
 1H-NMR spectroscopy  cohort  Mass spectrometry cohort 
 
Haemolysed 
(n=11) 
Clean 
(n=48) 
Haemolysed(n=13) 
Clean 
(n=56) 
Gestational Age (weeks) 39.6 (1.2) 40.3 (0.9) 39.7 (1.1) 40.2 (0.9) 
Gender (Male/Female) 7/4 32/16 12/12 38/18 
Birth Weight (gm) 3430 (595) 3667 (474) 3448 (484) 3627 (480) 
Weight Centile (%) 64 (10, 80) 62 (26, 86) 55.4 (32.0) 48.6 (31.0) 
Method of Delivery 
Spontaneous vaginal  
Instrumental assisted  
Emergency caesarean section 
Elective  caesarean section 
5 (46%) 
4 (36%) 
2 (18%) 
- 
12 (25%) 
25 (52%) 
10 (21%) 
1 (2%) 
5 (39%) 
6 (46%) 
2 (15%) 
- 
17 (30%) 
26 (46%) 
12 (21%) 
1 (2%) 
Apgar score 1 min 9 (8, 9) 9 (9, 9) 9 (8, 9) 9 (9, 9) 
Apgar score 5 min 9 (9, 10) 10 (10, 10) 9 (9,10) 10 (9, 10) 
Maternal Ethnicity 
Caucasian 
Indian 
Asian 
10 (91%) 
1 (9%) 
- 
47 (98%) 
- 
1 (2%) 
12 (92%) 
1 (8%) 
- 
55 (98%) 
- 
1 (2%) 
Maternal Age (years) 30.7 (6.7) 29.6 (4.5) 31.0 (6.2) 29.2 (4.7) 
Maternal BMI (kg/m2) 23.7 (4.0) 23.9 (3.5) 24.4 (4.0) 24.2 (4.2) 
Values are mean (SD), median (interquartile range), or n (%) 
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Table ‎6.2Metabolites significantly different when visually haemolysed and clean UCB serum 
samples were compared. 
Metabolite Clean serum† 
Haemolysed 
serum† 
%RSDQC Fold# 
up or 
down 
p-
value 
 Mass Spectrometry 
L-Acetylcarnitine 3.8 (3.3,4.2) 4.8 (3.7, 6.1) 3 1.2 ↑ 0.0205 
Hexanoylcarnitine 0.07 (0.07,0.08) 0.08 (0.07,0.1) 14 1.2 ↑ 0.0287 
PC aa C38:0 1.7 (1.5,1.8) 1.3 (1.1,2.0) 6 -1.3 ↓ 0.0355 
PC aa C38:3 40.1 (38.1,43.1) 32.2 (27.3,42.5) 8 -1.2 ↓ 0.0355 
PC aa C38:5 26.4 (24.4,28.2) 20.7 (16.7,25) 8 -1.3 ↓ 0.0097 
PC aa C38:6 75.5 (68.9,82.3) 57.3 (47.2,76.7) 4 -1.3 ↓ 0.0246 
PC aa C40:4 3.2 (2.9,3.6) 2.3 (2.0, 3.1) 4 -1.4 ↓ 0.0071 
PC aa C40:5 6.6 (5.6,7.6) 4.8 (3.6, 5.8) 2 -1.4 ↓ 0.0060 
PC aa C40:6 30.3 (26.7,32.2) 21.8 (15.1,30.1) 5 -1.4 ↓ 0.0089 
PC aa C42:0 0.5 (0.4,0.5) 0.4 (0.2,0.7) 3 -1.2 ↓ 0.0288 
PC ae C32:1 2.4 (2.1,2.6) 1.8 (1.2,2.5) 3 -1.4 ↓ 0.0209 
PC ae C34:3 1.2 (1.1,1.3) 0.9 (0.6,1.4) 3 -1.3 ↓ 0.0193 
PC ae C38:4 8.7 (8.0,9.8) 6.9 (6.1,9.7) 2 -1.3 ↓ 0.0255 
PC ae C38:5 7.7 (7.1,8.2) 6.4 (4.5,9.3) 2 -1.2 ↓ 0.0478 
PC ae C38:6 3.4 (3.2,3.8) 2.7 (1.6,3.8) 3 -1.3 ↓ 0.0266 
PC ae C40:4 1.8 (1.7,1.9) 1.3 (1.2,1.9) 5 -1.3 ↓ 0.0135 
PC ae C40:5 1.6 (1.4,1.7) 1.3 (1.0,1.8) 5 -1.2 ↓ 0.0222 
PC ae C40:6 2.5 (2.3,2.8) 2.0 (1.2,3.1) 3 -1.3 ↓ 0.0420 
PC ae C44:4 0.3 (0.3,0.3) 0.2 (0.2,0.3) 4 -1.4 ↓ 0.0362 
PC ae C44:5 1.1 (1,1.2) 0.8 (0.5,1.1) 2 -1.3 ↓ 0.0342 
PC ae C44:6 0.9 (0.8,0.9) 0.7 (0.4,1.0) 2 -1.3 ↓ 0.0390 
lysoPC a C16:0 59.75 (54.9,62.9) 49.9 (37,63.9) 5 -1.2 ↓ 0.0355 
lysoPC a C16:1 4.5 (3.9,4.9) 3.3 (2.5,4.8) 2 -1.4 ↓ 0.0156 
lysoPC a C18:0 10.3 (9.8,10.7) 8.3 (6.3,9.8) 6 -1.2 ↓ 0.0129 
lysoPC a C18:1 13 (11.6,14.6) 9.1 (6.3,14.1) 5 -1.4 ↓ 0.0266 
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SM (OH) C16:1 1.5 (1.4,1.6) 1.4 (1,1.8) 12 -1.1 ↓ 0.0444 
SM (OH) C22:2 3.5 (3,3.7) 2.8 (2,3.6) 4 -1.2 ↓ 0.0428 
SM (OH) C24:1 1 (0.9,1.1) 0.9 (0.6,1.1) 3 -1.1 ↓ 0.0428 
SM C16:1 10.2 (9.5,11.1) 7.8 (7.4,11.1) 4 -1.3 ↓ 0.0323 
SM C22:3 0.4 (0.3,0.4) 0.2 (0.1,0.4) 2 -1.6 ↓ 0.0121 
SM C24:0 16.4 (14.7,17.4) 12.5 (10.3,17.5) 3 -1.3 ↓ 0.0197 
SM C24:1 27.7 (25.7,29.1) 20.9 (12.2,30) 4 -1.3 ↓ 0.0305 
Hexose 4064 (3844,4500) 3451 (3361,4070) 3 -1.2 ↓ 0.0124 
Glycine* 252.5 (236,265) 220 (192,262) 1 -1.1 ↓ 0.0021 
Serine* 
128.5 
(124.1,133.1) 
116.8 
(103.7,131.5) 
3 -1.1 ↓ 0.0359 
 1H-NMR Spectroscopy 
Acetate 14.7 (12.7, 17.5) 21.3(12.4,46.1) 4 1.5 ↑ 0.0504 
Citrate 35.2 (23.4, 40.4) 44.5 (36.2,52.9) 17 1.3 ↑ 0.0185 
Formate 11.2 (10, 13.3) 20.7 (8.4,42) 14 1.8 ↑ 0.0293 
Glucose* 
1666.7  
(1575.7, 1763) 
1488.7 
(1411.8,1569.8) 
7 -1.2 ↓ 0.0037 
Glycerol 16.7 (14.6, 19.1) 23.1 (9.8,33.1) 16 1.4 ↑ 0.0460 
Ornithine 17.6 (15.5, 20.2) 26.9 (15.3,36.5) 8 1.5 ↑ 0.0265 
Phenylalanine 26.6(24.9, 30.9) 34.2 (23.6,38.8) 7 1.3 ↑ 0.0482 
Succinate 1.5 (1.2, 1.8) 2.8 (1.2,6.9) 12 1.9 ↑ 0.0022 
QC; quality control, RSD; relative standard deviation, PC; phosphatidylcholines,  
lysoPC; lysophosphatidylcholines and SM = sphingolipids 
#Fold change of increased ↑, or decreased ↓ concentration in haemolysed samples. 
†Median or *mean μM metabolite concentration with 95% confidence intervals (95%CI) 
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6.5 Discussion 
This study examined the effect of visual haemolysis on UCB serum metabolites using 
quantitative metabolomic methods DI and LC -MS/MS and 1H-NMR, and found that 43 
metabolites were significantly altered when comparing haemolysed and clean serum. These 
metabolites belonged to several classes; acylcarnitines (n=2), glycerophospholipids (n=23), 
sphingolipids (n=7), sugars (n=3), amino acids (n=4) and TCA cycle intermediates (n=4), 
seeTable ‎6.2. The p-values presented in Table 2 may seem marginal, but it is important to note 
that this was a retrospective study with only a small number of visually haemolysed samples. 
However, the fold-change values do indicate potential confounding effects in any true disease 
biomarker discovery. 
Concentration changes for each metabolite were examined as these may arise from the 
metabolite being either degraded or metabolized by enzymes released from haemolysed 
erythrocytes (197). Besides haemologlobin, erythrocytes also contain several structural 
proteins, lipids and carbohydrates which could influence and interfere with the sample (207). 
Out of a total of 185 quantified metabolites, 56 metabolites were found to have increased 
concentrations in visually haemolysed samples, 34 and 22 detected by DI and LC -MS/MS and 
1H-NMR respectively. Of the significantly altered metabolites, nine displayed concentration 
increases in haemolysed samples, while the remaining decreased. Increases occurred in both 
acylcarnitines; L-acetylcarnitine and hexanoylcarnitine, a sugar glycerol, an amino acid 
phenylalanine, a non-essential amino acid ornithine, and the TCA cycle intermediates, acetate, 
citrate, formate and succinate. A recent study evaluating the effect of preanalytical variables in 
blood and plasma found 81 blood metabolites which were significantly altered by haemolysis, 
with an increase in 50 metabolites and a decrease in 31 (199).  
The erythrocytes and monocytes released into the cytoplasm have the ability to convert 
arginine to ornithine (299), which is in agreement with our results. Though not significantly 
altered by haemolysis, arginine displayed a concentration decrease in haemolysed serum (78.9 
IQR 67.4-97.7 μM) compared to clean (86.8 IQR 74.0-97.7 μM) and ornithine the corresponding 
increase in concentration. Increasing acetate and decreasing glucose has also been previously 
shown by Theil et al., examining plasma metabolites from bovine samples (300). Likewise, false 
elevations in creatinine have been documented in haemolysed samples during clinical testing 
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(206). We found creatinine concentrations increased from clean (23.0 IQR 17.9-27.2 μM) to 
visually haemolysed (25.4 IQR 21.5-27.9 μM) serum.  
All remaining metabolites, particularly the lipids (phosphatidylcholines, 
lysophosphatidylcholines and sphingolipids), had decreased concentrations in haemolysed 
samples, potentially being degraded by erythrocyte enzymes or diluted by chemical 
interference. A study by Yin et al. using a non-targeted LC metabolomic approach found 69 
mass features significantly changed comparing haemolysed and control plasma samples. Two 
of these mass features were identified as the lysophosphatidylcholines (lyso-PCs) C16:0 and 
C18:0 which showed increased concentrations in haemolysed samples, while lyso-PC C16:0 
showed a strong correlation (P = 0.0003; r = 0.61) with free haemoglobin (197). Our results 
indicate that these lipids decrease with haemolysis in UCB.  
In the present study, UCB was meticulously biobanked in adherence to strict SOPs (218), to 
ensure samples were suitable for metabolomic analysis. The prevalence of haemolysis in 
routine venepuncture samples has been described as 3.3 % (206), however, the prevalence in 
biobanked UCB is unknown. Visible haemolysis as an indicator of erythrocyte breakdown is only 
apparent when the serum or plasma has been separated and does not look haemolysed until 
the concentration of haemoglobin reaches 0.2 g/L (301). A limitation of this study was the 
subjective visual verification of haemolysis (302). Instead a spectrophotometric technique 
could be used to quantify haemolysis using the haemolysis index.  
Though our results seem biologically plausible, the sample size of our study is relatively small 
and may be illustrating population differences in metabolites which are highly variable, rather 
than analytical differences. However our samples were selected from a homogeneous 
population of normal healthy full term infants in an attempt to leave haemolysis as the sole 
discernible difference.  
The results from our study have indicated potential differences in UCB serum metabolites in 
visually haemolysed samples. These differences may be the result of chemical interference or 
concentration changes of analytes, caused by the release of free haemoglobin and other 
intracellular contents from the erythrocyte.  This is the first time UCB metabolite levels have 
been compared in clean and haemolysed serum, from healthy term infants. Haemolysis 
remains a major concern for both clinical and research laboratories, by contributing to 
erroneous results. Excluding haemolysed samples from biomarker discovery is not always 
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feasible; therefore, future work in the field of metabolomics must concentrate on defining a list 
of peaks or metabolites that are unreliable to measure in haemolysed samples. 
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Chapter 8  
8 Concluding Summary 
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8.1 Summary of main findings 
This research was conducted with the overarching aim of making novel contributions to the 
field of metabolomic investigations in perinatal asphyxia and HIE, to discover candidate 
metabolomic markers which have thepotential to identify infants at risk ofneonatal HIE. This 
thesis has performed the first untargeted metabolomic mass spectrometry analysis of any 
cohort of infants with HIE. As my interest lay in the translation of metabolomic markers to 
clinical use, I also examined the ability of a metabolite modelto predict long-term 
neurodevelopmental outcome, and the robustness of metabolite measurements to withstand 
the preanalytical variable haemolysis. 
This thesis had three main aims; the first aim was to identify novel metabolomic markers of 
perinatal asphyxia and HIE through untargeted metabolomic analysis. This was achieved by 
using a direct injection mass spectrometry (DI FT-ICR MS) metabolomic workflow and cord 
blood samples from a previously recruited cohort of infants with perinatal asphyxia and HIE 
(Appendix E.1). This highly sensitive untargeted method was performed for both polar 
(hydrophilic) and non-polar (lipid) compounds enabling the broad characterisation of the cord 
blood metabolome and its response to hypoxia-ischaemia compared to healthy matched 
controls. To our knowledge this is the most extensive depiction of the cord blood metabolome 
in a cohort of infants with perinatal asphyxia. It enabled previously unsuspected individual 
metabolites, metabolic pathways and lipid classes, which were altered in response to hypoxia-
ischaemia to be elucidated.  In particular tryptophan and pyrimidine pathway metabolites 
displayed significant alterations associated with HIE alongside lipid classes including fatty acyl, 
prenol and glycerolipids. Individual metabolites from the tryptophan and pyrimidine pathway, 
and some glycerophospholipids showed potential to differentiate between injury severities and 
infants with or without an encephalopathy.  
The second aim of this thesis was to perform the technical study validation of previously 
identified cord blood metabolomic markers, and to evaluate their potential to predict long-
term outcome. Technical validation was carried out by repeating the metabolomic analysis 
using samples from the same cohort of infants previously analysed by our group using targeted 
(8) and semi-targeted (7) approaches, but this time employing an alternate untargeted DI FT-
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ICR MS workflow. This highly sensitive method allowed changes in previously identified 
metabolites to be detected and confirmed, including changes in amino acid compounds, energy 
metabolites for example succinate, glycerol and acetone, and fatty acid compounds. To our 
knowledge this is the first metabolomic biomarker study in HIE which has performed a 
technical study validation. It not only strengthens our previous work but also provides 
confidence in the untargeted workflow to detect novel alterations and progress these findings 
toward to the final step of validation in an independent neonatal cohort.  
Our group has previously reported two separate metabolite models predictive of HIE at birth; 
the first composed of decenoyl-L-carnitine, 3,5-tetradecadiencarnitine, PC ae C38:0, 
phenylalanine and proline (model A)(8),the second composed of succinate, glycerol, 3-
hydroxybutyrate and O-phosphocholine (model B) (7). This thesis examined the ability of early 
metabolite models to correlate with three year neurodevelopmental outcome in infants with 
HIE. Both model scores significantly correlated with outcome, model A showing potential to 
predict an abnormal outcome and model B being particularly robust to predict both a severe 
outcome and intact survival at three years. Most importantly the models outperformed other 
biochemical markers used routinely in clinic. Though further validation is required this 
highlights the potentially powerful clinical utility that early metabolite measurements in cord 
blood possess.  
Finally the third aim was to examine the robustness of metabolite markers to haemolysis. To do 
this I first conducted a preliminary study using retrospective metabolomic data from a healthy 
control population, and reported alterations in lipid metabolites including acylcarnitines, 
glycerophospholipids and sphingolipids, as well as sugars, amino acids and TCA cycle 
intermediates. Due to two limitations, the first being that haemolysis was confirmed visually 
and the second that differences may be due to inherent biological variability as 
haemolysed/non-haemolysed samples were taken from different infants, this preliminary study 
was not sufficient to draw concrete conclusions but did indicate that further investigation was 
warranted. Therefore I conducted the first paired analysis of cord blood serum samples using 
an untargeted metabolomic method similar to that used in the investigation of biomarkers of 
HIE, so that results from the two studies could be compared. Importantly this study revealed 
that the biological variability between individuals is still greater than the variation between a 
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haemolysed and non-haemolysed sample from the same individual. This means that the use of 
a haemolysed sample in investigative metabolomics is possible, if haemolysis is documented 
and controlled for in the interpretation of results. Several individual metabolic features were 
affected by haemolysis including somefound altered in perinatal asphyxia and HIE (see Chapter 
3 and 4), such as steroid compounds and the amino acids glutamine and tyrosine. Haemolysed 
samples were used in the investigation for biomarkers of HIE therefore results from these 
features should be approached with caution. Their susceptibility to interference by haemolysis 
may hamper validation and more importantly it may not be possible to robustly measure them 
at the cot-side.  
 
8.1.1 Strengths 
The primary strength of this study is the unique cohort of infants with perinatal asphyxia and 
HIE, which has enabled a thorough and methodological approach to biomarker discovery. This 
prospective cohort, namely The Biomarkers in Hypoxic Ischaemic Encephalopathy Study (The 
BIHIVE Study, Appendix E.1) was identified and recruited by my supervisors Dr D Murray and 
Prof G Boylan, along with clinical research fellow Dr Brian Walsh in Cork University Maternity 
Hospital, Ireland between 2009 and 2011. Several aspects of this cohort have strengthened the 
work in this thesis: 
 Demographic, biochemical, physiological and clinical data (>80 data points) was 
collected for each infant enrolled in The BIHIVE Study. 
 HIE was graded using a modified Sarnat score at 24hours, and the encephalopathy was 
confirmed using continuous multichannel EEG by an experienced 
electroencephalographer (Prof G Boylan). 
 Each infant had UCB drawn, processed and stored within three hours of birth. All 
samples were meticulously biobanked using strict standard operating procedures.  
 Infants were enrolled in follow-up and underwent standardised three year 
neurodevelopmental outcome assessment.  
 A healthy control population was recruited simultaneously as part of the Cork BASELINE 
Birth Cohort Study (218), providing matched controls.  
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Upon examining the literature, previous biomarker studies in this population not only 
metabolomic studies, are very heterogeneous; having different sample types, inclusion criteria 
and analysis methods, making comparison between studies and validation difficult. The 
thorough phenotyping of our cohort has enabled us to accurately grade perinatal asphyxia and 
HIE. Controls were similarly phenotyped at birth, which enabled the one to one matching of 
cases and controls for several variables including gender, gestational age and birthweight in an 
attempt to reduce biological variation unrelated to the injury itself. Biobanking high quality 
cord blood samples within three hours of birth, in an identical manner for both cases and 
controls, ensured that the samples were a representative snapshot of the metabolome at the 
time of collection (122). Post-natal samples are difficult to collect at a consistent time-point, 
and are inherently confounded by the rapidly changing metabolism. Importantly, samples were 
biobanked in microaliquots to allow multiple metabolomic experiments to be carried out for 
each infant enabling technical study validation.  Finally infant follow up to three years of age is 
a rarity in biomarker studies therefore its availability in this cohort has strengthened the clinical 
utility of the proposed metabolite models and will enable truly translational research.  
The untargeted metabolomic analysis was strengthened by the use of DI FT-ICR MS, a highly 
sensitive and mass accurate analytical platform. This platform enabled the high-throughput 
analysis of >200 samples of very small volume <20μl. This is the first time a platform with such 
sensitivity has been coupled with a population of this type, enabling the extensive 
characterisation of the metabolomic response to perinatal asphyxia and HIE. Most importantly 
it allowed us to achieve our aims in identifying novel unsuspected markers, which less sensitive 
methods such as NMR would be unable to detect, and also in technically validating previous 
markers. DI FT-ICR MS was coupled to an untargeted workflow, which was designed to produce 
only robust and reproducible data.  
 
8.1.2 Limitations 
Certain limitations are recognised. The study cohort has a relatively small number of infants 
with HIE (n=30) and therefore may be underpowered, particularly when injury severity was 
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examined (17 mild, 8 moderate, and 5 severe). Howeverthis is the largest cohort of infants 
used to date, when comparing this cohort to all metabolomic studies in the field of perinatal 
asphyxia and HIE. Neonatal biomarker studies are limited by the difficulty in recruiting a 
sufficient and appropriate study population, primarily because disease prevalence of HIE is low 
(0.3%) in high income countries, and the injury is highly unpredictable. Recruitment requires a 
regimented and multidisciplinary approach to identify participants and collect samples.  
Biological samples possess inherently large variation, for example serum is a complex biofluid 
containing thousands of possible metabolites(312). Though cases and controls were matched 
one to one for several variables to reduce biological variation, many confounding factors, which 
may alter the metabolomic fingerprint are outside the scope of this study including maternal 
diet, genetics and endogenous microbiotaetc. The heterogeneous nature of the HI injury may 
also introduce variation between infants depending on the timing and nature of the insult 
suffered. These factors may have affected our ability to discriminate between infant outcome 
groups (HIE and perinatal asphyxia) using the full metabolomic fingerprints. A metabolic 
fingerprint may not be useful for diagnosing HIE, instead a model based on a few key 
metabolites or a metabolic pathway could be more powerful, with the added advantage of 
being easier to translate to the cot-side. 
Finally due to limitations with regards cost and time, metabolites were ascribed putative 
annotations and not definitive metabolite identifications. This is the primary challenge facing 
the metabolomics community, particularly for those undertaking untargeted metabolomic 
techniques whereby a large number of features are detected (259). Metabolite identification is 
particularly important to allow meaningful biological interpretation of the data.  In this thesis 
we applied bioinformatics techniques such as ‘transformation mapping’ and metabolic 
pathways searching to increase our confidence in identifications(225). Our use of a highly mass 
accurate platform and robust data processing methods further increased our identification 
confidence. Despite putative annotations being used we were able to achieve the primary aims 
of the thesis, however future work will use targeted metabolomicswith pure compound 
standards to confirm identification and quantifymetabolite changes. 
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8.2 Impact of thesis 
This thesis contributes significantly to research in the area of metabolomic investigations in 
perinatal asphyxia and neonatal HIE. It has elucidated novel biochemical markers and pathway 
alterations associated with HIE, and performed the first step in validating previously proposed 
metabolomic markers. Importantly, the novel insight into the pathophysiological mechanisms 
of HIE provided by this thesis could direct future research by posing potential therapy targets. 
The association of metabolite markers with neurodevelopmental outcome, and ultimately 
comparison to standard early biochemical markers illustrates the potential clinical use of 
metabolites at the cot-side.  
The work has also highlighted a critical and previously overlooked preanalytical variable, 
haemolysis, as an important consideration in biomarker discovery. A recent editorial in Clinical 
Biochemistry cited the publication of our preliminary investigation into the effect of haemolysis 
on the metabolomic profile of umbilical cord blood (307) (see Chapter 6), stating ‘This is 
important information, that is seldom reported in studies derived from biobanks which may 
have profound implications in biomarker discovery, especially in the metabolomic field’ (313). 
 
 
Figure ‎8.1 The journey of a metabolite biomarker discovery study. This thesis enabled the 
completion of metabolite discovery and technical validation, from which a list of candidate 
metabolites has been complied. 
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8.3 Future work 
This thesis has enabled the discovery and technical validation of early cord blood metabolite 
markers. To translate these findings to the clinic and ultimately the cot-side, validation of 
markers in an independent cohort of infants is needed. I, along with several team members 
have recruited a prospective validation cohort, namely The Validation of Biomarkers in Hypoxic 
Ischaemic Encephalopathy Study (The BIHIVE2 Study, Appendix E.3). Recruitment took place in 
two large single maternity hospitals, Cork University Maternity Hospital, Ireland and Karolinska 
Maternity Hospital, Sweden between March 2013 and July 2015. Informed parental consent 
was a requirement in all cases and ethical approval for this study was granted by our local 
ethics board.All infants had UCB drawn, processed and biobanked within three hours of birth 
and neonatal HIE was carefully graded using early continuous multichannel EEG. Over 28 
months,we have recruited in total 275 cases (175 Cork and 118 Karolinska) and 225 controls 
(139 Cork and 86 Karolinska), and biobanked their cord blood. Of the 275 cases, 34 developed 
HIE with the breakdown of injury severity being, 21 mild, 12 moderate and 1 severe. This 
cohort has undergone detailed physiological and demographic phenotyping, and all infants are 
enrolled in a programme of neurodevelopmental follow up. 
This final stage of metabolomic biomarker validation will use a targeted approach, measuring a 
shortlist of pre-defined markers. Our shortlist will likely consist of metabolites from the 
tryptophan and pyrimidine pathways, several amino acids, acylcarnitines, energy metabolites 
and glycerophospholipids, including those compounds described in our previously reported 
models, seeTable ‎8.1. This list will also depend on the availability of commercial pure 
compound standards. During my thesis I have established collaborations with Dr Jennifer 
Kirwan and Prof Warwick Dunn, metabolomic experts from the University of Birmingham, 
UKwho have a strong track record in the field of human metabolomic analysis. I have also 
strengthened our ties with Prof David Broadhurst, an experienced metabolomic biostatistician 
from the University of Alberta, Edmonton. Working with our collaborators, it is envisaged the 
targeted validation will take place in the University of Birmingham, using a tailored 
metabolomic approach, for example, extensive sample preparation and chromatographic 
separation to isolate the candidate markers prior to detection by a highly sensitive analytical 
platform such as MS/MS and ultimately quantification using pure compounds as a reference. 
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Then we will need to complete bio-statistical modelling to identify the ideal combination of 
metabolites to provide optimum test sensitivity and specificity.  
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Table ‎8.1 Potential shortlist of metabolites suitable for cohort validation. 
Metabolite Class 
DI- & LC-
MS/MS 
1H-NMR DI FT-ICR MS 
1. Tetradecadiencarnitine  Acylcarnitines  
   
2. Butyrylcarnitine  Acylcarnitines  
 
 
 
3. Decenoylcarnitine  Acylcarnitines  
   
4. L-Acetylcarnitine  Acylcarnitines  
 
 
 
5. L-Palmitoylcarnitine  Acylcarnitines  
 
 
 
6. Phenylalanine Amino acid    
 
7. Alanine Amino acid   
  
8. Isoleucine Amino acid    
 
9. Leucine Amino acid    
 
10. Methionine Amino acid   
  
11. Proline Amino acid  
   
12. Tryptophan  Amino acid  
 
 
 
13. Tyrosine Amino acid  
 
 
 
14. Valine Amino acid   
  
15. Creatine Amino acid related     
16. Erythrose 4-phosphate  Amino acid related  
 
 
 
17. Taurine Biogenic Amines  
 
 
 
18. Glycerol Carbohydrate   
 
 
19. O-phosphocholine Choline 
 
 
  
20. Indolelactate Tryptophan Met.     
21. Kynurenine Tryptophan Met.     
22. Melatonin  Tryptophan Met.     
23. Succinate Energy Met.    
 
24. PC ae C38:0 Glycerophospholipid  
   
25. 3-hydroxybutyrate Ketone 
 
 
  
26. Acetone Ketone 
 
   
27. Oleic acid MUFA    
 
28. Linolenic acid  PUFA 
 
  
 
29. Linoleic acid  PUFA 
 
  
 
30. Uridine Pyrimidine Met. 
 
  
 
31. Dihydrothymine  Pyrimidine Met. 
 
  
 
32. Hydroxypropanoate  Pyrimidine Met. 
 
  
 
33. Glutamine Pyrimidine Met. 
 
  
 
PUFA; poly unsaturated fatty acid, MUFA mono unsaturated fatty acid, Met; metabolism. 
 ; Alterations detected using the corresponding analytical platform.  
 ; Potentially altered by haemolysis. 
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In addition to being accurate, the practicalities of a biomarker are important, to enable its 
seamless translation to the clinic. Ultimately the ideal biomarker panel will be measured 
quickly and cheaply, without user expertise being necessary. Though mass spectrometry is an 
extremely useful tool for biomarker discovery, the complex methods and statistical analysis, 
which require time and in depth knowledge would hamper its use clinically. Not to mention, 
each maternity hospital would require this expensive analytical instrument and technicians on 
site to complete the analysis in sufficient time for therapeutic hypothermia to be initiated.  
A more feasible approach is to create a point of care diagnostic tool, which could measure a 
panel of metabolomic markers immediately at the cot-side using a sample of cord blood. Here, 
small molecules have the advantage because they are well understood and many have been 
measured in the clinic for decades. For example hand held point of care devices which measure 
bilirubin, glucose, lactate, cholesterol and ketones from small sample volumes are routinely in 
use, therefore this type of device would require minimal staff training.  
To enhance the diagnostic accuracy of a metabolite panel, developments in bioinformatics and 
machine learning technology could also allow metabolite measurements to be combined with 
available clinical and physiological markers including foetal heart rate assessment, gender, 
gestational age, Apgar score and degree of lactic acidosis as well as EEG and heart rate 
variability. This would enable the development of a clinical support algorithm, incorporated 
into the point of care device to diagnose infants suitable for intervention and ‘at risk’ of HIE, 
with an optimal sensitivity and specificity > 90%. 
This thesis has completed an important step in the advancement of a rapid, low cost, robust, 
non-user dependent method for quantifying the severity of HIE and guiding therapy. The next 
steps include the validation of promising metabolite markers in an independent cohort and 
ultimately the development of a point of care device.  
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ATP Adenosine triphosphate 
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BASELINE Babies after SCOPE: Evaluating Longitudinal Impact using Neurological and 
Nutritional Endpoints 
BCAA Branched chain amino acids 
BIHIVE Biomarkers in hypoxic ischaemic encephalopathy 
CDP Cytidine diphphosphocholine 
CI  Confidence interval 
CNS Central nervous system 
CPR Cardiopulmonary resuscitation 
CREC Clinical research ethics committee 
CTP Cytidine  triphosphate 
CUMH  Cork university maternity hospital 
DI FT-ICR MS Direct injection Fourier-transform ion cyclotron resonance mass spectrometry 
DI MS Direct injection Mass spectrometry 
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
EEG Electroencephalogram 
ESI Electrospray Ionisation 
FADH Flavin adenine dinucleotide 
FT-ICR Fourier transform – ion cyclotron resonance 
GABA γ-aminobutyric acid 
GTP Guanosine triphosphate 
HI Hypoxic ischaemic 
HIE Hypoxic ischaemic encephalopathy 
HMDB Human metabolome database 
H-NMR Proton nuclear magnetic resonance  
HO Hydroxyl radical 
HPLC High performance liquid chromatography 
IL Interleukin 
IQR Interquartile range 
KEGG Kyoto Encyclopaedia of Genes and Genomes 
Log Logarithm  
LPS Lipopolysaccharide 
LV Latent variable 
M/Z Mass to charge ratio 
MR Magnetic resonance 
MRI Magnetic resonance imaging 
MS Mass spectrometry  
NADH Nicotinamide adenine dinucleotide 
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nESI Nano electrospray ionisation 
NICU Neonatal intensive care unit 
NMDA N-methyl-d-aspartic acid 
NO Nitric oxide 
NOS Nitric oxide synthase 
OXPHOS Oxidative phosphorylation  
PA Perinatal asphyxia 
PC Principal component  
PCA Principal component analysis 
PCR Polymerase chain reaction 
PLSDA Partial least squares discriminate analysis  
PQN Probable quotient normalisation 
QA Quality assurance 
QC Quality control 
RMSEC Root mean squared error of calibration 
RMSECV Root mean square error of cross-validation  
RNA Ribonucleic acid 
ROC Receiver operating curve 
ROM Reactive oxygen metabolites 
RPM Revolutions per minute 
RSD Relative standard deviation 
Sec Seconds 
SHO Senior house officer 
SIM Selected ion monitoring  
SOP Standard operating procedure 
TCA Tricarboxylic acid 
TIC Total ion current 
UCB Umbilical cord blood 
UDP Uridine diphosphate 
UK United Kingdom 
UMP Uridine monophosphate 
USA United States of America 
UTP Uridine triphosphate  
Chemical formulae 
Ca Calcium 
K Potassium 
Na Sodium 
▪O2
− Superoxide anion radical  
CHCl3 Chloroform 
H2O2 Hydrogen peroxide  
MeOH Methanol 
Units of measurement 
°C Degrees Celsius 
Da Dalton 
g Gravitational constant 
Kv Kilovolts 
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min Minutes 
ml Millilitre 
mM Millimolar 
PPM Parts per million 
PSI Pound/square inch 
μl Microliter 
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2012 Drug development and clinical trial design 
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2012 Fundamental biological imaging 
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Month/Year  Award 
March 2014 Pfizer Ireland innovation through teamwork award, audience selected prize 
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June 2014 College of Medicine and Health travel bursary of €1000. 
June 2013 UCC Doctoral showcase, finalist of the three minute thesis category. 
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2014 Process continuous improvement (LEAN) – White belt training 
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Year  Title 
2014-2016 College of Medicine and Health UCC, graduate student committee member. 
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Appendix E. Cohort identification 
E.1. Historical prospective cohort - The BIHIVE Study 
Study and setting 
My supervisors Dr D Murray and Prof G Boylan, along with Dr B Walsh assembled a previous 
prospective cohortof infants with perinatal asphyxia and neonatal HIE, namely The Biomarkers 
in Hypoxic Ischaemic Encephalopathy Study (The BIHIVE Study). This study was based in Cork 
University Maternity Hospital and recruited between September 2009 and June 2011.  Infants 
had clinical assessment, early multichannel EEG recorded, along with umbilical cord blood 
(UCB) and postnatal samples biobanked. This cohort has provided the potential for 
investigative metabolomic biomarker discovery studies, allowing two infant groups to be 
analysed (i) perinatal asphyxia group (no encephalopathy) and (ii) HIE group.  
Ethics and recruitment 
Ethical permission for this historical prospective cohort study was obtained from the Clinical 
Research Ethics Committee of the Cork Teaching Hospitals in 2009. Infants were recruited by Dr 
Walsh in a large single site maternity hospital with 9000 deliveries per annum. Eligibility 
required all infants to be in-born to allow UCB to be collected and biobanked within three 
hours of birth. Infants were recruited if they were born at ≥ 36 weeks gestational age and met 
one or more of the following criteria; 
 Apgar score ≤ 6 at 5 minutes 
 Cord arterial pH < 7.1 
 Requiring intubation or cardiopulmonary resuscitation at birth 
Infants were excluded if they were born less than 36 weeks gestational age, or if they were 
found to have an alternate, potentially confounding pathology (e.g. neonatal sepsis, cyanotic 
congenital cardiac lesions, neonatal stroke, CNS malformations or inherited neurological 
disorders). All infants with dysmorphic features or a confirmed chromosomal condition were 
excluded. UCB was collected from the placental cord within 20 minutes of birth, and samples 
were processed and stored within three hours of delivery (see ‎Appendix F).Following 
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resuscitation parents were approached and the study aims and procedures explained. Written 
informed consent was obtained. At this point if parents did not wish to take part in the study, 
the samples were discarded and no clinical details retained.  
Clinical data collection 
All demographic and clinical data from the neonatal period was collected by Dr Walsh 
prospectively, who compiled an excel file of over 85 data points for each infant. In addition, 
continuous multichannel video-EEG monitoring was commenced shortly after delivery for all 
cases whose parents consented. Monitoring continued until the background normalized or 
electrographic seizures had ceased for 24 hours. Using the NicoletOne video-EEG system 
(Carefusion, Madison, WI), silver-silver chloride electrodes were applied to the scalp using the 
international 10/20 system of electrode placement, modified for neonates (F3, F4, C3, C4, T3, 
T4, O2, O1, and Cz). The application and maintenance of the EEG was performed by Dr Walsh 
and two additional research fellows, Dr N Lynch and Dr E Low. 
Cases of perinatal asphyxia were defined asinfants with clinical or biochemical signs of asphyxia 
at birth (meeting the recruitment criteria), but who recovered quickly with no clinical signs of 
encephalopathy. Cases of HIE were defined as infants who developed an evolving clinical and 
electrographic encephalopathy consistent with HIE.Clinical grade of HIE was assigned using a 
modified Sarnat score at 24 hours. The EEG was visually analysed by an experienced neonatal 
neurophysiologist (Prof G Boylan) and a grade of encephalopathy was assigned at 24 hours. 
EEG grading of HIE in this cohort has been previously described (217) using a validated and 
published modified grading system (14, 15), outline in Table ‎2.2. Clinical examination was 
performed using the Amiel-Tison standardised newborn assessment on days 1, 2, 3 of lifeand at 
discharge(314). 
A Bayley Scales of Infant and Toddler Development Edition III (BSID-III) (111) structured 
developmental assessment was performed between 36-42 months. This included the Bayley’s 
Social-Emotional and Adaptive Behaviour Questionnaire (315) which was performed by the 
BIHIVE2 study research fellow Dr C Ahearne, as well as, the Child Behaviour Checklist (316) and 
Ages and Stages QuestionnaireThird Edition 3 (ASQ-3)(317).  
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E.2. Healthy prospective cohort - The BABYCORD Study 
Study and setting 
A prospective cohort study methodology was chosen. My aim was to recruit 50 healthy term 
infants and biobank their UCB for future metabolomic analysis to assess the effect of 
preanalytical variables. Recruitment was conducted over a three week period between January 
and February 2013 in the single maternity unit, Cork University Maternity Hospital. 
Ethics 
In my ethical submission I included a study specific proposal, consent form and patient 
information leaflet, staff information leaflet and protocol. Ethical approval to recruit a cohort of 
healthy term infants was granted in December 2012, from the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals. The ethically approved consent form and parent 
information leaflet are provided in Appendix ‎E.2.1, and the staff information leaflet in 
Appendix ‎E.2.2. In addition all amendments to the protocol were submitted through the CREC 
before proceeding.  The list and details of ethical amendments, and the reason for the 
amendments is given in Appendix ‎E.2.3. 
Recruitment 
Consent was obtained antenatally while the mother was in the early stages of labour by 
eithermyself, consultant obstetrician (Dr M O’Riordan) or obstetric SHO (Dr A Rashid). Parents 
were given time to read the information leaflet and consent form and a detailed verbal 
explanation was also given. The consent form was reviewed by the parents in their own time, 
and any questions they had were answered by myself, the consultant obstetrician or obstetric 
SHO. All study participation was entirely voluntary and full informed consent was taken in line 
with Good Clinical Practice (GCP) guidelines. 
Once consented healthy term infants of ≥37 week’s gestational age were recruited to the study 
following normal uncomplicated deliveries if met the following criteria;  
 Apgar scores ≥8 at 1 minute and ≥9 at 5 minutes 
 Cord arterial pH ≥7.2 
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 Duration of ruptured membrane <24 h 
This population had no clinical signs of asphyxia, no underlying medical issues, had normal 
neonatal exams and did not require admittance to the neonatal intensive care unit. Both 
maternal diabetes and foetal distress were the two main exclusion criteria. 
For all recruited participants, a sample of UCB (two serum bottles, one tempus tube) was 
drawn by either the midwife or obstetric SHO after birth. The time the sample was taken was 
recorded and I was notified immediately. I collected the UCB sample from the labour ward and 
assigned a study number before Iprocessed and biobanked it, see Appendix ‎F.1.  
Clinical data collection 
I collected both maternal and infant clinical data on each patient recruited by examining the 
patient charts and completing my own data collection sheet, see Appendix ‎E.2.4. 
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E.2.1 Information and consent form 
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E.2.2 Staff information leaflet 
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E.2.3 Amendments to ethical approval 
List of ethical amendments made in chronological order (The BABYCORD Study) 
1. Co-investigators, study population and number of subjects 
2. Co-investigator  
3. Analysis outside of University College Cork 
 
1. The additional co-investigators were added to the study to assist in the identification of the 
study population , recrutiment and consent. 
 Dr Mairead O’Riordan, Consultant Obstetrician & Gynaecologist/Senior Lecturer 
 Dr Aimi Rahayu Abdul Rashid, Obstetric SHO 
The study population was originally specified as normal term vaginal deliveries. This 
amendment was made to include pre-labour elective caesarean section deliveries.  This was 
to allow us to compare the metabolomic profile of umbilical cord in deliveries with and 
without labour, ultimately to describe the effect of labour on metabolites.  
The number of subjects was raised from 20 to 80 infants, to increase power.  
2. The additional co-investigator was added to the study. 
 Rachel Ronan 
 
3. Permission for samples collected in Cork to be analysed in the University of Birmingham. 
Approved on the 14 February 2015.  
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E.2.4 Data collection sheet 
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E.3. Prospective validation cohort - The BIHIVE2 Study 
Study and setting 
The prospective BIHIVE2 validation cohort was recruited in two large maternity hospitals based 
on separate sites; Cork University Maternity Hospital and Karolinska University Maternity 
Hospital, both with annual birth rates of approximately 9,000 deliveries per annum. The 
incidence of perinatal asphyxia is reported to be up to 20 per 1000 deliveries, with 
approximately 2 per 1000 progressing to HIE. Therefore, over a 24 month period (March 2013 – 
March 2015) with full recruitment at both sites we aimed to recruit approximately 300 cases of 
perinatal asphyxia, 60 of which would develop HIE, 20-30 cases of moderate-severe HIE and 30 
cases of mild HIE per annum. Meanwhile, we simultaneously aimed to recruited 300 healthy 
control infants. All infants had UCB drawn, processed and biobanked within three hours of birth 
and encephalopathy was carefully graded using early continuous multichannel EEG. Detailed 
phenotyping is central to the BIHIVE study allowing us to track infant development and identify 
confounding factors that may arise in our cohort. 
Ethics and recruitment 
Ethical approval for this study was granted by Clinical Research Ethics Committee (CREC) of the 
Cork Teaching Hospitals before proceeding (2012). In addition all amendments to the protocol 
were submitted to and approved by the CREC.  Informed parental consent was a requirement 
in all cases and controls. Consent forms and parent information leaflet for cases and controls 
are provided in Appendices ‎E.3.1, ‎E.3.2 and ‎E.3.3, ‎E.3.4 respectively.   
A prospective longitudinal cohort study was chosen as the most appropriate design to collect 
adequate numbers of infants with HIE for biomarker research. The inclusion criteria 
encompassed broad signs of birth asphyxia in infants (161), which inevitably meant that infants 
with perinatal asphyxia but without an encephalopathy were recruited. This recruitment 
method aimed for greater sensitivity in detecting all infants who would develop HIE, albeit with 
lower specificity. Approximately 20% of infants with HIE could be missed using a more rigid 
criteria such as the current criteria for therapeutic hypothermia (43), as some infants progress 
to display more severe clinical signs later in the postnatal period.  
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Due to the interdisciplinary nature of the study and the acute clinical setting, we relied on the 
co-operation of the medical and nursing staff of the neonatal unit, and the obstetric and 
midwifery staff of the labour ward.  We depend on these staff to identify study candidates, 
draw a sample of UCB and notify the research team immediately after delivery.  Prior to 
initiation I educated members of clinical staff on the labour ward about the study and visited at 
regular intervals to re-inform them of the study aims and recruitment criteria. I placed 
laminated posters with the recruitment criteria and on-call contact details in the labour ward 
and in theatre, with smaller versions on each resuscitaire and blood gas machine.  I also hung 
posters with pictures of the BIHIVE researchers in the labour ward so that staff would recognise 
us when we collected the cord blood samples. 
Infants were recruited if they were born at ≥ 36 weeks gestational age, with one or more of the 
following clinical markers of asphyxia: 
 Apgar score ≤ 6 at 5 minutes 
 Cord arterial pH< 7.1  
 Requiring intubation or cardiopulmonary resuscitation at birth 
Infants were excluded if they were born less than 36 weeks gestational age, or if they were 
found to have an alternate, potentially confounding pathology (e.g. neonatal sepsis, cyanotic 
congenital cardiac lesions, neonatal stroke, CNS malformations or inherited neurological 
disorders). All infants with dysmorphic features or a confirmed chromosomal condition were 
excluded.  
Once the obstetric and/or midwifery staff had identified study candidates, they drew an UCB 
sample from the placenta and filled four tubes; two serum, one plasma and one whole blood. 
Samples were placed in a 4°C dedicated research fridge and I, or another member of the 
BIHIVE2 team was contacted immediately. In all cases we ensured that less than 3 hours had 
elapsed from the time of delivery to the sample being processed and stored at -80 °C, see 
Appendix‎E.3.1 and Table ‎E.1. 
For all perinatal asphyxia and HIE infants, informed parental consent was sought after delivery 
once clinically appropriate due to the inability to identify cases prior to birth in the acute 
setting. All healthy control infants were consented prior to birth on both the antenatal and 
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labour ward while the mother was in early stages of labour. The parent information leaflet was 
provided and a detailed verbal explanation was given.  Parents were given time to review the 
consent form and information, then any questions they had were answered. When possible 
consent was obtained with both parents present, as in keeping with best practice (318). At all 
times it was explained to the parents that refusal of entry into this study would in no way 
impact upon the care of their child, nor was there any pressure upon them to enter into the 
study.  If the parents refused entry, the UCB samples were immediately discarded.  
Clinical data collection 
Using a secure online database we systematically collected over 350 data points on each infant 
related to clinical, demographic, physiological and lifestyle factors. For example, early outcome 
data collected includes; admission to the neonatal intensive care unit (NICU), length of 
ventilation, neurological examination, clinical and EEG grade of encephalopathy, occurrence of 
seizures and neurological status on discharge. Each infant is given a unique identifier in the 
database and each member of the study team had individual passwords so that data was 
securely stored and logged.  
A bedside EEG was performed as soon as possible during the first day of life. EEG was recorded 
for as long as feasible, only when appropriate, both clinically and taking the parents’ wishes 
into consideration. The EEG was recorded using the Viasys NicOne video-EEG system (Viasys 
International, Madison, WI), silver-silver chloride electrodes were applied to the scalp using the 
international 10/20 system of electrode placement, modified for neonates (F3, F4, C3, C4, T3, 
T4, O2, O1, and Cz). This system records the aEEG and multichannel-EEG simultaneously, 
making comparisons with either method possible. Application and maintenance of the EEG was 
performed by either neurophysiologists Mr R Goulding and Mr R Lloyd, or clinical research 
fellows Dr C Ahearne and Dr L Kharoshankaya. Anonymised EEGs were uploaded to the 
database as well as a remote and secure server for later blinded analysis by an experienced 
clinical neurophysiologist (Prof G Boylan). Clinical grade of HIE was assigned using the modified 
Sarnat score at 24 hours (88), and confirmed by EEG grade was assigned at 24 hours. EEG 
grading of HIE in this cohort has been previously described (217) using a validated and 
published modified grading system (14, 15),outline in Table ‎2.2. Neurological status was 
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assessed in all infants (perinatal asphyxia, HIE and controls) on days 1, 2 and 3 of life and prior 
to discharge using a modified Thompson score (90).   
Every child is enrolled in a programme of detailed ongoing neurological assessment and 
developmental follow up at 18-24 months (Dr C Aherne and Ms E Hennessy) which includes the 
Bayley Scales of Infant and Toddler Development Edition III (BSID-III) (111), the Bayley Social-
Emotional and Adaptive Behaviour Questionnaire, the Child-Behavioural Checklist (316) and 
assessment using a novel touch screen executive function testing platform. To retain 
participants for long-term follow up we have adopted a number of strategies including; 
collecting detailed contact information, sending out study newsletters, updating our website, 
birthday cards, text messages reminders of appointment details and a questionnaire pack 
before follow up appointment.   
For the current prospective validation cohort I was responsible for the collection, processing 
and biobanking of both UCB and post-natal samples, as part of a three person rota, 24 hours 
seven days a week as well as maintenance of the biobank and database. Table ‎E.1 details a 
summary of recruitment, sample collection and follow up in the BIHIVE2 study, including an 
outline of my role as on-call laboratory researcher.  
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Table ‎E.1 Chain of events in the BIHIVE2 study. Highlighted in bold is my role as laboratory 
(lab) on-call researcher. 
Who What When 
Attending 
obstetrician or 
midwife 
 Identifies infant meeting inclusion criteria 
 Clamps umbilical cord and extracts blood 
sample (serum, whole blood, plasma) 
 Stores samples in labour ward fridge @ 4°C 
 Immediately notifies laboratory on call 
researchers 
 
Within 20 minutes 
of placental 
delivery 
 
 
Lab oncall 
researcher 
 Collect blood from labour ward in 4 °C cold 
bag  
 Process and aliquot blood in sterile 
environment 
 Create patient file and enter 
sample/anlytical details into database 
 Process and biobank samples @ -80 °C  
 Follow up on infant status (a or b) 
24/7 
 
 
 
All within 3 hours 
of birth 
Infant status; two immediate possiblities 
a) The infant has recovered well after birth and has accompanied the mother to the ward. 
b) The infant requires further monitoring and has gone to the neonal unit. 
 
 
 
a) 
Lab oncall 
researcher 
 Notifies the clinical research fellow  Monday-Sunday  
9am-5pm 
Clinical 
research 
fellow 
 Clinically asess and consent infant to study 
 Records clinical details 
 Preform Thompson Score 
 Neurological assessment using the Bayley’s 
III score 
 
Prior to discharge 
 
 
18 months of life 
 
 
 
b) 
Lab oncall 
researcher 
 Immediately notifies the EEG oncall 
specialist 
24/7 
EEG oncall 
specialist 
 Clinically asess and consent infant to study 
 Records multichannel EEG up to 72 hours 
24/7 
Lab oncall 
researcher 
 Collect postnatal serum sample (1.5 ml) 
from neonatal unit in 4°C cold bag 
 Process and biobank samples @ -80 °C  
 Enter sample details into database 
Day 1, 2 and 3 of 
life 
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Clinical 
research 
fellow 
 Record clinical details 
 Perform Thompson Score  
 MRI for infants with moderate/severe HIE 
 Neurological assessment using the Bayley’s 
III score 
Prior to discharge 
Day 1, 2 and 3 of 
life 
Day 5-10 of life 
18-24 months of 
life 
E.3.1 Case consent form 
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E.3.2 Case patient information leaflet 
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E.3.3 Control consent form 
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E.3.4 Control patient information leaflet  
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Appendix F. Sample biobanking 
F.1. Umbilical cord blood (UCB) 
Though UCB is not routinely stored, large volumes can be non-invasively extracted from the 
placenta, allowing whole blood, serum and plasma to be collected, see Table ‎F.1. This research 
used a mixed arterial/venous cord sample to simplify collection and user friendly testing in the 
acute setting.  
UCB was drawn from the placenta within 20 minutes of birth and immediately stored at 4°C 
before processing, to quench enzymatic activity and ensure subsequent biological observations 
are accurate. Cool pack bags at 4°C were used to transport samples between the labour 
ward/neonatal unit and the laboratory. All samples are collected, processed and stored within 
three hours of birth using strict standard operating procedures (SOPs) generated for UCB 
specimens.  Time of birth and time in -80°C freezer were noted in the online BIHIVE2 database 
and laboratory book, if three hours had elapsed before samples were biobanked in full, 
samples were discarded. The online database presented in Figure ‎F.1 was used to track each 
sample with details such as; barcode, freezer location (row, column, box, shelf and freezer), 
collection centre, usage status, time and date at -80 °C, and preanalytical details were recorded 
including the presence of haemolysis. 
Consumables: Serum tube (BD Vacutainer no. 366431) 
Micro-tube (VWR no. 89179-704, SCT-050-SS-B-S) 
TEMPUS blood RNA tube (Applied Biosystems no. 4342792) 
EDTA tube (BD Vacutainer no. 367863) 
Filter pipette tips (PIP7876) 
Second spin tubes (VWR no, 60818-500) 
Plastic Pasteur pipettes (Fisher Scientific no.FB55348) 
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Table ‎F.1Required blood collection tubes. Filling order is from left to right. 
Sample Plain serum Whole blood Plain serum EDTA plasma 
Cap Top Red Blue Red Purple 
Volume (ml) 6  3 6 6  
 
Serum biobanking SOP  
UCB was collected in a plain serum tube, ≤ 20 min of placental delivery and allowed to sit at 4°C 
for at least 30 min post collection for the clot to form.  
 Keep all tubes on ice until aliquots are complete.   
 Check clot is present prior to centrifugation. 
 Centrifuge the 6 ml red capped tube at 2400 x g for 10 min at 4°C. 
 Using asterile Pasteur pipette, transfer theserum into a sterile labelled second spin tube 
and centrifuge at 3000 x g for 10 min at 4°C. 
 Collect the red capped barcoded micro-tubes from the -20°C freezer. 
 In a sterile fume hood, aliquot250 μlof serum into micro-tubes on ice, using filtered 
pipette tips. 
 Fit cap, scan barcode into the BIHIVE database and store samples at -80C until analysis. 
  
 Figure ‎F.1Test screenshot of the biospecimen section of the BIHIVE2 database. 
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Plasma and buffy coatSOP 
EDTA plasma tubes will be utilized in two ways: 
i. EDTA plasma 
ii. Buffy coat for later DNA extraction 
 
EDTA plasma 
 Keep all tubes on ice until aliquots and buffy coat are completed.   
 Centrifuge the 6 ml purple capped tubeat 2400 x g for 10 min at 4°C.  
 Using a sterile Pasteur, pipette the plasma into a sterile labelled second spin tube and 
centrifuge at 3000 x g for 10 min at 4°C. 
 Collect the lavender capped barcoded micro-tubesfrom the -20°C freezer. 
 In the sterile fume hood, aliquot 250 μlaliquots of plasma into the micro-tubes using 
filtered pipette tips  
 Fit caps, scan the barcodes into the BIHIVE database and store at -80 C. 
 
EDTA buffy coat  
 Following removal of the plasma, use a sterile Pasteur pipette to carefully remove the 
white cells (buffy coat) just above the red blood cells (interface between the plasma and 
red blood cells). 
 Transfer the buffy coat into a sterile, white topped barcoded micro-tube and centrifuge 
at 2400 x g for 10 min at 4 °C. 
 Using new sterile pipette tips remove residual plasma from the buffy coat and discard. 
 Fit caps, scan the barcodes into the BIHIVE database and store at -80 C. 
 
  
261 
 
Whole blood SOP 
 Draw 3 ml of whole blood directly into the Tempus blood RNA tube. 
Note: Filling the tube to the black mark on the tube label indicates the collection of 
approximately 3 ml of blood. 
 To stabilise the sample, shake the tube vigorously immediately after filling to ensure 
that the applied biosystems reagent makes uniform contact with the sample. 
 Place a barcode sticker on the Tempus tube, scan into the BIHIVE database and store at 
-80C.  
IMPORTANT: Failure to mix the stabilizing reagent with the blood leads to inadequate 
stabilization of the gene expression profile and the formation of micro-clots that can potentially 
clog the purification filter, hindering later analysis. 
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F.2. Postnatal samples 
If parents gave consent, post-natal research samples were drawn at the same time as clinical 
samples.  An attempt was made to draw these at 24 hours, 48 hours and 72 hours post birth. If 
the infant did not require a clinical blood sample, no post-natal research sample was drawn. 
The circulating blood volume of a neonate is approximately 80 ml per kg body weight; 
therefore, the average 3.5 kg infant will have only 280 ml of blood. Ethical guidelines limit 
sampling for research purposes to 1% of circulating blood volume per 24 hours giving an upper 
limit of 3 ml for postnatal sampling, or approximately 1-1.3 ml of serum or plasma. Regular 2 ml 
serum collection tubes from neonatal unit were used to collect this sample. Once the post-
natal samples were drawn, they were processed using a standardised SOP similar to the UCB 
samples.  
Postnatal Serum 
UCB was collected in a serum tube and allowed to sit at 4 °C for ≥ 30 min post collection for the 
clot to form.  
 
 Keep all tubes on ice until aliquots are complete.   
 Check the clot is present prior to centrifugation. 
 Centrifuge the 6 ml red capped tube at 2400 x g for 10 min at 4°C. 
 Using asterile Pasteur pipette, transfer theserum into a sterile labelled second spin tube 
and centrifuge at 3000 x g for 10 min at 4°C. 
 Collectthe red capped barcoded micro-tubes from the -20°C freezer. 
 In a sterile fume hood, aliquot 250 μl of serum into micro-tubes on ice, using filtered 
pipette tips. 
 Fit cap, scan barcode into the BIHIVE database and store samples at -80C until analysis. 
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F.3. Sample storage and transport 
Storage 
All samples are stored at -80 °C in dedicated biobank freezers housed in a well ventilated room 
containing generator backup power. Freezers are monitored 24/7 using internal and external 
temperature probes, to ensure the safe preservation of samples. In the BIHIVE study, an 
automatic emergency call is made to either myself or a member of the laboratory on-call team 
if a freezers temperature rises above -75°C . We immediately respond, day or night, to rectify 
any problem and ensure the temperature never rises above -70°C for more than three hours.   
Aliquotes are stored in small made for purpose boxes, with the position of each aliquot recored 
in the online BIHIVE database and laboratory book. The aliquots row-column position in the 
box is noted, along with the box, rack, shelf and freezer identification numbers. 
Transport 
Samples required transport to the University of Birmingham prior to the metabolomic analysis. 
To ensure that samples maintained the cold chain through-out, they were transported on dry-
ice which was topped up at regular intervals and monitored constantly using an internal 
temperature probe. Samples were transported by Marken (www.Marken.com), an 
international courier company who specialise in the transport of biological samples who could 
ensure their safe and appropriate transport.   
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Appendix G. Metabolomic analysis 
I conducted the metabolite extraction, sample preparation and mass spectrometry analysis in 
the Biomolecular Analysis Facility, School of Biosciences, University of Birmingham, UK under 
the supervision of Dr J Kirwan. 
 
G.1. Metabolite extraction 
A modified Bligh-Dyer biphasic extraction method was used to obtain polar and non-polar 
fractions from UCB serum, as described previously (142, 219). Extractions were conducted on 
ice to minimise metabolic activity.  Methanol was added to the frozen serum followed by 
chloroform and water to achieve a ratio of 2:2:1.8. All solvents were HPLC grade, pre-chilled 
and kept on ice 4 °C to reduce evaporation. Chloroform was transferred via a Hamilton glass 
syringe with metal plunger. To avoid cross contamination the syringe was washed three times 
in three separate wash solutions (MeOH:H2O Rinse, CHCL3 Rinse and CHCL3) between every 
sample. 
 
Equipment 1.8 ml and 7 ml glass vials with aluminium lined caps (Fisher TUL 520 006 J) 
  2 ml micro test tubes (Eppendorf, Germany) 
  Glass Pasteur pipettes 
  Hamilton syringe (Fisher Scientific UK 500 µl) 
Nitrogen sample concentrator (Techne, Bibby Scientific, UK) 
 
Solvents 100 % Methanol (MeOH) (Fisher Scientific, UK) 
  100 % Chloroform (CHCl3) (Pesticide Grade) 
  100 % Water (H2O) (J.T. Baker) 
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Protocol 
 Assuming 90% water content of serum(312), 450 µl MeOH was added directly to the 
200 µl frozen serum samples while on dry ice, after which, they defrosted on ice for 20 
min and were vortex mixed for 15 sec. 
 Separately, 1350 µl MeOH, 1800 µl CHCl3, and 1440 µl H2O was placed in 7 ml glass vials 
on ice. 
 The defrosted serum:MeOH sample was transferred into the pre-filled solvent vials 
using a glass Pasteur pipette. 
 Vials were vortex mixed for 15 sec and left on ice for 10 min to separate. 
 Vials were centrifuged at 1800 x g for 10 min, at 4 °C and left at room temperature for 5 
min for the phases to fully separate. 
The extracted samples were now biphasic, with proteins and other insoluble molecules forming 
a solid interphase layer which separated the two solvent layers, the upper (polar) and lower 
(non-polar) layers, see Figure G.1.  
 Using a pipette, 4 x 400 µl aliquots (1 positive, 1 negative and 2 extra) of the upper polar 
layer (MeOH:H2O) was transferred into micro-tubes. 80 µl aliquots from each sample 
were pooled in a separate micro tube to use later as a quality control (QC) sample. 
 Polar samples were dried using a vacuum centrifuge until dry (approx. 10 hours) at 
35°C. 
 The lower non-polar layer (CHCl3) was removed using a Pasteur pipette, placed in 1.8 ml 
glass vials and centrifuged at 1800 x g at 4 °C for 10 min to remove any particulate 
matter from the protein interface. 
 Using a glass syringe 4 x 200 µl aliquots (1 positive, 1 negative and 2 extra) of the non-
polar layer were transferred into micro-tubes, washing the syringe three times between 
samples. A 120 µl aliquot from each sample was placed into a separate vial as a QC 
sample.Care was taken not to remove any of the interface region, 1-2mm either side of 
the protein debris layer. 
 Non-polar samples were dried under nitrogen to reduce oxidation. 
 All dried samples were stored at -80 °C until mass spectrometry (MS) analysis. 
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Figure ‎G.1 Picture of three biphasic samples mid-extraction process. Three distinct sections 
are visible, the upper polar layer (hydrophilic metabolites) the middle interface consisting of 
protein and other insoluble debris and the lower non-polar layer (hydrophobic lipid 
metabolites). 
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G.2. Sample preparation for mass spectrometry 
Polar samples  
 Samples were re-suspended on ice in 400 µl of 4 °C MeOH: H2O, 80:20 w. 0.25% formic acid 
(positive ion analysis)or 4 °C MeOH: H2O, 80:20 w. 20 mM ammonium acetate (negative ion 
analysis).  
 Samples were sonicated for 5 min, vortex mixed for 30 sec and centrifuged at 1800 x g for 
10 min at 4°C to remove solid contaminants. 
 Without disturbing the sample, 20 µl of the supernatant was transferred by manual pipette 
into individual wells on a 384-well polymerase chain reaction (PCR) plate (ABgene, Thermo 
Fisher Scientific, USA), and covered immediately with strips of self-adhesive foil. 
 When all samples were loaded, the self-adhesive foil strips were replaced by a single heat 
sealed foil sheet (ALPS 50V, Thermo Fisher Scientific, USA). 
 
Non-polar samples 
 Samples were re-suspended on ice in 50 µl of 4 °C MeOH: H2O, 2:1 w. 5 mM ammonium 
acetate, for both ion modes.  
 Samples were vortex mixed for 30 sec and centrifuged at 1800 x g for 10 min at 4°C to 
remove solid contaminants. 
 The 384-well PCR plate was cooled on ice for 10 min before 10 µl of the supernatant was 
transferred by manual pipette with carbon pipette tips (Advion, USA) and covered 
immediately with strips of self-adhesive foil. 
 When all samples were loaded, the self-adhesive foil strips were replaced by a single heat 
sealed foil sheet (ALPS 50V, Thermo Fisher Scientific, USA). 
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G.3. FT-ICR mass spectrometry – acquisition of spectra 
Metabolomic analysis was performed using a hybrid 7-Tesla FT-ICR mass spectrometer (LTQ FT 
Ultra, Thermo Fisher Scientific, Bremen, Germany) via chip-based direct infusion 
nanoelectrospray ionisation (nESI) source (Triversa, Advion Biosciences, Ithaca NY) in both 
positive and negative ion mode. Nanoelectrospray conditions were controlled using ChipSoft 
software (version 8.1.0) and mass spectrometry conditions are controlled using Xcalibur 
software (version 2.0, Thermo Fisher Scientific). Conditions for both are listed in Table ‎G.1.  
To increase metabolome coverage and maintain mass accuracy, spectra were collected using 
the ‘SIM stitching’ methodology (220, 221, 319). Spectra are acquired as transients, across 
seven selected ion monitoring (SIM) mass ranges or ‘windows’ to cover a total mass range of 70 
– 590 Da for polar compounds (Figure ‎G.2) and 100-2000 Da for non-polar compounds 
(Figure ‎G.3). The individual SIM mass ranges overlap with each other by30 Da and are stitched 
together during data processing. Data from each sample was collected as both a Thermo.raw 
mass spectral file and as multiple individual transient files.  
Table ‎G.1 Nanoelectrospray and mass spectrometry conditions. 
Parameters Polar settings Non-polar setting 
 (+) (-) (+) (-) 
Nanoelectrospray conditions    
Flow rate (nl/ml) 200 200 200 200 
Gas pressure (PSI) 0.3 0.3 0.4 0.4 
Spray voltage (kV) +1.7 -1.7 +1.2 -1.2 
Mass spectrometry conditions 
No. of windows  7 7 7 7 
Window width (Da)  100 100 200-480 200-480 
Range (m/z) 70 – 590 70 – 590 100-2000 100-2000 
Automatic gain control 1 x 106 1 x 106 1 x 106 1 x 106 
Mass resolution 100,000 100,000 100,000 100,000 
Acquisition time (s)  2.25 2.25 2.5 2.5 
Sample volume (μl) 8 8 6 6 
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Figure ‎G.2 SIM-windows used during polar DI FT-ICR MS analysis. A typical pre-processing spectrum from umbilical cord blood metabolite 
extract is shown with SIM-windows and their corresponding range above in red. 
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Figure ‎G.3 SIM-windows used during non-polar DI FT-ICR MS analysis. A typical pre-processing spectrum from umbilical cord blood metabolite 
extract is shown with SIM-windows and their corresponding range above in red. 
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G.4. Processing mass spectral data 
Each.raw mass spectral files were assessed manually to ensure only spectra of sufficient quality 
were processed. Samples were removed based on eletrospray stability and the subsequent 
total ion current (TIC) profile. A failed electrospray current was perceived by a recording of zero 
in one or more scans in the TIC profile. For each patient sample a minimum of two replicates 
(two spectra per sample) were required to pass TIC inspection, otherwise the sample was re-
analysed on a subsequent plate.  
The SIM-stitch work flow was implemented using a custom written Matlab code (The 
MathWorks R2009a, Natick, MA) (221). The transients containing the mass spectral data were 
averaged and converted from a time to frequency domain. To yield a single spectrum for each 
replicate containing only real peaks, peak-picking was performed above a selected signal-to-
noise ratio threshold (SNR = 10) with regularly observed ‘high noise regions’ removed [74.04-
74.08, 90.5-90.53, 101.75-101.9, 105.3-105.4, 116.35-116.4]. External mass calibration was 
then used to convert the frequency domain to m/z values. Calibrants of known mass value 
were determined at the FT-ICR mass spectrometer’s weekly calibration and are contained in 
the instruments .RAW files. Next, for each individual replicate the seven SIM windows were 
‘stitched’ together into a single file via the alignment of peaks in overlapping (30 Da) windows. 
The overlap allowed the very outer regions of each SIM window to be removed. This file 
contains the frequency, resolution, intensity and SNR for each peak.  
A three step filtering process was used to enhance spectral reliability (221). First, a ‘replicate 
filter’ combined the replicate spectra for each sample to retain peaks which were present in a 
fraction of the spectra within an error range (<2ppm) but remove random noise and yield a 
single robust peak list per sample.  Secondly, a ‘blank filter’ removed peaks from the biological 
samples that were also present in the blank samples, namely a threshold of 10-fold was set 
such that peaks in the biological samples which were less than 10 fold greater than intensity in 
the blank sample were removed. Finally ‘sample filtering’ removed peaks not present in 80 % of 
the biological samples per single class.  
The resultant data file is displayed as an intensity matrix with rows and columns, corresponding 
to samples (quality control or biological) and m/z values of spectral features. Missing intensity 
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values may occurs in the matrix where no mass feature of sufficient intensity and 
reproducibility was detected at the specified m/z for a particular sample. To further enhance 
data quality samples with a high percentage of missing values were identified and removed, 
the sample filtering process was repeated to yield a refined matrix.  
Following US FDA guidelines, metabolites with a relative standard deviation for QC samples 
(RSDQC) of > 20% are considered to be below accepted quantification precision. To reduce inter 
and intra batch variation the Quality Control-Robust Spline Correction (QC-RSC) batch 
correction algorithm was applied in conjunction with three spectral cleaning algorithms (135) 
to remove unreliable, inconsistent or unreproducible (>20% RSDQC) features. A peak was 
removed if: (i) the difference in median intensity between QC samplesand biological sample 
intensity was inconsistent between batches, (ii) there was a relatively large difference in 
median intensity between the QC sample and biological sample (iii) if the technical variation of 
the peak was considered too high. 
The intensity matrix was processed further to allow statistical analyses. First, probable quotient 
normalisation (PQN) normalised the sample TICs to each other. This step is necessary due to 
differences in measured TIC arising from inherent sample differences that affect measurement 
by a mass spectrometer, for example minor differences in sample concentration, by using 
intensities of consistently arising peaks (224). For each peak present in 100% of samples, 
quotients of intensity over mean intensity across all spectra were calculated. The median of all 
quotients within a SIM-window was defined as the most probable quotient and used to 
normalise all peaks within that window. The intensity matrix can be dominated by the more 
intense peaks which have intrinsically higher variation. To normalise and reduce technical 
variation the dataset underwent logarithm (log10) transformation. Finally to allow for 
multivariate statistical analysis, any remaining missing intensity values were imputed using k-
nearest neighbour and the data was autoscaled (145).  
 
G.5. Putative metabolite annotation and pathway analysis 
A list of metabolic features containing their associated mean intensities was input into MI-Pack 
software (version 2 beta), and annotation was performed by applying the Metabolite 
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Identification Package (MI-Pack) workflow described previously (225). MI-Pack incorporates 
metabolomic databases for example, the Human Metabolome Database (HMDB) (117), Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) database (154) and Lipid Metabolites and 
Pathway Strategy (Lipid MAPS) database (153) to allow the putative annotation of features 
based on accurate mass. 
A single peak search was conducted using these databases, KEGG being restricted to the 
dedicated Homo sapiens (HSA) metabolite library, to putatively annotate metabolites. For polar 
features ‘Transformation mapping’ was also performed using the HSA subsection of the KEGG 
database to increase confidence in metabolite annotations. This method associates the 
empirical formula difference of a detected pair of peaks to a known difference between 
substrate-product pairs derived from a known metabolic pathway (225). A chain of linked 
metabolites in a single pathway would be deemed to have a higher level of confidence in the 
identification of each of the individual metabolites than alternative annotations which placed 
each metabolite in a different pathway. Where no putative annotations could be ascribed, the 
putative empirical formulae could be calculated based on the following conditions(225);  
 Thirteen atoms (C, 13C, H, N, O, P, S, 34S, NaCl, Na(37Cl), Ca, Fe, Cu),  
 Four positive ion adducts ([M+H]+, [M+Na]+,[M+K]+, [M+(41K)]+)or six negative ion adducts 
([M-H]-, [M+Na-2H]-,[M+K-2H]-, [M+(37Cl)]-, [M+Cl]-, [M+Hac-H]-) 
 Three isotopes C, S, Cl   
 Mass error of <1.25 ppm for polar and <2ppm for non-polar features 
It is important to remember that metabolite isomers may occur whereby several metabolites 
can be detected with the same accurate mass therefore a single metabolic feature may have 
multiple ‘identifications’. Likewise, multiple spectral features with different accurate masses 
can define a single metabolite, as different adducts can be formed from the same metabolite, 
for example ([M+H]+, [M+Na]+ or [M-H]-, [M+Hac-H]-). Herein, metabolic features were 
identified by putative annotation based on accurate mass, equivalent to ‘level 2’ identification 
as defined by The Metabolomics Standards Initiative (155).  
 
274 
 
Appendix H. Putatively annotated metabolic features 
Table ‎H.1 The identification parameters of putatively identified polar metabolic features, detected in both positive and negative ionisation 
mode, which were significantly altered (p<0.05) between perinatal asphyxia vs. matched control and/or HIE vs. matched control. (See Chapter 
3) 
m/z 
 Empirical 
Formula 
Ion form 
Theoretical 
mass 
Mass 
error %RSDQC Putative identifications 
(Da) (ppm) 
83.02159 CH4N2O [M+Na]
+ 60.032363 0.07 17 N-nitrosomethanamine OR Urea 
94.9904 C3H6O [M+K-2H]
- 58.041865 -0.75 9 Acetone OR Propanal 
94.99064 C2H4O2 [M+Cl]
- 60.02113 1.14 12 Acetate OR Glycolaldehyde 
113.02091 C3H6O3 [M+Na]
+ 90.031695 -0.06 17 Lactate OR 3-Hydroxypropanoate OR Glyceraldehyde (>3) 
115.03656 C3H8O3 [M+Na]
+ 92.047345 -0.06 13 Glycerol 
125.00092 C4H8O2 
OR 
C2H7O4P 
[M+K-2H]- 
OR 
[M-H]- 
88.05243 
OR 
126.008198 
-0.93 
OR 
-0.01 
9 2-Methylpropanoate OR Acetoin OR Butanoic acid 
OR  
Ethylphosphate  
127.01656 C7H6O 
OR 
C4H10O2 
[M+Na-2H]- 
OR 
[M+K-2H]- 
106.041865 
OR 
90.06808 
0.21 
OR 
-1 
9 Aromatic aldehyde 
OR  
2,3-Butanediol 
132.07674 C4H9N3O2 [M+H]
+ 131.069477 -0.1 12 3-Guanidinopropanoate OR Creatine 
132.94622 H3O4P [M+Cl]
- 97.976898 -0.6 7 Orthophosphate 
137.07092 C7H8N2O [M+H]
+ 136.063663 -0.14 9 N-Methylnicotinamide 
141.01582 C4H6O4 [M+Na]
+ 118.02661 -0.08 10 Methylmalonate OR Succinate OR Threonolactone (>3) 
148.00386 C2H7NO3S [M+Na]
+ 125.014666 -0.19 7 Taurine 
148.06041 C5H9NO4 [M+H]
+ 147.053159 -0.17 11 
Glutamate OR L-4-Hydroxyglutamate semialdehyde  
OR O-Acetyl-L-serine (>3) 
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151.04777 C5H8N2O2 [M+Na]
+ 128.058578 -0.19 8 5,6-Dihydrothymine OR γ-Amino-γ-cyanobutanoate 
154.08382 C6H13NO2 [M+Na]
+ 131.094629 -0.2 12 6-Aminohexanoate OR L-Isoleucine OR L-Leucine  (>3) 
159.02771 C5H4N4O [M+Na]
+ 136.038511 -0.14 11 Hypoxanthine 
164.07161 
OR 
204.04209 
C9H11NO2 
[M-H]- 
OR 
[M+K]+ 
165.078979 
-0.56 
OR 
-0.24 
8 
OR 
9 
4-Hydroxy-1-(3-pyridinyl)-1-butanone OR L-Phenylalanine OR  
3-Pyridinebutanoic acid  (>3) 
167.02099 C5H4N4O3 [M-H]
- 168.028341 -0.45 9 Urate 
167.03144 C6H8O4 [M+Na]
+ 144.04226 -0.25 13 
3-Hexenedioic acid OR 3-Methylglutaconic acid  
OR Methylitaconate (>3) 
170.09237 C7H11N3O2 [M+H]
+ 169.085127 -0.2 10 1-Methylhistidine OR N(pi)-Methyl-L-histidine 
171.02741 C5H10O5 [M+Na-2H]
- 150.052825 -0.49 5 2-Deoxyribonic acid OR D-Ribose OR D-Xylose  (>3) 
171.06275 C6H12O4 [M+Na]
+ 148.07356 -0.18 27 
(R)-2,3-Dihydroxy-3-methylpentanoate OR  
(R)-Mevalonate OR (R)-Pantoate 
181.03847 C5H10N2O3 [M+Cl]
- 146.069143 -0.41 12 3-Ureidoisobutyrate OR Glutamine OR Alanylglycine (>3) 
181.0471 C7H10O4 [M+Na]
+ 158.05791 -0.17 18 Isopropylmaleate OR Succinylacetone 
188.17571 C9H21N3O [M+H]
+ 187.168462 -0.15 9 N1-Acetylspermidine OR N8-Acetylspermidine 
191.01966 C6H8O7 
OR 
C4H4O5 
[M-H]- 
OR 
[M+Hac-H]- 
192.027005 
OR 
132.005875 
-0.36 
OR 
-0.36 
9 Citrate OR Isocitrate OR 5-Dehydro-4-deoxy-D-glucarate (>3) 
OR 
2-HydroxyethylenedicarboxylateOR Oxaloacetate OR trans-2,3-
Epoxysuccinate (>3) 
193.0471 C8H10O4 [M+Na]
+ 170.05791 -0.16 15 
1,2-Dihydroxy-6-methylcyclohexa-3,5-dienecarboxylate,  
1,6-Dihydroxy-5-methylcyclohexa-2,4-dienecarboxylate,  
2-Hydroxy-6-oxo-octa-2,4-dienoate (>3) 
196.05907 C7H13NO4 [M+Na-2H]
- 175.084459 -0.29 7 N-Carboxyethyl-g-aminobutyric acid 
197.09369 C9H18O2 [M+K]
+ 158.13068 -0.76 14 Nonanoic acid OR Oenanthic ether 
199.02234 C6H10O6 [M+Na-2H]
- 178.04774 -0.34 16 
3-Keto-beta-D-galactose OR  Galactonolactone  
OR L-Gulono-1,4-lactone (>3) 
199.97885 C5H9NOS2 
OR 
[M+(37Cl)]-
OR 
163.012558 
OR163.030
-0.8 
OR 
7 3-Methylsulfinylpropyl isothiocyanate 
OR  
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C5H9NO3S [M+K-2H]
- 316 -0.36 Acetylcysteine 
200.06825 C7H15NO3 
OR 
C10H11NO2 
[M+K]+ 
OR 
[M+Na]+ 
161.105194 
OR 
177.078979 
-0.52 
OR 
0.25 
13 
L-Carnitine 
OR 
1,2-Dehydrosalsolinol OR 5-Hydroxytryptophol 
201.01594 C6H10O5 
OR  
C4H9O7P 
[M+K]+ 
OR 
 [M+H]+ 
162.052825 
OR 
200.008593 
-0.22 
OR 
0.35 
16 
(2R,3S)-2,3-Dimethylmalate OR 2(R)-Hydroxyadipic acid  OR Glucosan (>3) 
OR  
D-Erythrose 4-phosphate (>3) 
203.03158 C9H8O4 
 
OR 
C6H12O5 
[M+Na]+ 
 
OR 
[M+K]+ 
180.04226 
 
OR 
164.068475 
0.49  
 
OR 
-0.27 
10 3-(4-Hydroxyphenyl)pyruvate OR Caffeate OR 3-Hydroxyphenylpyruvic acid 
(>3) 
OR 
1,5-Anhydro-D-glucitol OR L-Rhamnose OR 2-Deoxy-D-galactose (>3) 
204.06656 C11H11NO3 [M-H]
- 205.073894 -0.28 8 5-Methoxyindoleacetate OR Cinnamoylglycine OR Indolelactate 
204.99449 C6H6N4S [M+K]
+ 166.031318 0.06 8 6-Methylmercaptopurine 
205.01749 C11H8N2 [M+K-2H]
- 168.068748 0.66 6 Beta-Carboline 
205.0471 C9H10O4 [M+Na]
+ 182.05791 -0.15 7 
3,4-Dihydroxyphenylpropanoate OR 3-(2,3-Dihydroxyphenyl)propanoate 
OR 3-(4-Hydroxyphenyl)lactate (>3) 
205.06822 
OR 
241.09284 
C6H14O6 
[M+Na]+ 
OR 
[M+Hac-H]- 
182.07904 
-0.2 
OR 
-0.22 
6 
OR 
7 
D-Sorbitol OR Galactitol OR Mannitol (>3) 
209.06662 C7H14O7 
OR 
C11H12N2 
[M-H]- 
OR 
[M+(37Cl)]- 
210.073955 
OR 
172.100048 
-0.28 
OR 
0.58 
12 Sedoheptulose  
OR  
1,2,3,4-tetrahydro-beta-carboline 
209.09203 C10H12N2O3 [M+H]
+ 208.084793 -0.19 10 Formyl-5-hydroxykynurenamine OR L-Kynurenine 
212.00226 C8H7NO4S [M-H]
- 213.009581 -0.21 6 Indoxyl sulfate 
213.07469 C6H14N4O2 [M+K]
+ 174.111676 -0.68 12 D-Arginine OR L-Arginine 
214.04745 C7H13NO4 
OR 
C10H9NO3 
[M+K]+ 
OR 
[M+Na]+ 
175.084459 
OR 
191.058244 
-0.79 
OR 
-0.07 
6 N-Carboxyethyl-g-aminobutyric acid  
OR 
5-Hydroxyindoleacetate OR 5-Phenyl-1,3-oxazinane-2,4-dione 
215.01757 C4H8N4O4 [M+K]
+ 176.054556 -0.68 10 Allantoate 
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217.06239 C11H14O2 [M+K]
+ 178.09938 -0.69 13 5-Phenylvaleric acid 
219.0265 
C9H8O5 
OR 
C6H12O6 
[M+Na]+ 
OR 
[M+K]+ 
196.037175 
OR 
180.06339 
0.47 
OR 
-0.23 
6 
3-(3,4-Dihydroxyphenyl)pyruvate  
OR  
D-Glucose OR 3-Deoxyarabinohexonic acid OR myo-Inositol (>3) 
219.04168 C10H12O3 [M+K]
+ 180.078645 -0.57 12 3-Methoxybenzenepropanoic acid OR Coniferyl alcohol 
220.03701 C9H11NO3 [M+K]
+ 181.073894 -0.2 7 
4-Hydroxy-4-(3-pyridyl)-butanoic acid OR L-Threo-3-Phenylserine  
OR L-Tyrosine (>3) 
225.03456 C9H12O4 [M+(41K)]
+ 184.07356 -1.23 9 
3-Methoxy-4-hydroxyphenylethyleneglycol OR 
cis-3-(Carboxy-ethyl)-3,5-cyclo-hexadiene-1,2-diol 
225.06151 C5H10O6 [M+Hac-H]
- 166.04774 -0.37 13 D-Xylonate OR L-Arabinonate OR D-Ribonate 
226.10498 C9H17NO4 [M+Na]
+ 203.115759 0 8 L-Acetylcarnitine 
227.07910 C8H16N2O3 
OR 
C11H12N2O2 
[M+K]+ 
OR 
[M+Na]+ 
188.116093 
OR 
204.089878 
-0.67 
OR 
0 
6 Glycyl-leucine OR N-Alpha-acetyllysine OR N6-Acetyl-L-lysine 
OR 
D-Tryptophan  
232.05918 C10H13NO4 [M+Na-2H]
- 211.084459 0.23 9 3-Methoxytyrosine OR Methyldopa anhydrous 
232.15433 C11H21NO4 [M+H]
+ 231.147059 -0.02 7 Isobutyryl-L-carnitine OR O-Butanoylcarnitine  
233.07853 C11H14O4 [M+Na]
+ 210.08921 0.42 30 Sinapyl alcohol 
233.11482 C12H18O3 [M+Na]
+ 210.125595 0.02 14 (+)-7-Isojasmonic acid OR (-)-Jasmonic acid 
235.13046 C12H20O3 [M+Na]
+ 212.141245 -0.03 15 12-Oxo-9(Z)-dodecenoic acid OR, Traumatin 
237.14611 C12H22O3 [M+Na]+ 214.156895 -0.03 17 3-Oxododecanoic acid 
241.01200 C7H10O7 
 
OR 
C6H11O8P 
[M+Cl]- 
 
OR 
M-H]- 
206.042655  
 
OR 
242.019158 
-0.23  
 
OR 
0.49 
10 (R)-2-Hydroxybutane-1,2,4-tricarboxylate OR 2-Methylcitrate OR 
Homoisocitrate(>3) 
OR 
6-Deoxy-5-ketofructose 1-phosphate OR D-myo-Inositol 1,2-cyclic 
phosphate  
267.05878O
R 
243.06225 
C9H12N2O6 
[M+Na]+ 
OR 
[M-H]- 
244.069538 
0.08 
OR 
-0.05 
7 
OR 
10 
Pseudouridine OR Uridine  
247.13046 C13H20O3 [M+Na]
+ 224.141245 -0.03 15 (+)-7-Isomethyljasmonate OR Methyl jasmonate 
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255.09918 C11H20O4 [M+K]
+ 216.13616 -0.55 9 Undecanedioic acid 
255.13569 C12H24O3 [M+K]
+ 216.172545 -0.06 35 
(R)-3-Hydroxydodecanoic acid OR 12-Hydroxydodecanoic acid  
OR 3-Hydroxydodecanoic acid  
262.12852 C11H19NO6 [M+H]
+ 261.121239 0.02 14 Methylglutarylcarnitine 
262.97611 C6H11O6PS [M+Na-2H]
- 242.0014 0.16 8 
2,3-Diketo-5-methylthiopentyl-1-phosphate OR  
2-Hydroxy-3-keto-5-methylthiopentenyl-1-phosphate 
263.00829 
OR 
298.94947 
C5H12O8P2 
[M+H]+ 
OR 
[M+K-2H]- 
262.000746 
1.02 
OR 
0.39 
5 
OR 
8 
1-Hydroxy-2-methyl-2-butenyl 4-diphosphate 
265.17741 C14H26O3 [M+Na]
+ 242.188195 -0.02 11 3-Oxotetradecanoic acid 
265.21381 C15H30O2 [M+Na]
+ 242.22458 0.03 12 Pentadecanoic acid 
267.1567 C13H24O4 [M+Na]
+ 244.16746 0.07 11 1,11-Undecanedicarboxylic acid 
269.08776 C13H16N2O2 [M+(37Cl)]
- 232.121178 0.48 17 Melatonin 
276.14418 C12H21NO6 [M+H]
+ 275.136889 0.05 23 Glutarylcarnitine 
280.09207 C8H20NO6P [M+Na]
+ 257.102827 0.08 9 Glycerophosphocholine 
293.24513 C17H34O2 [M+Na]
+ 270.25588 0.1 11 Heptadecanoic acid 
       
307.26083 C18H36O2 [M+Na]
+ 284.27153 0.26 21 Octadecanoic acid 
308.09868 C11H19NO9 [M-H]
- 309.105984 -0.09 13 N-Acetylneuraminate 
325.17765 C19H26O3 
 
OR 
C16H30O4 
[M+Na]+ 
 
OR 
[M+K]+ 
302.188195 
 
OR 
286.21441 
0.72  
 
OR 
0.25 
18 11beta-Hydroxyandrost-4-ene-3,17-dione OR 19-Oxotestosterone OR 2-
Methoxyestradiol-17beta(>3) 
OR  
Hexadecanedioic acid  
329.04344 C14H14O7 [M+Cl]
- 294.073955 0.25 9 Cyclic de-hypoxanthine futalosine 
330.9958 C6H14O10P2 [M+Na]
+ 308.006226 1.07 6 (R)-5-Diphosphomevalonate OR (R)-Mevalonic acid-5-pyrophosphate  
331.04028 C15H14O6 [M+(41K)]
+ 290.07904 -0.11 6 (+)-Catechin OR (-)-Epicatechin OR cis-3,4-Leucopelargonidin  
367.15846 C19H28O5S [M-H]
- 368.165747 -0.03 4 
Dehydroepiandrosterone sulfate OR Epitestosterone sulfate  
OR Testosterone sulfate  
373.02921 C9H19O11P [M+K]
+ 334.066503 -1.21 7 sn-glycero-3-Phospho-1-inositol  
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383.15335 C19H28O6S [M-H]
- 384.160662 -0.09 5 3b,16a-Dihydroxyandrostenone sulfate 
389.03021 C12H16O12 [M+(37Cl)]
- 352.06418 -1.08 5 4-(4-Deoxy-alpha-D-gluc-4-enuronosyl)-D-galacturonate 
395.18974 C21H32O5S [M-H]
- 396.197047 -0.08 8 Pregnenolone sulfate 
416.27487 C24H41NO2 [M+(41K)]
+ 375.313729 -0.33 10 7,10,13,16-Docosatetraenoylethanolamine 
425.08048 C13H22N4O8S2 [M-H]
- 426.08791 -0.36 10 Cysteineglutathione disulfide OR S-Glutathionyl-L-cysteine 
426.02184 C12H16N5O8P 
OR 
C10H15N5O10P2 
[M+K-2H]- 
OR 
[M-H]- 
389.073653 
OR 
427.029421 
-0.98 
OR 
-0.71 
14 ADP OR dGDP OR Adenosine 3',5-bisphosphate 
OR 
Acetyl adenylate 
441.15886 C19H26O6S [M+Hac-H]
- 382.145012 -0.01 9 2-Methoxyestradiol-17beta 3-sulfate 
471.03289 C10H14N4O10P2 [M+Hac-H]
- 412.018522 1.09 6 dIDP 
502.94334 C9H15N2O14P3 [M+Cl]
- 467.973622 0.63 6 dUTP 
519.29317 C27H44O8 [M+Na]
+ 496.30362 0.63 6 
3-alpha,20-alpha-dihydroxy-5-beta-pregnane 3-glucuronide OR 
Pregnanediol-3-glucuronide 
524.92947 C9H15N2O15P3 [M+(41K)]
+ 483.968537 -0.65 17 UTP 
531.96968 C10H18N3O14P3 [M+Cl]
- 497.000171 0.2 7 2-Deoxy-5-hydroxymethylcytidine-5-triphosphate 
534.29592 C24H50NO7P [M+K]
+ 495.332492 0.5 8 LysoPC(16:0) 
557.25259 C33H34N4O3 [M+Na]
+ 534.263091 0.5 7 Pyropheophorbide a 
(>3); indicates more than three possible putative annotations, OR; indicates more than one possible empirical formulae or multiple adducts.  
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Table ‎H.2The identification parameters of putatively identified non-polar metabolic features, detected in both positive and negative ionisation 
mode, which were significantly altered (p<0.05) between perinatal asphyxia vs. matched control and/or HIE vs. matched control. (See Chapter 
4) 
m/z Formula Ion form 
Theoretical 
mass 
Mass 
error %RSDQC Putative identifications 
(Da) (ppm) 
179.05739 C7H8N4O2 [M-H]
- 180.064726 -0.33 14 1,7-Dimethylxanthine, Theobromine, Theophylline 
223.17032 C14H24O2 [M-H]
- 224.17763 -0.15 9 14:2(6,9), 5,8-Tetradecadienoic acid, Alepric acid, R-cucujolide III(>3) 
235.18054 C14H22N2O [M+H]
+ 234.173213 0.22 26 Lidocaine 
251.20166 C16H28O2 [M-H]
- 252.20893 0.03 10 7,10-hexadecadienoic acid, 7Z,10Z-Hexadecadienoic acid, Palmitolinoleic 
acid(>3) 
261.22135 C18H28O [M+H]
+ 260.214015 0.22 10 4,5-(methanoxyethano)isolongifol-4-ene, 5-(1-oxopropan-2-yl)isolongifol-5-
ene 
271.24208 C20H30 [M+H]
+ 270.23475 0.2 10 Axerophthene, Erogorgiaene 
277.21731 C18H30O2 [M-H]
- 278.22458 0.02 15  (6Z,9Z,12Z)-Octadecatrienoic acid, Crepenynate, octadeca-9Z,11E,15Z-
trienoic acid(>3) 
315.20965 C18H32O2 [M+Cl]
- 280.24023 0.06 19 (R)-laballenic acid, 7-trans,9-cis-octadecadienoic acid, Linoelaidic acid(>3) 
319.22247 C18H34O2 [M+(37Cl)]
- 282.25588 0.43 18 (11E)-Octadecenoic acid, 17:1(12)(7Me), cis-10-oleic acid(>3) 
319.22783 C20H32O3 [M-H]
- 320.235145 -0.12 7 18-Hydroxyarachidonic acid, 11(R)-HETE, 14,15-EET(>3) 
325.23844 C19H34O4 [M-H]
- 326.24571 0.02 18 Ceriporic acid A 
344.27963 C19H37NO4 [M+H]
+ 343.272259 0.27 11 N-palmitoyl serine 
359.29559 C24H40O2 [M-H]
- 360.30283 0.1 10 5alpha-Cholanoic acid, 5beta-Cholanoic acid, Tetracosatetraenoic acid 
(24:4n-6)(>3) 
363.25168 C20H38O4 [M+Na-2H]
- 342.27701 0 13 Eicosanedioic acid, PGF1a alcohol 
281 
 
372.31094 C21H41NO4 [M+H]
+ 371.303559 0.28 9 N-stearoyl serine 
381.30108 C21H38O2 [M+Hac-H]
- 322.28718 0.12 8 21:2(5Z,14Z), 21:2(5Z,16Z) 
385.23605 C22H36O4 [M+Na-2H]
- 364.26136 0.06 23 11-deoxy-16,16-dimethyl-PGE2, 16,16-dimethyl-PGA1 
389.23348 C21H30O3 
OR  
C23H34O5 
[M+Hac-H]- 
OR  
[M-H]- 
330.219495 
OR  
390.240625 
0.34 
OR  
0.34 
10 11-Deoxycorticosterone, 11alpha-hydroxyprogesterone, 17alpha-
Hydroxyprogesterone(>3) OR  
15R-PGA2 methyl ester, 15-acetate, Digoxigenin 
395.18983 C21H32O5S [M-H]
- 396.197047 0.15 16 3beta-Hydroxypregn-5-en-20-one sulfate 
395.31671 C22H40O2 [M+Hac-H]
- 336.30283 0.07 9 13,16-Docosadienoic acid, 22:2(3Z,16Z), 22:2(7Z,13Z)(>3) 
400.34225 C23H45NO4 [M+H]
+ 399.334859 0.29 8 L-Palmitoylcarnitine 
407.20756 C20H28O5 [M+Hac-H]
- 348.193675 0.08 31 12-oxo-Resolvin E1, 18-oxo-Resolvin E1, Gibberellin A14(>3) 
413.3061 
OR  
415.32089 
C27H42O3 
[M-H]- 
OR  
[M+H]+ 
414.313395 
-0.05 
OR  
0.53 
11 
OR  
11 
(22E)-(24R)-1alpha,24-dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24R)-
1alpha,24-dihydroxy-22,23-didehydrocholecalciferol, (22E)-(24R)-24,25-
dihydroxy-22,23-didehydrovitamin D3 / (22E)-(24R)-24,25-dihydroxy-22,23-
didehydrocholecalciferol(>3) 
421.33245 C24H42O2 [M+Hac-H]
- 362.31848 0.28 9 24:3(15Z,18Z,21Z) 
433.36787 C28H48O3 [M+H]
+ 432.360345 0.57 13 22,23-dihydroxycampesterol, 3-Dehydro-6-deoxoteasterone, Cathasterone 
435.20253 C21H28O6 [M+Hac-H]
- 376.18859 0.2 18 18-Oxocortisol 
437.32729 C24H42O3 [M+Hac-H]
- 378.313395 0.09 15 C-9,11,21-Trisnor-17-methyl-1alpha,25-dihydroxyvitamin D3 
447.34715 C28H46O4 [M+H]
+ 446.33961 0.59 12 3-Dehydroteasterone, (20S)-1alpha,20,25-trihydroxy-24a-homovitamin D3 / 
(20S)-1alpha,20,25-trihydroxy-24a-homocholecalciferol, (20S)-1alpha,25-
dihydroxy-20-methoxyvitamin D3 / (20S)-1alpha,25-dihydroxy-20-
methoxycholecalciferol(>3) 
449.36287 C28H48O4 [M+H]
+ 448.35526 0.74 10 Chlorogenin, Teasterone, Typhasterol 
463.34297 C26H44O3 
 
[M+Hac-H]- 
 
404.329045 
 
0.15 
 
14 1,25-dihydroxy-2-nor-1,2-secovitamin D3 / 1,25-dihydroxy-2-nor-1,2-
secocholecalciferol, 1alpha,25-dihydroxy-19-norvitamin D3 / 1alpha,25-
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OR  
C28H48O5 
 
OR  
[M-H]- 
 
OR  
464.350175 
 
OR  
0.15 
dihydroxy-19-norcholecalciferol, 2-Nor-1,3-seco-1alpha,25-
dihydroxyvitamin D3  OR  
7-oxotyphasterol, Castasterone,Trihydroxycoprostanoic acid(>3) 
476.27823 C23H44NO7P 
OR  
C28H41NO4 
[M-H]- 
OR  
[M+Na-2H]- 
477.285542 
OR  
455.303559 
-0.07 
OR  
0.01 
9 LysoPE(18:2(9Z,12Z)/0:0) 
OR  
15-HETE-DA, 15-HETE-VA 
478.2939 C23H46NO7P [M-H]
- 479.301192 -0.03 7 LysoPE(18:1(9Z)/0:0), PC(15:1(9Z)/0:0) 
480.30949 C23H48NO7P [M-H]
- 481.316842 -0.16 5 LysoPC(15:0), LysoPE(18:0/0:0), PC(14:0/O-1:0) (>3) 
481.29926 C27H46O5S [M-H]
- 482.306597 -0.13 20 26-hydroxycholesterol 3-sulfate 
494.32444 C24H48NO7P [M+H]
+ 493.316842 0.65 10 LysoPC(16:1(9Z)), PC(16:1(9E)/0:0), PE(19:1(9Z)/0:0) 
497.2941 C30H42N2O2 [M+Cl]
- 462.324628 0.14 18 Arachidonoyl Serotonin 
498.29743 C24H48NO6P [M+Na-2H]
- 477.321927 1.67 16 PE(P-19:1(12Z)/0:0) 
500.27813 C25H44NO7P 
OR  
C26H43NO6 
[M-H]- 
OR  
[M+Cl]- 
501.285542 
OR  
465.309039 
-0.27 
OR  
-0.62 
9 LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0) 
OR  
3a,7b,12a-Trihydroxyoxocholanyl-Glycine, Glycocholate 
501.28136 C27H46O4S [M+Cl]
- 466.311682 0.55 9 Cholesterol sulfate 
502.29373 C23H50N2O5P 
OR 
C25H46NO7P 
[M+K-2H]- 
OR 
[M-H]- 
465.345736 
OR 
503.301192 
-1.22 
OR 
-0.37 
9 Sphingosyl-phosphocholine 
OR 
LysoPE(20:3(8Z,11Z,14Z)/0:0) 
508.34073 C25H52NO7P [M-H]
- 509.348142 -0.27 10 LysoPC(17:0), LysoPE(20:0/0:0), PC(16:0/O-1:0) (>3) 
512.29935 C21H44NO7P [M+Hac-H]
- 453.285542 -0.09 13 LysoPE(16:0/0:0), PC(13:0/0:0) 
518.32194 C24H50NO7P [M+Na]
+ 495.332492 0.44 12 LysoPC(16:0), PC(0:0/16:0), PC(16:0/0:0)rac, PE(19:0/0:0) (>3) 
520.34005 
OR 
542.32182 
C26H50NO7P 
[M+H]+ 
OR 
[M+Na]+ 
519.332492 
0.54 
OR 
0.2 
9 
OR 
18 
LysoPC(18:2(9Z,12Z)), PC(18:2(2E,4E)/0:0) 
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522.35569 C26H52NO7P [M+H]
+ 521.348142 0.52 9 LysoPC(18:1(9Z)), PC(0:0/18:1(6Z)), PC(0:0/18:1(9E)) (>3) 
524.2781 C27H44NO7P [M-H]
- 525.285542 -0.32 8 LysoPE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) 
527.29682 C30H50O3S [M+K-2H]
- 490.348067 0.28 20 26,27-diethyl-1alpha,25-dihydroxy-22-thia-20-epivitamin D3 / 26,27-diethyl-
1alpha,25-dihydroxy-22-thia-20-epicholecalciferol, 26,27-diethyl-1alpha,25-
dihydroxy-22-thiavitamin D3 / 26,27-diethyl-1alpha,25-dihydroxy-22-
thiacholecalciferol 
538.31485 C25H50NO9P [M-H]
- 539.322322 -0.36 14 PS(19:0/0:0) 
546.35584 C28H52NO7P [M+H]
+ 545.348142 0.77 10 LysoPC(20:3(8Z,11Z,14Z)) 
547.35917 C31H54O5 [M+(41K)]
+ 506.397125 1.4 11 (20R)-24-Hydroxy-19-norgeminivitamin D3, (20S)-24-Hydroxy-19-
norgeminivitamin D3 
547.43656 C34H60O5 [M-H]
- 548.444075 -0.44 14 DG(13:0/18:3(9Z,12Z,15Z)/0:0)iso2, DG(14:1(9Z)/17:2(9Z,12Z)/0:0)iso2 
547.47239 C35H62O4 [M+H]
+ 546.46481 0.55 9 bacteriohopane-32,33,34,35-tetrol 
549.48863 
OR 
551.50371 
C35H66O4 
[M-H]- 
OR 
[M+H]+ 
550.49611 
-0.37 
OR 
0.59 
10 
 OR 
9 
1-O-(1Z-Tetradecenyl)-2-(9Z-octadecenoyl)-sn-glycerol 
559.47286 C34H60O2 
OR 
C36H64O4 
[M+Hac-H]- 
OR 
[M-H]- 
500.45933 
OR 
560.48046 
-0.58 
OR 
-0.58 
14 34:4(19Z,22Z,25Z,28Z), Linolenyl palmitatoleate, Palmitoleyl linolenate OR 
 2-methylbacteriohopane-32,33,34,35-tetrol, Mayolene-18 
561.48858 C34H62O2 [M+Hac-H]
- 502.47498 -0.45 12 Linolenyl palmitate, Linoleyl palmitatoleate, Palmitoleyl linoleate(>3) 
563.50427 C34H64O2 [M+Hac-H]
- 504.49063 -0.38 14 Linoleyl palmitate, Oleyl palmitoleate, Palmitoleyl oleate(>3) 
568.34011 C30H50NO7P [M+H]
+ 567.332492 0.6 9 LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
649.50491 C37H66O5 [M+Hac-H]
- 590.491025 0.05 7 DG(12:0/22:3(10Z,13Z,16Z)/0:0)iso2, DG(14:0/20:3(8Z,11Z,14Z)/0:0), 
DG(14:1(9Z)/20:2(11Z,14Z)/0:0) (>3) 
661.50495 C38H66O5 [M+Hac-H]
- 602.491025 0.11 20 DG(13:0/22:4(7Z,10Z,13Z,16Z)/0:0)iso2, DG(15:0/20:4(5Z,8Z,11Z,14Z)/0:0), 
DG(15:1(9Z)/20:3(8Z,11Z,14Z)/0:0)iso2(>3) 
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663.52043 C38H68O5 [M+Hac-H]
- 604.506675 -0.15 10 DG(13:0/22:3(10Z,13Z,16Z)/0:0)iso2, DG(15:0/20:3(8Z,11Z,14Z)/0:0), 
DG(15:1(9Z)/20:2(11Z,14Z)/0:0)iso2(>3) 
665.53613 C38H70O5 [M+Hac-H]
- 606.522325 -0.07 13 DG(13:0/22:2(13Z,16Z)/0:0)iso2, DG(15:0/20:2(11Z,14Z)/0:0), 
DG(15:1(9Z)/20:1(11Z)/0:0)iso2(>3) 
675.54389 C37H75N2O6P [M+H]
+ 674.536276 0.5 10 SM(d16:1/16:0), SM(d18:1/14:0) 
677.53619 C39H70O5 [M+Hac-H]
- 618.522325 0.02 12 DG(14:0/22:3(10Z,13Z,16Z)/0:0)iso2, DG(14:1(9Z)/22:2(13Z,16Z)/0:0), 
DG(16:0/20:3(8Z,11Z,14Z)/0:0) (>3) 
685.52906 C38H75N2O6P [M-H]
- 686.536276 0.09 12 SM(d18:2/15:0) 
687.54457 C38H77N2O6P [M-H]
- 688.551926 -0.12 13 Etn-1-P-Cer(d14:1/18:0), SM(d16:1/17:0), SM(d18:1/15:0) 
706.53855 C38H76NO8P [M+H]
+ 705.530857 0.59 4 PC(20:0/10:0), PC(9:0/21:0), PE(12:0/21:0) (>3) 
707.54195 C41H78O6 [M+(41K)]
+ 666.57984 1.18 4 TG(12:0/12:0/14:0)iso3, TG(12:0/13:0/13:0)iso3 
715.57586 C40H81N2O6P [M-H]
- 716.583226 -0.13 30 SM(d18:1/17:0), SM(d19:1/16:0) 
715.62211 C44H84O5 
OR 
C46H82O5 
[M+Na]+ 
OR 
[M+H]+ 
692.631875 
OR 
714.616225 
1.42 
OR 
-1.94 
9 DG(19:0/22:1(13Z)/0:0)iso2, DG(19:1(9Z)/22:0/0:0)iso2, 
DG(20:1(11Z)/21:0/0:0)iso2 OR 
DG(21:0/22:4(7Z,10Z,13Z,16Z)/0:0)iso2 
716.52346 C39H76NO8P [M-H]
- 717.530857 -0.17 29 PC(19:1(9Z)/12:0), PE(12:0/22:1(11Z)), PE(14:0/20:1(11Z)) (>3) 
716.55939 C40H78NO7P 
OR 
C45H75NO4 
[M+H]+ 
OR 
[M+Na]+ 
715.551592 
OR 
693.569609 
0.73 
OR 
0.78 
13 PC(O-14:0/18:2(9Z,12Z)), PE(O-18:0/17:2(9Z,12Z)), PE(P-16:0/19:1(9Z)) (>3) 
OR 
Cholesteryl nitrolinoleate 
719.59811 C46H76O2 [M+Hac-H]
- 660.58453 -0.38 8 Ergosteryl oleate 
726.66159 C42H85NO4 [M+Hac-H]
- 667.647859 -0.17 13 Cer(d18:0/h24:0), Cer(t18:0/24:0) 
718.5392 
OR 
720.55434 
C39H78NO8P 
[M-H]- 
OR 
[M+H]+ 
719.546507 
-0.04 
OR 
0.77 
24 
OR 
9 
PC(21:0/10:0), PC(9:0/22:0), PE(12:0/22:0) 
730.53876 C40H76NO8P [M+H]
+ 729.530857 0.86 7 PC(20:2(11Z,14Z)/12:0), PE(13:0/22:2(13Z,16Z)), PE(15:0/20:2(11Z,14Z)) (>3) 
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730.53914 C40H78NO8P [M-H]
- 731.546507 -0.12 9 PC(12:0/20:1(11Z)), PC(13:0/19:1(9Z)), PE(22:1(11Z)/13:0)(>3) 
732.55508 C38H76NO6P 
OR 
C40H80NO8P 
[M+Hac-H]- 
OR 
[M-H]- 
673.541027 
OR 
733.562157 
0.27 
OR 
0.27 
11  CerP(d18:1/20:0) 
OR 
PC(10:0/22:0), PE(22:0/13:0) (>3) 
733.5498 C49H76O2 [M+(37Cl)]
- 696.58453 -1.61 11 22:6 Cholesteryl ester 
742.57485 C42H80NO7P [M+H]
+ 741.567242 0.45 5 PC(O-16:0/18:3(6Z,9Z,12Z)), , PC(P-16:0/18:2(9Z,12Z)), PE(P-
20:0/17:2(9Z,12Z)) (>3) 
744.55417 C41H78NO8P [M+H]
+ 743.546507 0.52 5 PC(13:0/20:2(11Z,14Z)), PC(14:1(9Z)/19:1(9Z)), PE(22:2(13Z,16Z)/14:0) (>3) 
746.56995 C41H80NO8P [M+H]
+ 745.562157 0.69 5 PC(13:0/20:1(11Z)), PC(14:0/19:1(9Z)), PE(22:1(11Z)/14:0) (>3) 
747.57334 C44H82O6 [M+(41K)]
+ 706.61114 1.24 9 TG(12:0/12:0/17:1(9Z))iso3, TG(12:0/13:0/16:1(9Z))iso6, 
TG(12:0/14:0/15:1(9Z))iso6(>3) 
753.56307 
OR 
757.55715 
C45H80O6 
[M+(37Cl)]- 
OR 
[M+(41K)]+ 
716.59549 
1.5 
OR 
0.51 
9 
OR 
4 
TG(12:0/12:0/18:3(6Z,9Z,12Z))iso3, TG(12:0/12:0/18:3(9Z,12Z,15Z))iso3, 
TG(14:1(9Z)/14:1(9Z)/14:1(9Z)) 
756.55372 C42H78NO8P [M+H]
+ 755.546507 -0.08 4 PC(14:0/20:3(8Z,11Z,14Z)), PC(14:1(9Z)/20:2(11Z,14Z)), 
PE(22:2(13Z,16Z)/15:1(9Z)) (>3) 
757.62281 C43H87N2O6P [M-H]
- 758.630176 -0.12 8 SM(d16:1/22:0), SM(d18:1/20:0) 
770.57039 C43H80NO8P [M+H]
+ 769.562157 1.24 10 PC(15:0/20:3(8Z,11Z,14Z)), PC(15:1(9Z)/20:2(11Z,14Z)), 
PE(22:2(13Z,16Z)/16:1(9Z)) (>3) 
770.60732 C44H84NO7P [M+H]
+ 769.598542 1.95 5 PC(O-16:0/20:3(8Z,11Z,14Z)), PC(O-18:0/18:3(6Z,9Z,12Z)), PC(O-
18:0/18:3(9Z,12Z,15Z)) (>3) 
772.58547 C43H82NO8P [M+H]
+ 771.577807 0.5 4 PC(13:0/22:2(13Z,16Z)), PC(15:0/20:2(11Z,14Z)), PE(22:2(13Z,16Z)/16:0) 
(>3) 
773.58881 C46H84O6 [M+(41K)]
+ 732.62679 0.96 8 TG(12:0/13:0/18:2(9Z,12Z))iso6, TG(12:0/14:0/17:2(9Z,12Z))iso6, 
TG(12:0/14:1(9Z)/17:1(9Z))iso6(>3) 
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774.60122 
OR 
832.60842 
C43H84NO8P 
[M+H]+ 
OR 
[M+Hac-H]- 
773.593457 
0.63 
OR 
1.33 
5 
OR 
10 
PC(13:0/22:1(11Z)), PC(14:1(9Z)/21:0), PE(22:1(11Z)/16:0) (>3) 
775.60451 C46H86O6 [M+(41K)]
+ 734.64244 1.02 5 TG(12:0/12:0/19:1(9Z))iso3, TG(12:0/13:0/18:1(9Z))iso6, 
TG(12:0/14:0/17:1(9Z))iso6(>3) 
776.54452 C41H80NO10P [M-H]
- 777.551987 -0.25 18 PS(13:0/22:0), PS(14:0/21:0), PS(15:0/20:0) (>3) 
780.55289 C42H80NO8P 
OR 
C44H78NO8P 
[M+Na]+ 
OR 
[M+H]+ 
757.562157 
OR 
779.546507 
1.94 
OR 
-1.14 
7 PC(12:0/22:2(13Z,16Z)), PE(22:2(13Z,16Z)/15:0), PE-NMe(18:1(9E)/18:1(9E)) 
(>3) OR 
PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)), PC(16:0/20:5(5Z,8Z,11Z,14Z,17Z)),  
PE(22:4(7Z,10Z,13Z,16Z)/17:1(9Z)) (>3) 
781.55635 C47H80O6 [M+(41K)]
+ 740.59549 -0.53 6 TG(12:0/12:0/20:5(5Z,8Z,11Z,14Z,17Z))iso3, 
TG(12:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))iso6 
783.63741 
OR 
841.64374 
C45H87N2O6P 
[M+H]+ 
OR 
[M+Hac-H]- 
782.630176 
-0.05 
OR 
-0.34 
6 
OR 
9 
 SM(d18:2/22:1) 
784.58616 C44H82NO8P [M+H]
+ 783.577807 1.37 4 PC(14:1(9Z)/22:2(13Z,16Z)), PC(16:0/20:3(5Z,8Z,11Z)), 
PE(22:2(13Z,16Z)/17:1(9Z)) (>3) 
785.58902 C47H84O6 [M+(41K)]
+ 744.62679 1.21 4 TG(12:0/12:0/20:3(8Z,11Z,14Z))iso3, TG(12:0/14:0/18:3(6Z,9Z,12Z))iso6, 
TG(12:0/14:0/18:3(9Z,12Z,15Z))iso6 (>3) 
792.59052 C46H82NO7P [M+H]
+ 791.582892 0.44 5 PC(P-18:0/20:5(5Z,8Z,11Z,14Z,17Z)), PC(o-
16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
793.59386 C43H85O10P [M+H]
+ 792.588038 -1.83 5 PG(15:0/22:0), PG(16:0/21:0), PG(17:0/20:0) (>3) 
794.57036 C45H80NO8P [M+H]
+ 793.562157 1.17 7 PC(15:1(9Z)/22:4(7Z,10Z,13Z,16Z)),PC(20:5(5Z,8Z,11Z,14Z,17Z)/17:0), 
PE(20:1(11Z)/20:4(5Z,8Z,11Z,14Z)) (>3) 
798.6023 C45H84NO8P [M+H]
+ 797.593457 1.96 6 PC(15:1(9Z)/22:2(13Z,16Z)), PC(17:0/20:3(8Z,11Z,14Z)),  
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PE(22:2(13Z,16Z)/18:1(9Z)) (>3) 
806.56984 C46H80NO8P [M+H]
+ 805.562157 0.5 6 PC(16:0/22:6(4E,7E,10E,13E,16E,19E)), 
PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), 
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/19:0) (>3) 
807.57326 C49H82O6 [M+(41K)]
+ 766.61114 1.04 6 TG(12:0/12:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))iso3, 
TG(12:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))iso6, 
TG(14:1(9Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))iso3 
813.62081 C49H88O6 [M+(41K)]
+ 772.65809 1.77 5 TG(12:0/12:0/22:3(10Z,13Z,16Z))iso3, TG(12:0/14:0/20:3(8Z,11Z,14Z))iso6, 
TG(12:0/14:1(9Z)/20:2(11Z,14Z))iso6(>3) 
818.60602 C48H84NO7P [M+H]
+ 817.598542 0.25 8 PC(P-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
820.62241 C48H86NO7P [M+H]
+ 819.614192 1.15 7 PC(P-20:0/20:5(5Z,8Z,11Z,14Z,17Z)), PC(o-
18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
821.62551 C45H89O10P [M+H]
+ 820.619338 -1.34 8 PG(17:0/22:0), PG(18:0/21:0), PG(19:0/20:0) (>3) 
822.63826 C48H88NO7P [M+H]
+ 821.629842 1.39 6 PC(O-18:0/22:5(4Z,7Z,10Z,13Z,16Z)), PC(O-18:0/22:5(7Z,10Z,13Z,16Z,19Z)), 
PC(O-20:0/20:5(5Z,8Z,11Z,14Z,17Z)) (>3) 
824.65414 C48H90NO7P [M+H]
+ 823.645492 1.66 6 PC(O-18:0/22:4(7Z,10Z,13Z,16Z)), PC(P-20:0/20:3(8Z,11Z,14Z)), PC(o-
20:0/20:4(8Z,11Z,14Z,17Z)) 
829.55525 C44H85O9P [M+(41K)]
+ 788.593123 1.03 14 PG(O-16:0/22:2(13Z,16Z)), PG(O-18:0/20:2(11Z,14Z)), PG(O-
20:0/18:2(9Z,12Z)) (>3) 
829.64395 C44H87N2O6P [M+Hac-H]
- 770.630176 -0.1 11 SM(d18:2/21:0) 
830.64879 C48H91NO8 [M+Na-2H]
- 809.674469 -0.42 10 GalCer(d18:1/24:1(15Z)), GlcCer(d18:1/24:1(15Z)) 
831.65994 C44H89N2O6P [M+Hac-H]
- 772.645826 0.31 10 SM(d16:1/23:0), SM(d17:1/22:0), SM(d18:1/21:0) (>3) 
832.6645 C48H93NO8 [M+Na-2H]
- 811.690119 -0.35 9 GalCer(d18:1/24:0), GlcCer(d18:0/24:1(15Z)), Glucosylceramide 
(d18:1/24:0) 
834.60124 C48H84NO8P [M+H]
+ 833.593457 0.61 7 PC(18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), 
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PC(18:0/22:6(9Z,11Z,13Z,15Z,17Z,19)), 
PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/21:0) (>3) 
834.62192 C45H88NO10P 
OR 
C47H89NO8 
[M+H]+ 
OR 
[M+K]+ 
833.614587 
OR 
795.658819 
0.07 
OR 
-0.07 
7 PS(17:0/22:0), PS(18:0/21:0), PS(19:0/20:0) (>3) 
OR 
GalCer(d18:2/23:0), GlcCer(d18:2/23:0) 
835.6045 C51H86O6 [M+(41K)]
+ 794.64244 0.94 6 TG(12:0/14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))iso6, 
TG(12:0/14:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z))iso6, 
TG(12:0/16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))iso6(>3) 
845.67565 C45H91N2O6P [M+Hac-H]
- 786.661476 0.38 7 SM(d16:1/24:0), SM(d18:1/22:0) 
848.62943 C47H92NO7P [M+Cl]
- 813.661142 -1.31 11 PC(P-20:0/19:1(9Z)), PE(O-20:0/22:2(13Z,16Z)), PE(P-20:0/22:1(11Z)) 
848.65364 C50H90NO7P [M+H]
+ 847.645492 1.03 10 PC(O-20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
850.66926 C50H92NO7P [M+H]
+ 849.661142 0.99 8 PC(P-20:0/22:4(7Z,10Z,13Z,16Z)) 
858.68022 C50H95NO8 [M+Na-2H]
- 837.705769 -0.25 9 GalCer(d18:1/26:1(17Z)), GlcCer(d18:1/26:1(17Z)) 
859.69186 C46H93N2O6P [M+Hac-H]
- 800.677126 1.02 8 SM(d16:1/25:0), SM(d17:1/24:0), SM(d18:1/23:0) 
860.6957 C50H97NO8 [M+Na-2H]
- 839.721419 -0.45 8 GalCer(d18:0/26:1), GalCer(d18:1/26:0), GlcCer(d18:0/26:1(17Z)) (>3) 
864.57572 C48H84NO10P [M-H]
- 865.583287 -0.34 11 PS(20:1(11Z)/22:4(7Z,10Z,13Z,16Z)), PS(20:3(8Z,11Z,14Z)/22:2(13Z,16Z)), 
PS(20:4(5Z,8Z,11Z,14Z)/22:1(11Z)) (>3) 
873.70799 C47H95N2O6P [M+Hac-H]
- 814.692776 1.56 9  SM(d18:0/24:1(15Z)), SM(d18:1/24:0) 
876.57584 C47H80NO8P 
 
OR 
C49H84NO10P 
[M+Hac-H]- 
 
OR 
[M-H]- 
817.562157 
 
OR 
877.583287 
-0.19 
 
OR 
-0.19 
9 PC(17:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), 
PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/17:1(9Z)), 
PE(20:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (>3) OR 
 PS(21:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), 
PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/21:0) 
879.74216 C55H100O6 
 
[M+Na]+ 
 
856.75199 
 
1.08 
 
13 TG(12:0/18:0/22:3(10Z,13Z,16Z))iso6, TG(12:0/18:1(9Z)/22:2(13Z,16Z))iso6, 
TG(12:0/18:2(9Z,12Z)/22:1(11Z))iso6 (>3) OR 
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OR 
C57H98O6 
OR 
[M+H]+ 
OR 
878.73634 
OR 
-1.66 
TG(12:0/20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))iso6, 
TG(12:0/20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))iso6, 
TG(12:0/20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))iso6(>3) 
885.70648 C48H95N2O6P [M+Hac-H]
- 826.692776 -0.17 11  SM(d17:1/26:1), SM(d18:2/25:0), SM(d19:1/24:1) 
890.59169 C48H82NO8P 
 
OR 
C50H86NO10P 
[M+Hac-H]- 
 
OR 
[M-H]- 
831.577807 
 
OR 
891.598937 
0.03 
 
OR 
0.03 
11 PC(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), 
PC(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), 
PC(18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (>3) OR 
PS(22:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), 
PS(22:2(13Z,16Z)/22:4(7Z,10Z,13Z,16Z)), 
PS(22:4(7Z,10Z,13Z,16Z)/22:2(13Z,16Z)) (>3) 
892.60723 C50H88NO10P [M-H]
- 893.614587 -0.09 12 PS(22:1(11Z)/22:4(7Z,10Z,13Z,16Z)), PS(22:4(7Z,10Z,13Z,16Z)/22:1(11Z)) 
(>3); indicates more than three possible putative annotations, OR; indicates more than one possible empirical formulae or multiple adducts.  
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Table ‎H.3The identification parameters of putatively identified polar and non-polar metabolic features, detected in both positive and negative 
ionisation mode, which were significantly altered (p<0.05) between haemolysed and clean cord blood serum pairs. (See Chapter 7) 
m/z 
Empirical 
formula 
Ion form 
Theoretical 
mass 
Mass 
error %RSDQC Putative annotations 
(Da) (ppm) 
Polar metabolic features     
121.06241 C6H10O [M+Na]
+ 98.073165 0.19 13 Cyclohexanone OR 3-Hexenal 
125.05733 C5H10O2 [M+Na]
+ 102.06808 0.23 14 2-Methylbutyrate OR 3-Methylbutanoic acid OR Pentanoate 
127.01643 C7H6O [M+Na-2H]
- 106.041865 -0.82 17 Aromatic aldehyde 
142.0475 C4H9NO3 [M+Na]
+ 119.058244 0.24 4 L-Allothreonine OR L-Homoserine OR L-Threonine 
154.04749 C5H9NO3 [M+Na]
+ 131.058244 0.16 6 3-Hydroxy-L-proline OR 5-Amino-2-oxopentanoic acid OR L-Glutamate 5-
semialdehyde (>3) 
169.05842 C5H10N2O3 [M+Na]
+ 146.069143 0.33 3 Glutamine OR 3-Ureidoisobutyrate OR Alanylglycine 
184.0581 C6H11NO4 [M+Na]
+ 161.068809 0.38 8 L-2-Aminoadipate OR O-Acetyl-L-homoserine OR  
3-Amino-2,3-dideoxy-scyllo-inosose 
185.043 C6H12O5 [M+Na-2H]
- 164.068475 -0.78 14 6-Deoxy-L-galactose OR L-Rhamnose OR   
β-D-Fucose (>3) 
190.08392 C9H13NO2 [M+Na]
+ 167.094629 0.37 11 Methoxytyramine OR Phenylephrine OR Synephrine 
203.02918 C10H10O2 [M+(41K)]
+ 162.06808 -0.87 10 1,2-Dihydronaphthalene-1,2-diol OR Isosafrole 
203.05265 C6H12O6 [M+Na]
+ 180.06339 0.19 3 Allose OR Fructose OR myo-Inositol (>3) 
203.05391 C7H8N4O2 [M+Na]
+ 180.064726 -0.18 3 1,7-Dimethylxanthine OR Theobromine OR Theophylline 
205.04482 C10H12O2 [M+(41K)]
+ 164.08373 -0.91 4 Phenylbutyric acid OR Benzenebutanoic acid OR Eugenol 
207.02406 C9H10O3 [M+(41K)]
+ 166.062995 -1.02 7 Phenyllactate OR 3-Phenoxypropionic acid OR  
4-Methoxyphenylacetic acid (>3) 
212.97956 C6H6O6 [M+K]
+ 174.01644 -0.18 9 Dehydroascorbic acid OR Aconitate 
214.06868 C7H13NO5 [M+Na]
+ 191.079374 0.4 4 2-Amino-3,7-dideoxy-D-threo-hept-6-ulosonic acid 
291 
 
216.04322 C10H13NO2 
OR 
C9H11NO3 
[M+K-2H]- 
OR 
[M+Cl]- 
179.094629  
OR 
181.073894 
-0.07 
OR 
-0.35 
13 (R)-Salsolinol OR 2(N)-Methyl-norsalsolinol 
OR 
Tyrosine OR 3-Amino-3-(4-hydroxyphenyl)propanoate OR  
4-Hydroxy-4-(3-pyridyl)-butanoic acid  (>3) 
244.07929 C8H15NO6 [M+Na]
+ 221.089939 0.53 4 N-Acetyl-D-glucosamine OR N-Acetyl-D-mannosamine OR N-Acetyl-β-D-
galactosamine  (>3) 
402.09919 C11H22NO7PS [M+Hac-H]
- 343.085464 -0.32 11 N-(7-Mercaptoheptanoyl)threonine 3-O-phosphate 
416.27509 C24H41NO2 [M+(41K)]
+ 375.313729 0.2 4 7,10,13,16-Docosatetraenoylethanolamine 
441.15868 C19H26O6S [M+Hac-H]
- 382.145012 -0.42 8 2-Methoxyestradiol-17-β-3-sulfate 
443.17437 C19H28O6S [M+Hac-H]
- 384.160662 -0.33 9 3β,16α-Dihydroxyandrostenone sulfate 
487.19446 C24H32O9 [M+Na]
+ 464.204635 1.24 6 15-hydroxynorandrostene-3,17-dione glucuronide OR 16-Glucuronide-
estriol OR 16-α,17-β-estriol 17-β-D-glucuronide (>3) 
519.29341 C27H44O8 [M+Na]
+ 496.30362 1.09 7 Pregnanediol-3-glucuronide OR  
3-α,20-α-dihydroxy-5-β-pregnane 3-glucuronide 
Non-polar metabolic features     
365.27000 C20H34O2 [M+Hac-H]
- 306.25588 0.73 10 5,8,11-Eicosatrienoic acid OR Icosatrienoic acid OR Oncobic acid (>3) 
367.26432 C25H36O2 [M-H]
- 368.27153 0.18 7 Didesmethyl tocotrienol  
389.23347 C23H34O5 
OR 
C21H30O3 
[M-H]- 
OR 
[M+Hac-H]- 
390.240625  
OR 
330.219495 
0.31  
OR 
0.31 
13 15R-PGA2 methyl ester OR acetate OR Digoxigenin 
OR 
11-Deoxycorticosterone OR hydroxyprogesterone OR 1α-hydroxy-20-oxo-
22,23,24,25,26,27-hexanorvitamin D3 / 1α-hydroxy-20-oxo-
22,23,24,25,26,27-hexanorcholecalciferol (>3) 
429.37301 C29H48O2 [M+H]
+ 428.36543 0.71 2 1-Hydroxyvitamin D5 OR (24R,24R)-Fucosterol epoxide OR  (6R)-6,19-
ethano-25-hydroxy-6,19-dihydrovitamin D3 / (6R)-6,19-ethano-25-hydroxy-
6,19-dihydrocholecalciferol (>3) 
445.36803 C29H48O3 [M+H]
+ 444.360345 0.92 8 11α-ethyl-1α,25-dihydroxyvitamin D3/11α-ethyl-1α,25-
dihydroxycholecalciferol OR 1α,25-dihydroxy-24a,24b-dihomo-20-
epivitamin D3/1α,25-dihydroxy-24a,24b-dihomo-20-epicholecalciferol OR 
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1α,25-dihydroxy-24a,24b-dihomovitamin D3/1α,25-dihydroxy-24a,24b-
dihomocholecalciferol (>3) 
445.36881 C27H46O 
 
OR 
C29H50O3 
[M+Hac-H]- 
 
OR 
[M-H]- 
386.354865  
 
OR 
446.375995 
0.21  
 
OR 
0.21 
19 Cholesterol OR Lathosterol OR toxisterol3 R1/6,19-dihydrovitamin D3/6,19-
dihydrocholecalciferol  
OR 
 13-hydroxy-α-tocopherol OR 24-hydroperoxy-24-vinylcholesterol OR 
Nebrosteroid M (>3) 
524.27814 C27H44NO7P [M-H]
- 525.285542 -0.24 9 LysoPE(0:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) OR 
LysoPE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) (>3) 
537.37957 C29H50O5 [M+Hac-H]
- 478.365825 -0.2 6 1α,25-dihydroxy-2α-(3-hydroxypropoxy)-19-norvitamin D3 / 1α,25-
dihydroxy-2α-(3-hydroxypropoxy)-19-norcholecalciferol OR   
1α,25-dihydroxy-2β-(3-hydroxypropoxy)-19-norvitamin D3 / 1α,25-
dihydroxy-2β-(3-hydroxypropoxy)-19-norcholecalciferol (>3) 
715.57588 C40H81N2O6P [M-H]
- 716.583226 -0.1 11 SM(d18:1/17:0) OR SM(d19:1/16:0)  
733.59866 C43H78O5 [M+Hac-H]
- 674.584925 -0.16 9 DG(18:1(9Z)/22:2(13Z,16Z)/0:0) OR DG(18:2(9Z,12Z)/22:1(13Z)/0:0) OR 
DG(18:3(6Z,9Z,12Z)/22:0/0:0) (>3) 
745.59421 C45H84O5 [M+(41K)]
+ 704.631875 1.42 4 DG(18:1(11Z)/24:1(15Z)/0:0) OR DG(20:0/22:2(13Z,16Z)/0:0) OR  
DG(24:1(15Z)/18:1(9Z)/0:0) (>3) 
761.66639 C48H90O6 [M-H]
- 762.67374 -0.1 6 TG(12:0/13:0/20:1(11Z))iso6 OR TG(12:0/14:0/19:1(9Z))iso6 OR 
TG(12:0/14:1(9Z)/19:0)iso6  (>3) 
(>3); indicates more than three possible putative annotations, OR; indicates more than one possible empirical formulae or multiple adducts.  
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Appendix I. Metabolic features assigned 
empirical formulae 
Table ‎I.1Empirical formulae ascribed to the polar metabolic features detected in positive and 
negative ionisation mode which were significantly altered (p<0.05) when effect size between 
ΔPA and ΔHIE was examined, and for which a putative annotation could not be ascribed. (See 
Chapter 3) 
m/z Intensity Empirical formula Ion 
Theoretical 
mass 
Mass 
error 
(Da) (ppm) 
Positive ionisation mode 
359.03024 
(>5) 
79111.2 C3H15N10OP3[NaCl]  
C8H7N12OPCa  
C9H18N3O6PCu  
C11H20N2OS2Ca[NaCl]  
C12H21N2OPS2Fe 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]+ 
358.022942 
358.022932 
358.022924 
358.022921 
358.022907 
0.060.09
0.110.12
0.16 
380.90488 
(>5) 
39007.8 C6H7N4O5P3SCa  
C5HN10OPSCa[Na(37Cl)]  
C5H6N9P3SCu  
C5H12N2O5S5Ca 
C8H14OS3Ca[NaCl][Na(37Cl)] 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]+ 
379.897598 
379.897579 
379.897576 
379.897574 
379.897568 
0.010.06
0.070.08
0.09 
386.80562 
(>5) 
47843.4 C7H2O8S2Fe2 
C3H6N2O2P4S5 C4H2N4OP2S2Ca2[NaCl] 
C5H3N4OP3S2CaFe 
C4H7NO2S2CaCu[NaCl][Na(37Cl)] 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]
+
 
385.798338 
385.79834 
385.798336 
385.798322 
385.798309 
0.010.01
0.020.06
0.09 
471.04405 
(>5) 
35227.9 C7H17N14O3PCaFe 
C13H14N12SCa[Na(37Cl)] 
C14H25N3O5SCu[Na(37Cl)]  
C20H16N4O4P2S 
C17H28N2S3Fe[Na(37Cl)] 
[M+H]
+
 [M+H]
+ 
[M+H]+ [M+H]+ 
[M+H]+ 
470.036772 
470.036774 
470.036766 
470.036754 
470.036749 
0 
0 
0.020.04
0.05 
263.12538 
 
46559.6 C13H20O4 
C11H14N6O2 
C5H18N8O2Ca 
[M+Na]
+
 [M+H]
+ 
[M+H]+ 
240.13616 
262.117824 
262.117863 
-
0.011.06
0.91 
324.10306 
(>5) 
131160.5 C7H19N9P2S  
C13H23N3OSFe  
C12H22NO5PS  
C5H19N9O4Fe  
C10H22N3O3P[Na(37Cl)] 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]+ 
323.095939 
323.095796 
323.095634 
323.095613 
323.095553 
-0.48 
-
0.040.46
0.530.71 
338.11872 
(>5) 
125161.3 C8H21N9P2S  
C14H25N3OSFe  
C13H24NO5PS  
C6H21N9O4Fe  
C11H24N3O3P[Na(37Cl)] 
[M+H]
+
 [M+H]
+ 
[M+H]+ [M+H]+ 
[M+H]+ 
337.111589 
337.111446 
337.111284 
337.111263 
337.111203 
-0.43 
-
0.010.47
0.530.71 
445.16951 
(>5) 
11881.2 C17H38N2OP2S3 
C18H34N4Ca2[NaCl]  
C14H29N4O10P  
C19H35N4PCaFe  
[M+H]
+
 [M+H]
+ 
[M+H]+ [M+H]+ 
[M+H]+ 
444.162155 
444.162151 
444.162134 
444.162137 
0.180.19
0.22 
0.22 
0.27 
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C24H30N2Ca[NaCl] 444.162112 
447.06506 
(>5) 
28140.5 C10H22O17S  
C15H28O7SCaFe  
C13H29N4P3SCa2 
C8H10N14O7S  
C14H27N5O2SFeCu 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]+ 
446.057777 
446.05778 
446.057764 
446.057763 
446.057758 
0.01 
0.01 
0.04 
0.05 
0.06 
469.04711 
(>5) 
35692.1 C17H27NO4S3Cu  
C8H15N10O8P[NaCl] C9H26N8OP2S2Ca2 
C18H26N2OP2Ca3 
C15H28N2O4Fe2[Na(37Cl)] 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]+ 
468.039824 
468.039821 
468.039809 
468.039812 
468.039805 
0.02 
0.03 
0.05 
0.05 
0.06 
497.00216 
(>5) 
18699.1 C15H25N4O2PS2Fe2 
C16H6N12O2Ca[NaCl] C10H23N9P4CaCu 
C10H18N10OP2Ca2[Na(37Cl)] 
C17H17N3O7Cu[NaCl] 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]+ 
495.994882 
495.994882 
495.994883 
495.994886 
495.994874 
0 
0 
0 
0 
0.02 
541.27509 
(>5) 
51117.5 C17H46N10OP2SCa  
C23H42N8OP2S  
C24H48O7S[Na(37Cl)] 
C28H52CaFe[NaCl]  
C23H46O10[NaCl] 
[M+H]+ [M+H]+ 
[M+H]+ [M+H]+ 
[M+H]
+
 
540.267794 
540.267755 
540.26775 
540.267726 
540.267723 
0.04 
0.11 
0.12 
0.16 
0.17 
Negative ionisation mode 
381.01801 
(>5) 
20078.5 C13H25PSCa2 
C14H26P2SCaFe 
C9H20O10P2S 
C7H8N14P2S 
C10H21N4PS3 
[M-H]
-
 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
382.025265 
382.025251 
382.025248 
382.025234 
382.025223 
0.06 
0.09 
0.1 
0.14 
0.17 
463.02103 
(>5) 
49254.7 C15H27N3P2SCu 
C20H19N5SCaCu 
C10H26N6O4P2Fe2 
C11H19N11S3Cu 
C18H16N4O5S3 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]
-
 
[M-H]- 
464.028317 
464.028307 
464.028304 
464.028304 
464.028287 
-0.02 
0 
0.01 
0.01 
0.04 
545.02366 
(>5) 
44075.1 C19H31N3O3Ca2FeCu C9H23N10O8P3Fe 
C14H25N3O13CaCu 
C15H31O9PS5 
C7H21N15O3P2Cu 
[M-H]
-
 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
546.030935 
546.030936 
546.030932 
546.030933 
546.030928 
0 
0 
0.01 
0.01 
0.02 
187.00699 
 
126669.4 C7H8O4S  
C4H8N4Ca 
C10H4N2 
C5H4O2S 
[M-H]- [M+Cl]- 
[M+Cl]
- 
[M+Hac-H]- 
188.014332 
152.037487 
152.037448 
127.993202 
-0.35 
0.54 
0.75 
-0.35 
384.80864 
(>5) 
11903.6 C4H4N6O3CaFe3 
C4H2N2O7P4SCa 
C7H2N2O4S3Fe 
C7H7N3OCa3FeCu 
C3HN7O2P4SCu 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
385.815916 
385.815918 
385.815909 
385.815896 
385.815896 
0 
0 
0.02 
0.05 
0.05 
131.09052 8035.4 - - - - 
224.06376 29701.9 C4H11N5O6 
C8H16N3PCa 
C2H7N5O4 
[M-H]- 
[M-H]- 
[M+Hac-H]
-
 
225.070935 
225.070776 
165.049805 
0.45 
1.16 
0.45 
295.00472 
(>5) 
23895.9 C10H14N2O3SFe 
C7H18N3PCu 
C9H13O7PS 
C2H10N8O6Fe 
C5H14N6Ca2 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
296.012127 
296.012057 
296.011965 
296.011944 
296.011799 
-0.44 
-0.21 
0.11 
0.18 
0.67 
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318.95238 
(>5) 
12224.8 C7H14N4Fe2 
C5HN10O3PCa 
C6H12NO8PCu 
C8H14O3S2Ca 
C9H15O3PS2Fe 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
319.959693 
319.959664 
319.959656 
319.959653 
319.959639 
-0.11 
-0.02 
0 
0.01 
0.05 
371.04529 
(>5) 
29596.3 C10H23N4OP3S2 
C8H15N10PS 
C6H17N10O2PCa2 
C7H21N6O2P3 
C12H13N8O2PCa 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
372.052619 
372.052573 
372.05254 
372.052511 
372.052501 
-0.14 
-0.02 
0.07 
0.15 
0.18 
450.11248 
(>5) 
10875.8 C16H33N5OSFe2 
C9H28N9O4P3S 
C17H33NO4S3Ca 
C7H20N15O3P 
C14H31N3O5SCa 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
451.119806 
451.119787 
451.119766 
451.119741 
451.119658 
-0.11 
-0.07 
-0.02 
0.03 
0.22 
476.81948 
(>5) 
12749.9 C4H2N12O2P2SCa2Fe 
C20H2N4FeCu2 
C10H10N2O3S6Ca2 
C15H6N4S4Fe2 
C11H15O3P3S2Cu2 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]
-
 
[M-H]- 
477.82676 
477.826756 
477.826757 
477.826758 
477.826751 
-0.01 
0 
0 
0 
0.01 
489.0481 
(>5) 
7754.1 C18H31N2PSCaFe 
C13H25N2O10PS 
C28H17N2OP3 
C19H32N2P2SFe2 
C6H22N10O9Fe 
[M-H]- 
[M-H]- 
[M-H]
-
 
[M-H]- 
[M-H]- 
490.055384 
490.055381 
490.055377 
490.05537 
490.05536 
-0.02 
-0.01 
0 
0.01 
0.03 
543.26307 
(>5) 
37401.2 C19H40N6O12 
C30H42N4O2Fe 
C19H47N6O4PS 
C23H45N4O6PCa 
C22H44N9OPCu 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
544.270424 
544.270388 
544.270337 
544.270265 
544.270243 
-0.14 
-0.08 
0.02 
0.15 
0.19 
(>5); indicates more than five possible empirical formulae. 
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Table ‎I.2 Empirical formulae ascribed to the non-polar metabolic features detected in positive 
and negative ionisation mode which were significantly altered (p<0.05) when effect size 
between ΔPA and ΔHIE was examined, and for which a putative annotation could not be 
ascribed.(See Chapter 4) 
m/z Intensity Empirical formula Ion  
Theoretical 
mass 
Mass 
error 
(Da) (ppm) 
Negative ionisation mode 
393.29724 
(>5) 
5714.3 C17H38N2O4 
C15H38N10 
C23H47PCa 
C19H42N2O6 
C14H39N10OP 
[M+Hac-H]- 
[M+Cl]- 
[M-H]- 
[M-H]- 
[M-H]- 
334.283158 
358.32809 
394.304129 
394.304288 
394.304593 
0.58 
-0.64 
0.99 
0.58 
-0.19 
409.36877 16988.7 C24H46O 
C26H50O3 
[M+Hac-H]- 
[M-H]- 
350.354865 
410.375995 
0.13 
0.13 
435.38442 10961.5 C26H48O 
C25H55N2P 
C28H52O3 
[M+Hac-H]- 
[M+Na-2H]- 
[M-H]
-
 
376.370515 
414.410286 
436.391645 
0.12 
-1.23 
0.12 
443.35311 11877.6 C27H44O 
C26H51N2P 
C29H48O3 
C22H48N6OS 
[M+Hac-H]- 
[M+Na-2H]- 
[M-H]- 
[M-H]- 
384.339215 
422.378986 
444.360345 
444.361031 
0.09 
-1.23 
0.09 
-1.45 
454.39828 14828.5 C22H49N9O [M-H]
- 455.406006 -0.99 
455.33786 
(>5) 
8604.5 C21H45N8OP 
C24H44O4 
C26H48O6 
C18H46N10S 
C15H46N12P2 
[M-H]- 
[M+Hac-H]- 
[M-H]- 
[M+Na-2H]- 
[M-H]- 
456.345395 
396.32396 
456.34509 
434.362762 
456.344364 
-0.57 
0.1 
0.1 
0.94 
1.7 
466.39826 5911.6 C25H55N3O3 
C17H50N13P 
C23H49N9O 
[M+Na-2H]- 
[M-H]
-
 
[M-H]
-
 
445.424342 
467.404975 
467.406006 
-1.61 
1.2 
-1.01 
541.33341 
(>5) 
113779.1 C18H45N14O2P 
C24H51O5PS 
C26H55O7PS 
C31H52O4S 
C29H51N2O3P 
[M+Na-2H]- 
[M+Hac-H]- 
[M-H]
-
 
[M+Na-2H]- 
[M+Cl]
-
 
520.358754 
482.319485 
542.340615 
520.358632 
506.363731 
-0.02 
0.13 
0.13 
0.2 
0.51 
556.46601 
(>5) 
7558.3 C25H55N9O 
C3HP5CaFe3Cu2 
C23H61N13 
C22H59N13O 
C27H59N9O3 
[M+Hac-H]- 
[M+K-2H]- 
[M+K-2H]- 
[M+Cl]- 
[M-H]- 
497.452956 
519.517265 
519.517287 
521.496552 
557.474086 
-1.44 
0.25 
0.21 
0.1 
-1.44 
579.46286 
(>5) 
6777.1 C30H61N8OP 
C33H60O4 
C27H62N10S 
C4HP5Ca2Fe2Cu3 
C24H62N12P2 
[M-H]- 
[M+Hac-H]- 
[M+Na-2H]
-
 
[M-H]- 
[M-H]- 
580.470595 
520.44916 
558.487962 
580.469843 
580.469564 
-0.79 
-0.27 
0.4 
0.51 
0.99 
673.50513 
(>5) 
7737.5 C5H4O9P6FeCu3 
C10H3N3OS4CaFe3Cu2 
C6HNO4P2S6Ca3Fe[NaCl] 
C3H5N4O2P5SCa2FeCu3 
C5H4N3OP7SCa3Fe3 
[M+K-2H]- 
[M+K-2H]
-
 
[M+K-2H]- 
[M+Cl]- 
[M+Na-2H]- 
636.556522 
636.556525 
636.556525 
638.535729 
652.530459 
0 
0 
0 
0 
0 
739.51108 79913.9 C8H6NO10PSFe4Cu2[Na(37Cl)] [M-H]
- 740.518328 0.04 
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(>5) N10O7P3Ca3Fe4[Na(37Cl)] 
C(13C)H2N2O11P5S6CaCu[Na(37Cl)] 
C10(13C)H6NP2S4(34S)Ca3Cu2[NaCl][Na(37Cl)] 
C10(13C)HN7P4S(34S)CaFe4Cu 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
740.518328 
740.518328 
740.518328 
740.518328 
0.04 
0.04 
0.04 
0.04 
762.50769 
(>5) 
261017.8 C9(13C)H4N2O3P7S(34S)Fe3[NaCl][Na(37Cl)] 
C6H3N7O5(34S)Ca2Fe4Cu[NaCl][Na(37Cl)] 
C13HN6OP2S(34S)CaFe4Cu[Na(37Cl)] 
C8(13C)H4NO5P6S3(34S)Ca3Cu[NaCl] 
C2(13C)H8N5O7P4(34S)CaFe4Cu[Na(37Cl)] 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
763.514961 
763.514961 
763.514961 
763.514961 
763.514961 
0.01 
0.01 
0.01 
0.01 
0.01 
763.51109 
(>5) 
122012.4 H9N9O8PS(34S)Fe4Cu3 
C7N5O8P2(34S)Ca2Cu3[NaCl][Na(37Cl)] 
C13NO11P2Fe2Cu3[Na(37Cl)] 
C9H6N7OP2S2Fe3Cu3[Na(37Cl)] 
C5(13C)H5O15S(34S)Ca2FeCu3[NaCl] 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
764.518359 
764.518359 
764.518359 
764.518359 
764.518359 
0.01 
0.01 
0.01 
0.01 
0.01 
864.60728 
(>5) 
262092.8 C3(13C)H14N6O17PS3Ca2FeCu2[Na(37Cl)] 
C14(13C)H17N3O7P6(34S)Fe2Cu2[Na(37Cl)] 
C12H8N5O15P3S2Cu3[NaCl] 
C5H27NO12P4S4(34S)CaCu3[NaCl] 
C12H25O8P6S5(34S)Cu3 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]
-
 
865.614548 
865.614548 
865.614548 
865.614548 
865.614548 
0.01 
0.01 
0.01 
0.01 
0.01 
851.56552 
(>5) 
11850.3 CH25N8O7P5SFe4Cu3 
C10(13C)H6N12P5S2Ca2Cu3[NaCl] 
C18(13C)H10N4O2PS5(34S)FeCu3[NaCl] 
C2(13C)H27N5O4P4S3Ca2Fe2Cu3[NaCl] 
C13(13C)H18N4PS2(34S)Ca3FeCu3[NaCl][Na(37Cl)] 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]
-
 
[M-H]- 
852.572754 
852.572754 
852.572754 
852.572754 
852.572754 
0.05 
0.05 
0.05 
0.05 
0.05 
879.59676 
(>5) 
126974.4 C27H3N2O8P2(34S)Ca2Fe3[Na(37Cl)] 
C12(13C)H16N7O4P4S(34S)Ca2Fe4[Na(37Cl)] 
C18H3N11OP5S5(34S)Ca2Cu 
C6H13N15O2PS5Ca2Fe3Cu[NaCl] 
C11(13C)H3N13O6S6(34S)Fe2Cu[NaCl] 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
880.604028 
880.604028 
880.604028 
880.604028 
880.604028 
0.01 
0.01 
0.01 
0.01 
0.01 
918.54751 
(>5) 
19151.4 C(13C)H34N6O5P6S(34S)CaFe4Cu3 
C8(13C)H25N2O5P7(34S)Ca3Cu3[NaCl][Na(37Cl)] 
C19(13C)H16N4P2S3(34S)Fe2Cu3[NaCl][Na(37Cl)] 
C19(13C)H3N2O13P6(34S)Fe3[NaCl] 
C14H25NO5P6S4CaFe4Cu 
[M-H]- 
[M-H]
-
 
[M-H]- 
[M-H]
-
 
[M-H]- 
919.554778 
919.554778 
919.554778 
919.554778 
919.554778 
0.01 
0.01 
0.01 
0.01 
0.01 
Positive ionisation mode 
327.22714 
 
8097.9 C21H34 
C13H32N6O 
C16H28N6 
C11H31N6O3P 
C19H35PS 
[M+(41K)]+ 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
286.26605 
288.263759 
304.237544 
326.219527 
326.21971 
-0.57 
0.68 
1.14 
1.03 
0.47 
409.23024 
(>5) 
4300.5 C19H33N6PS 
C14H34N6O4 
C15H36N6OS 
C17H36N4O3S2 
C22H38OS 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
408.222504 
408.222777 
408.222804 
408.222885 
408.22296 
1.12 
0.46 
0.39 
0.19 
0.01 
926.79986 
(>5) 
60903.6 C2H36N9O15P4S8Ca3 
C12H41N3O12P7S4Fe3 
C17H28N2O18P5S5Cu 
C28H20O17P4Ca3Fe 
C2H36N9O15P4S8Ca3 
[M+H]+ 
[M+H]
+
 
[M+H]+ 
[M+H]+ 
[M+H]+ 
925.792492 
925.792492 
925.792492 
925.792492 
925.792492 
0.1 
0.1 
0.1 
0.1 
0.1 
1290.19044 
(>5) 
235573.2 C24H2NO14P3S7CaFe4Cu3 
C25N4O7P5S8(34S)Ca2Fe2Cu3 
C23HN2O15P6(34S)Ca3Fe4Cu3 
C28N4O3P7S8Ca2Fe2Cu3 
C32HO6P7S3(34S)Ca3Fe4Cu2 
[M+H]+ 
[M+H]
+
 
[M+H]+ 
[M+H]+ 
[M+H]
+
 
1289.183163 
1289.183163 
1289.183162 
1289.183161 
1289.183159 
0 
0 
0 
0 
0 
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1342.22159 
(>5) 
398598.5 C13H13N6O15P6S6Ca3Fe3Cu3 
C31N8O3P4S7Ca3Fe4Cu2 
C25HN5O11P7S7Ca3Fe2Cu2 
C18(13C)H4N6O14P6S8Ca2Fe4Cu 
C12N14O14P7SCa3Fe3Cu3[NaCl] 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
1341.21431 
1341.214312 
1341.2143 
1341.214292 
1341.214288 
0 
0 
0.01 
0.02 
0.02 
(>5); indicates more than five possible empirical formulae.   
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Table ‎I.3 Empirical formulae ascribed to the polar metabolic features detected in positive and 
negative ionisation mode which were significantly altered (p<0.05) between haemolysed and 
clean cord blood serum pairs, for which a putative annotation could not be ascribed.(See 
Chapter 7) 
Mass Intensity Empirical formula Ion 
Theoretical 
mass 
Mass 
error p-
value 
(Da) (ppm) 
Positive ionisation mode 
119.08964 10679.7 - - - - 0.008 
121.97442 16227.9 C2H3N [M+Na]
+ 98.985172 0.22 0.039 
132.10277 3364.7 - - - - 0.039 
132.98724 10991.6 C4H5OPS [M+H]
+ 131.979875 0.67 0.031 
135.00289 981662.1 C4H7OPS [M+H]
+ 133.995525 0.66 0.008 
136.00625 34843.7 CH5N3O 
C3H5NO3S 
[M+H]+ 
[M+H]
+
 
134.998935 
134.999016 
0.28 
-0.31 
0.039 
137.00713 7367.9 C2H2N4O2 
C3H9P 
[M+Na]+ 
[M+H]+ 
114.017776 
135.999861 
0.97 
-0.05 
0.039 
143.05083 4859.2 - - - - 0.023 
149.01854 127171 C5H9OPS [M+H]
+ 148.011175 0.59 0.008 
158.96412 872696.7 CH5N2P 
C3H5O2PS 
C4H4OS 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
135.974709 
135.97479 
157.95691 
1.19 
0.68 
-0.42 
0.023 
159.96747 19742.8 CH4N3O2P 
C2H3NO4S 
[M+K]+ 
[M+Na]+ 
121.004115 
136.978281 
1.22 
-0.2 
0.008 
163.1094 21273.2 C9H16O [M+Na]
+ 140.120115 0.39 0.016 
164.02947 114231.9 C5H10NOPS [M+H]
+ 163.022074 0.73 0.008 
164.93006 29686.2 CH4O2P2S 
C5H2Ca2 
C2H3OPS 
[M+Na]
+
 
[M+Na]+ 
[M+H]+ 
141.940728 
141.940832 
163.922848 
0.67 
0.04 
-0.39 
0.008 
165.01348 87645.9 C7H10S 
C3H9N2P 
C5H9O2PS 
[M+K]+ 
[M+H]
+
 
[M+H]+ 
126.050322 
164.006009 
164.00609 
-0.01 
1.18 
0.69 
0.023 
168.07128 7912.9 - - - - 0.008 
179.06211 5988.9 C10H11OP 
C6H14O2 
[M+H]+ 
[M+H]+ 
178.054753 
178.055053 
0.45 
-1.23 
0.047 
188.06935 7595.6 C7H17NS 
C5H10N5OP 
[M+(41K)]+ 
[M+H]+ 
147.108171 
187.062298 
-0.52 
-1.19 
0.023 
191.04038 544488.1 C8H10N2O 
C6H11N2OPS 
[M+(41K)]+ 
[M+H]+ 
150.079313 
190.032973 
-1.1 
0.68 
0.008 
191.07677 219541.1 C9H14N2 
C7H15N2PS 
[M+(41K)]+ 
[M+H]+ 
150.115698 
190.069358 
-1.07 
0.71 
0.023 
192.04374 34415.2 C3H9N5O 
C5H9N3O3S 
[M+H]+ 
[M+H]+ 
191.036383 
191.036464 
0.42 
0 
0.023 
193.0448 33370.5 C9H12O2 
C9H14S 
C5H13N2P 
C7H13O2PS 
[M+(41K)]+ 
[M+K]+ 
[M+H]
+
 
[M+H]+ 
152.08373 
154.081622 
192.037309 
192.03739 
-1.07 
0.1 
1.11 
0.69 
0.008 
194.95861 
(>5) 
481777.6 C5H6O2 
C5H8S2Ca 
[M+K]+ 
[M+Na]+ 
155.995403 
171.969335 
0.24 
0.27 
0.039 
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C4H7OPS 
C4H6N2Fe 
C4H5NO4Cu 
[M+H]+ 
[M+H]+ 
[M+H]+ 
193.951198 
193.951333 
193.951458 
0.7 
0 
-0.64 
198.10434 13059.4 C10H16NOP [M+H]
+ 197.096952 0.56 0.023 
200.97471 32010.3 C3H7N2OP 
C5H7O3PS 
C4H6N2 
C6H6O2S 
[M+Na]
+
 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
177.985274 
177.985355 
199.967394 
199.967475 
1.07 
0.66 
0.2 
-0.21 
0.008 
202.1187 31109.8 C8H15N3O3 [M+H]
+ 201.111342 0.4 0.039 
202.99036 
(>5) 
1839740 C5H2N6O 
C3H9N2OP 
C5H9O3PS 
C4H8N2 
C6H8O2S 
[M+(41K)]+ 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
162.029009 
180.000924 
180.001005 
201.983044 
201.983125 
0.37 
1.06 
0.66 
0.2 
-0.2 
0.016 
203.05101 133101.6 C9H16Ca 
C3H4N10 
C7H15O2PCa 
C3H10N2O8 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
164.087791 
180.06204 
202.043559 
202.043718 
0.29 
-1.24 
0.86 
0.08 
0.039 
203.99371 
(>5) 
79387.9 C4H7NO5S 
C4H9N3S2Ca 
C2H7N3O3 
C10H5NS2 
C2H8N5OPFe 
[M+Na]+ 
[M+H]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
181.004496 
202.986382 
181.004415 
202.986343 
202.98626 
-0.04 
0.25 
0.36 
0.44 
0.85 
0.016 
204.05604 1281409 C5H11N5P2 [M+H]
+ 203.048971 -1.02 0.023 
204.05892 37545.5 C4H11N3O5 
C10H9N3S 
C4H13N5SCa 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
181.069872 
203.051719 
203.051758 
-0.85 
-0.37 
-0.56 
0.016 
204.91861 
(>5) 
12374.7 C3H4O2SCa 
C2H2O5Ca 
C2H4N2O2CaFe 
C3H3O5PFe 
C7HOPSCa 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
[M+H]
+
 
[M+H]+ 
203.911466 
203.911439 
181.929481 
203.911425 
203.911166 
-0.65 
-0.51 
-0.45 
-0.45 
0.82 
0.016 
205.06653 30834.4 C9H18Ca [M+K]
+ 166.103441 -0.34 0.039 
208.96771 
(>5) 
324544.8 C4H7N3OSCu 
C6H9PS3 
C9H6OCa 
C3H7N2OPS 
C6H6N2Ca2 
[M+H]+ 
[M+H]+ 
[M+K]+ 
[M+H]+ 
[M+Na]+ 
207.960583 
207.960404 
170.004456 
207.960296 
185.97828 
-0.71 
0.14 
0.45 
0.66 
1 
0.039 
214.05644 20774.2 C10H11N3 
C8H12N3PS 
C6H15NO3S2 
[M+(41K)]+ 
[M+H]+ 
[M+H]+ 
173.095297 
213.048957 
213.049338 
-0.62 
0.97 
-0.81 
0.031 
217.00602 
(>5) 
168480 C4H11N2OP 
C6H11O3PS 
C5H10N2 
C2H8N4O4S2 
C7H10O2S 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
194.016574 
194.016655 
215.998694 
215.9987 
215.998775 
1.03 
0.66 
0.23 
0.2 
-0.14 
0.008 
217.04486 
(>5) 
9452.6 C11H12O2 
C3H10N6O3 
C11H14S 
C2H10N8OFe 
C9H13O2PS 
[M+(41K)]+ 
[M+K]+ 
[M+K]+ 
[M+H]+ 
[M+H]+ 
176.08373 
178.081439 
178.081622 
216.037369 
216.03739 
-0.67 
1.21 
0.36 
0.99 
0.89 
0.039 
217.92613 
(>5) 
65528.1 C3H5NOS2 
C2H3NO4S 
C4H6NOPS2 
[M+Na]+ 
[M+Na]+ 
[M+K]+ 
194.936931 
194.936904 
178.962846 
-0.1 
0.02 
0.57 
0.008 
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C6H3NOSCa2 
CH4N3O2P 
[M+H]+ 
[M+K]+ 
216.918718 
178.962738 
0.62 
1.07 
218.91982 
(>5) 
967787.2 C4H4OS 
C9HNSCu 
C3H4N2OFe 
C3H5O2PS 
C2H3O5P 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
[M+Na]+ 
[M+Na]+ 
217.912583 
217.91257 
195.930598 
195.930463 
195.930436 
-0.18 
-0.12 
0 
0.62 
0.74 
0.008 
218.92121 
(>5) 
29557.6 C3H5N2OPS2 
C5H2N2OSCa2 
CH4N2O3P2S2 
C6HN2PS2 
C3H7P3 
[M+K]+ 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
[M+Na]+ 
179.958095 
217.913967 
217.913863 
195.93188 
195.931737 
-0.2 
-0.15 
0.32 
0.5 
1.15 
0.008 
218.92702 
(>5) 
23380.1 C3HN5OSCu 
C2H2N2O4Ca 
C2H7NO3P2Cu 
C2H7OP 
C7H4NPCu 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
[M+Na]+ 
217.919781 
217.919722 
217.919719 
195.937749 
195.937736 
-0.17 
0.1 
0.11 
0.23 
0.29 
0.016 
220.06695 34834.1 C9H13N3O 
C7H14N3OPS 
[M+(41K)]+ 
[M+H]
+
 
179.105862 
219.059522 
-0.86 
0.69 
0.016 
226.03802 20402.5 C4H13N5OCa 
C5H11N5P2 
C4H11N3O4 
C6H11NO6S 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
[M+H]
+
 
187.074601 
203.048971 
225.03063 
225.030711 
1.15 
-0.76 
0.5 
0.14 
0.031 
232.01697 
(>5) 
38827.2 C4H12N3OP 
C6H12NO3PS 
C5H11N3 
C2H9N5O4S2 
C7H11NO2S 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
209.027473 
209.027554 
231.009593 
231.009599 
231.009674 
1.19 
0.84 
0.43 
0.41 
0.08 
0.039 
233.12455 36246.4 C8H16N4O4 [M+H]
+ 232.117156 0.5 0.039 
239.1636 18025.3 - - - - 0.039 
250.97338 
(>5) 
45988.5 C6H10O3Ca 
C7H11O3PFe 
C2H8N4O4 
C7H4N2O5S 
C8H13PSCa 
[M+Na]+ 
[M+Na]
+
 
[M+K]
+
 
[M+Na]+ 
[M+K]+ 
227.984209 
227.984195 
212.010229 
227.984095 
212.010151 
-0.2 
-0.15 
-0.03 
0.25 
0.28 
0.039 
256.82284 
(>5) 
23603.7 C4H2Cu2 
CHN3P2FeCu 
C2HNS3Cu 
C2H2O2SFe2 
C2HNP2SCu 
[M+Na]
+
 
[M+Na]
+
 
[M+H]+ 
[M+H]+ 
[M+H]+ 
233.833471 
233.833784 
255.815337 
255.815399 
255.815769 
0.57 
-0.64 
0.88 
0.64 
-0.8 
0.047 
259.96505 
(>5) 
19704.8 C6H10N2O2SCu 
C7H13NOCaFe 
C5H4N5O2P3 
C4H9N3O2S4 
C4H10N4Cu 
[M+Na]+ 
[M+K]+ 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
236.975899 
221.001917 
258.957789 
258.957765 
236.975818 
-0.27 
-0.1 
-0.06 
0.03 
0.04 
0.031 
262.17787 118549.7 C14H25NO2 [M+Na]
+ 239.188529 0.46 0.016 
269.23374 74043.5 C14H28N4O [M+H]
+ 268.226311 0.57 0.047 
270.16775 14600.4 C12H25NO4 [M+Na]
+ 247.178359 0.63 0.039 
272.04353 
(>5) 
126751.1 C7H7N9S 
C6H13N5O2P2 
C7H13NO8S 
C4H7N11P2 
C5H13N3O6 
[M+Na]
+
 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
249.054513 
249.054451 
271.036191 
271.036115 
271.03611 
-0.75 
-0.52 
0.23 
0.51 
0.53 
0.023 
280.20389 35682.8 C15H31NO [M+K]
+
 241.240564 0.59 0.039 
302 
 
 C18H27N 
C13H30NO3P 
[M+Na]+ 
[M+H]+ 
257.214349 
279.196332 
1.14 
1 
292.2524 14310.1 - - - - 0.039 
302.24841 74538 - - - - 0.039 
303.24902 468240.7 - - - - 0.039 
305.2608 26484.6 C19H38 [M+K]
+
 266.29735 0.95 0.023 
305.26468 6104302 - - - - 0.039 
307.27133 37832.4 - - - - 0.039 
315.95808 
(>5) 
41593.6 C3H9N7O4Fe2 
C6H12N4O2Ca2Cu 
C4H9N3O7S2Ca 
C4H9N5O6Fe 
C7H11NO3Ca 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+K]+ 
[M+H]+ 
314.950827 
314.950807 
314.950787 
276.994897 
314.950781 
-0.07 
-0.01 
0.05 
0.07 
0.07 
0.039 
316.93900 
(>5) 
90386.4 C9H4N4O3P2 
C13H7P3 
C2H6N8P2S 
C8H12N2O2CaFe2 
C8H9NO5SCu 
[M+K]+ 
[M+H]+ 
[M+Na]+ 
[M+H]+ 
[M+Na]+ 
277.975867 
315.931737 
293.949763 
315.931693 
293.949745 
-0.08 
-0.04 
0.05 
0.1 
0.11 
0.023 
334.18867 
(>5) 
36952.6 C11H29N5O3S 
C16H31NO 
C19H25N3O 
C13H29N5OCa 
C14H28N3O4P 
[M+Na]+ 
[M+Na]
+
 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
311.199112 
311.199187 
311.199762 
311.199801 
333.181745 
1.01 
0.78 
-0.94 
-1.05 
-1.05 
0.031 
334.23089 6591.9 C11H27N9O3 
C19H31N3S 
[M+H]+ 
[M+H]+ 
333.223686 
333.223869 
-0.22 
-0.76 
0.016 
336.20431 
(>5) 
56553.5 C18H34NP 
C16H33NO 
C19H27N3O 
C13H31N5OCa 
C14H30N3O4P 
[M+(41K)]+ 
[M+Na]+ 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
295.242887 
313.214837 
313.215412 
313.215451 
335.197395 
0.44 
0.75 
-0.96 
-1.08 
-1.07 
0.039 
336.89963 
(>5) 
28350.3 C3H15N2P5S2 
C5H9N3O2SCaCu 
C5H12N2P4SCa2 
C6H10N3O2PSFeCu 
C3H6N2O7S3 
[M+K]+ 
[M+H]+ 
[M+H]+ 
[M+H]
+
 
[M+H]
+
 
297.936482 
335.892362 
335.892354 
335.892348 
335.892342 
-0.03 
-0.02 
0 
0.02 
0.03 
0.016 
337.23348 
(>5) 
143163.2 C19H37PCa 
C15H32N2O6 
C10H29N10OP 
C17H39P3 
[M+H]+ 
[M+H]+ 
[M+H]
+
 
[M+H]+ 
336.225879 
336.226038 
336.226343 
336.226464 
0.96 
0.49 
-0.41 
-0.77 
0.031 
339.02770 
(>5) 
519139.5 C5H8N12OS2 
C9H24P4 
C20H4N4O 
C4H14N8O3P2S 
C11H18O4S2 
[M+Na]+ 
[M+Na]+ 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
316.038547 
316.038525 
316.038511 
316.038485 
338.020327 
-0.2 
-0.14 
-0.1 
-0.02 
0.28 
0.023 
362.22000 
(>5) 
134989.9 C13H33N5O3S 
C18H35NO 
C21H29N3O 
C15H33N5OCa 
C16H32N3O4P 
[M+Na]+ 
[M+Na]
+
 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
339.230412 
339.230487 
339.231062 
339.231101 
361.213045 
1.01 
0.81 
-0.78 
-0.89 
-0.89 
0.016 
365.22048 
(>5) 
27184.6 C6H26N14O3 
C14H30N8S 
C17H34N4OFe 
C11H30N10P2 
C14H35N4OP 
[M+Na]+ 
[M+Na]
+
 
[M+H]+ 
[M+H]+ 
[M+H]
+
 
342.231231 
342.231414 
364.212873 
364.213016 
364.213472 
0.08 
-0.43 
0.91 
0.51 
-0.73 
0.039 
303 
 
365.24952 
(>5) 
47830.2 C22H38Ca 
C13H30N10O 
C20H40P2 
C16H37N4OPS 
[M+Na]+ 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
342.259941 
342.260405 
342.260526 
364.242571 
0.98 
-0.29 
-0.62 
-0.9 
0.008 
370.84958 
(>5) 
14596.8 C4H6O11SFe2 
C3H12OP4S2 
C7H3N4PCa 
C6H2N4O2P6 
C2H7N4O4P3SCaFe 
[M+H]+ 
[M+H]+ 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
369.842311 
369.842307 
331.886421 
347.860354 
369.842295 
-0.02 
-0.01 
0 
0.01 
0.02 
0.039 
371.14042 
(>5) 
51876.2 C8H22N10O2 
C15H34P4S 
C8H24N10OP2S 
C19H30Fe 
C12H27N6P3 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
348.151343 
370.133174 
370.133053 
370.132985 
348.151008 
-0.39 
-0.08 
0.24 
0.43 
0.51 
0.039 
372.97414 
(>5) 
15388.8 C8H15NO9CaCu 
C15H13O2P3S 
C11H18O4S2CaFe 
C7H9N8OPCa 
C7H14N6O4Cu2 
[M+H]+ 
[M+Na]+ 
[M+H]+ 
[M+Na]+ 
[M+H]
+
 
371.966874 
349.984916 
371.966857 
349.984909 
371.966852 
-0.03 
0.01 
0.02 
0.03 
0.03 
0.039 
382.85037 
(>5) 
31292.5 C7H8N2OP2S2Ca3 
C7H8N4P2Ca2Fe 
C5H8N2O5Cu2 
C5H11NO3P4CaCu 
C5H6N2O4P2Ca2 
[M+H]+ 
[M+K]+ 
[M+Na]+ 
[M+Na]
+
 
[M+Na]+ 
381.843106 
343.887216 
359.861144 
359.861136 
359.861139 
-0.03 
-0.01 
0.01 
0.03 
0.03 
0.008 
383.05401 
(>5) 
242846.5 C10H16N8O2Ca2 
C11H15N6O5PCa 
C5H17N10OP 
C10H14N11PCu 
C11H20N4O2P2 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
360.064804 
382.046748 
382.046739 
382.046726 
360.064775 
-0.04 
-0.04 
-0.01 
0.02 
0.04 
0.016 
385.34272 19554.2 C22H44N2O3 [M+H]
+ 384.335193 0.65 0.047 
386.962 
(>5) 
8142.2 C12H15N4PSFe2 
C6H10N6O7SFe 
C4H11N10P3SCa 
C5H10N8O3P4S 
C9H16N4O2Ca3Fe 
[M+H]+ 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
385.95473 
363.972783 
363.972767 
385.954711 
385.954711 
-0.02 
-0.01 
0.03 
0.03 
0.03 
0.039 
389.13230 
(>5) 
50922.2 C19H29OP3 
C8H16N14O3S 
C15H33N3SCu 
C6H23N12O2PCa 
C7H22N10O5P2 
[M+Na]
+
 
[M+H]+ 
[M+K]+ 
[M+Na]
+
 
[M+H]+ 
366.143129 
388.125053 
350.169118 
366.143047 
388.124991 
-0.13 
-0.08 
0.06 
0.08 
0.08 
0.031 
395.33841 126253.5 C22H42N4O2 
C15H42N10S 
[M+H]+ 
[M+H]+ 
394.330776 
394.331462 
0.9 
-0.83 
0.016 
404.3139 51406.8 C23H43NO3 [M+Na]
+ 381.324294 0.95 0.031 
405.03593 
(>5) 
26852.2 C13H27NS2Cu 
C13H28P4 
C17H11N4O5P 
C18H20N2P2Ca 
C9H20N8P2S2 
[M+Na]+ 
[M+K]+ 
[M+Na]+ 
[M+K]
+
 
[M+K]+ 
382.046715 
366.072775 
382.046709 
366.072765 
366.072762 
-0.02 
-0.01 
0 
0.01 
0.02 
0.016 
405.09829 
(>5) 
145000.8 C10H23N8O3PS 
C14H26N4P2S 
C12H20N8O3Ca2 
C12H25N6PCa 
C13H24N4O3P2 
[M+K]+ 
[M+H]+ 
[M+H]
+
 
[M+Na]+ 
[M+H]+ 
366.135147 
404.091017 
404.091019 
382.109046 
404.09099 
-0.04 
-0.01 
-0.01 
0.06 
0.06 
0.023 
418.32951 66871.7 C24H45NO3 [M+Na]
+ 395.339944 0.82 0.031 
304 
 
442.76735 
(>5) 
74429.6 C4H8N4SFeCu2 
C2H2N8OP2S3Fe2 
C6H6O4P2S3Ca3 
C11H2N2OP2SCaFe2 
C2H5N7OP2Ca3FeCu 
[M+H]+ 
[M+Na]+ 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
441.760074 
419.778123 
419.778125 
419.778126 
441.760068 
0 
0.01 
0.01 
0.01 
0.01 
0.023 
454.70280 
(>5) 
29367.8 C6H2NP3S4Cu 
C3H3O7P3Ca2Fe2 
C6HO2P3S8 
C6H3P7S2 
C4HNO9Fe3Cu 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
[M+K]+ 
[M+Na]+ 
431.713573 
431.713575 
453.69552 
415.739633 
431.713569 
0.01 
0.01 
0.01 
0.02 
0.02 
0.039 
458.69690 
(>5) 
44965.8 C6HN2O4P3Fe3 
C5H6O4S4Fe3 
C10H2O4Fe2Cu2 
C4H4N2OS2FeCu2 
C2HN5O2P2SCa3FeCu 
[M+K]+ 
[M+K]+ 
[M+K]+ 
[M+H]+ 
[M+H]+ 
419.733758 
419.733734 
419.733732 
457.689613 
457.689607 
-0.04 
0.01 
0.02 
0.02 
0.04 
0.039 
467.12793 
(>5) 
5867.8 C14H33N6PS4 
C7H28N12O2S3 
C16H28N6O2SCa 
C11H24N8O9S 
C17H29N6O2PSFe 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+Na]
+
 
[M+H]+ 
444.13872 
466.120657 
466.12066 
444.138699 
466.120646 
-0.02 
-0.01 
-0.01 
0.02 
0.02 
0.039 
468.12457 
(>5) 
59470 C11H32N5O5P3 
C6H23N15O4 
C16H21N9O3 
C5H23N15O5SCa 
C16H29N5O2P2 
[M+H]+ 
[M+K]+ 
[M+Na]
+
 
[M+Na]+ 
[M+Na]+ 
467.117307 
429.161418 
445.135359 
445.135323 
445.135324 
-0.03 
-0.02 
-0.02 
0.05 
0.05 
0.023 
472.69458 
(>5) 
16390.4 C3HN2O4P3CaFe 
C6H3N3O3Ca2Cu3 
C3H5N2O3PS2FeCu2 
C9H2S3Cu2 
C3H6NO3P5FeCu 
[M+K]+ 
[M+K]+ 
[M+Na]+ 
[M+Na]+ 
[M+K]+ 
433.731421 
433.731421 
449.705358 
449.70536 
433.731418 
0 
0 
0 
0 
0.01 
0.016 
483.09531 
(>5) 
42208 C18H23N9OCu 
C20H30O4P2S2 
C7H24N14O2SFe 
C25H20N2O6 
C12H26N8O3SCa 
[M+K]
+
 
[M+Na]+ 
[M+H]
+
 
[M+K]+ 
[M+Na]+ 
444.132155 
460.10608 
482.088023 
444.132138 
460.106073 
-0.01 
0.02 
0.02 
0.03 
0.03 
0.008 
488.29896 
(>5) 
36886.9 C27H47NOS2 
C24H45N3O2 
C19H43N7O4S 
C17H43N9O2 
C24H47N3OP2S 
[M+Na]+ 
[M+Na]+ 
[M+Na]+ 
[M+Na]
+
 
[M+H]+ 
465.309908 
465.3098 
465.309725 
465.309644 
487.29151 
-0.35 
-0.13 
0.03 
0.19 
0.36 
0.039 
489.08786 
(>5) 
21674.7 C11H30N8OP2S3Ca 
C11H30N10P2SFe 
C12H26N10Ca3 
C13H27N10PCa2Fe 
C9H28N8O4P2S 
[M+H]+ 
[M+K]+ 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
488.08059 
450.1247 
488.080586 
488.080572 
466.098623 
-0.01 
0 
0 
0.02 
0.03 
0.016 
519.029 
(>5) 
25005.8 C12H23N8O3PS2 
C21H25N2OPS2Ca2 
C13H13N14P3 
C28H21PS 
C13H25N7O2P2Cu 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
[M+K]+ 
[M+Na]
+
 
480.065842 
496.039777 
518.021723 
480.065833 
496.039771 
0 
0 
0 
0.01 
0.01 
0.016 
519.09144 
(>5) 
42346.1 C10H33N8OP5 
C19H31N4O2PS2Fe 
C15H34N2O7P2S2 
C12H26N10O4SFe 
C27H28NPCu 
[M+Na]+ 
[M+Na]+ 
[M+K]+ 
[M+H]+ 
[M+H]+ 
496.10222 
496.10222 
480.128273 
518.084157 
518.084159 
0 
0 
0.01 
0.01 
0.01 
0.047 
305 
 
519.29341 
(>5) 
109666.3 C18H44N8O4 
C26H42N6OS2 
C24H49N4PSCa 
C25H48N2O3P2S 
C17H44N10O2Ca 
[M+Na]+ 
[M+H]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
496.304225 
518.286153 
496.304147 
518.286091 
518.286084 
-0.07 
-0.04 
0.08 
0.08 
0.1 
0.031 
524.68747 
(>5) 
45928.6 C3H7N5P2S3CaFeCu 
C11HO3P5SCa2Fe 
C4H10NP7SCa2Cu 
C4H3N4O2PS5Ca2Fe 
C7H6O5P2S2Ca3Fe2 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
485.724312 
501.698251 
523.680191 
523.680191 
523.680192 
0 
0 
0 
0 
0 
0.031 
525.08005 
(>5) 
44071.9 C20H26N4O3SCa 
C21H25N2O6PS 
C20H19N10P3S 
C9H23N6O16P 
C11H26N10O3S3 
[M+Na]+ 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
[M+Na]+ 
502.090827 
524.072771 
524.072776 
502.090822 
502.090824 
0 
0 
0 
0.01 
0.01 
0.031 
531.48665 242430.7 C32H64N2O2 [M+Na]
+ 508.496778 1.22 0.016 
532.19270 
(>5) 
21452.7 C25H42O4P2Cu 
C15H44N7OP5 
C22H40NO6PS2 
C24H36N6Cu 
C15H35N7O8S 
[M+H]+ 
[M+K]+ 
[M+Na]
+
 
[M+H]+ 
[M+H]+ 
531.185435 
493.229548 
509.203471 
531.185416 
531.185408 
-0.02 
-0.01 
0.01 
0.01 
0.03 
0.008 
532.48991 84705.3 - - - - 0.008 
533.27271 
(>5) 
158330.4 C25H53O2P3Fe 
C20H44N8O2S2Ca 
C20H44N10OFe 
C18H42N8O5 
C26H40N6O2S2 
[M+H]+ 
[M+H]+ 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
532.265456 
532.265457 
494.309567 
510.28349 
532.265418 
-0.04 
-0.04 
-0.03 
0 
0.03 
0.039 
534.27605 
(>5) 
49030 C18H41N9O7 
C21H45N7OCa 
C22H44N5O4P 
C21H50N6P2Cu 
C27H41N5O 
[M+K]+ 
[M+Na]+ 
[M+H]+ 
[M+Na]+ 
[M+Na]
+
 
495.312896 
511.286822 
533.268766 
511.286819 
511.286783 
-0.01 
0.01 
0.01 
0.02 
0.09 
0.031 
535.28833 
(>5) 
221207.5 C18H44N8O5 
C26H42N6O2S2 
C25H49N4P 
C18H46N10SCa 
C24H49N4OPSCa 
[M+Na]
+
 
[M+H]+ 
[M+K]+ 
[M+H]
+
 
[M+Na]
+
 
512.29914 
534.281068 
496.325157 
534.281026 
512.299062 
-0.06 
-0.03 
0.03 
0.05 
0.09 
0.039 
536.29158 
(>5) 
63569.9 C28H51NP2SCa 
C16H42N9O9P 
C21H39N9O6 
C22H48N7OPCa 
C28H44N5OP 
[M+H]+ 
[M+H]+ 
[M+Na]+ 
[M+K]+ 
[M+K]+ 
535.284338 
535.284314 
513.302331 
497.328387 
497.328348 
-0.06 
-0.02 
0.05 
0.06 
0.14 
0.008 
545.50222 
(>5) 
95383.7 C2HOP3S4FeCu3 
C3HP5SCaFeCu3 
C33H66N2O2 
C3HP3S3Fe2Cu3 
[M+(41K)]+ 
[M+K]+ 
[M+Na]+ 
[M+Na]+ 
504.540726 
506.539712 
522.512428 
522.513351 
0.4 
-1.19 
1.05 
-0.65 
0.008 
546.50555 32745.3 - - - - 0.008 
558.27328 
(>5) 
31125.6 C28H50N2OS2Cu 
C14H36N15O7P 
C26H51NO4CaFe 
C21H45NO14 
C25H48N4O2Cu 
[M+H]
+
 
[M+H]+ 
[M+Na]+ 
[M+Na]+ 
[M+H]+ 
557.266056 
557.265978 
535.284012 
535.284009 
557.265948 
-0.09 
0.05 
0.08 
0.09 
0.1 
0.023 
560.63748 
(>5) 
40551.3 C5H6N2OP2S8CaFe 
C4H7N4P7SFe3 
C5H8P6S4Ca2 
[M+K]
+
 
[M+K]+ 
[M+K]
+
 
521.674318 
521.67432 
521.674321 
0 
0 
0 
0.039 
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C4H6N3O3P3SCa2Cu3 
C4H6N5P3S3Fe3Cu 
[M+Na]+ 
[M+Na]+ 
537.648257 
537.64826 
0 
0 
562.83057 
(>5) 
45880.2 C14H2N12Cu2 
C7H3N8O13PSFe 
C9H19N2O3P3S4Ca 
C9H6N12S4Fe 
C7H13N6O6PS3Ca3 
[M+K]+ 
[M+K]+ 
[M+K]+ 
[M+K]+ 
[M+K]+ 
523.867409 
523.867409 
523.867409 
523.867411 
523.867411 
0 
0 
0 
0 
0 
0.023 
Negative ionisation mode 
95.00152 25530.6 - - - - 0.023 
96.99856 16598.5 - - - - 0.016 
168.02426 10797.5 - - - - 0.047 
210.00116 7753 C2H5N3OS2 
C7H13NP2 
C6H11NOP2 
C4H9N3O3S2 
[M+Hac-H]- 
[M+K-2H]- 
[M+Cl]
-
 
[M-H]- 
150.987406 
173.052325 
175.03159 
211.008536 
-0.47 
1.09 
0.8 
-0.47 
0.023 
213.58769 47837.9 - - - - 0.039 
215.08187 29696.3 C7H14 
C7H12N6 
C8H19O3P 
C9H18O2 
[M+Hac-H]- 
[M+Cl]- 
[M+Na-2H]- 
[M-H]- 
156.068173 
180.112344 
194.107183 
216.089303 
-0.73 
0.58 
0.09 
-0.73 
0.008 
236.06512 16463.1 C4H3N9 
C7H14N5P 
C8H13N3O4 
C6H7N9O2 
[M+Hac-H]- 
[M+(37Cl)]- 
[M+Na-2H]- 
[M-H]- 
177.051141 
199.098683 
215.090607 
237.072271 
0.53 
-0.06 
-0.66 
0.53 
0.031 
239.58683 67383.3 - - - - 0.016 
260.91016 
(>5) 
15637.7 C7H3O4P 
C2H8N2O2P2SCa 
C8H4O2P2S 
C2HN4O6PS 
C3H10N2OP2SCa 
[M+Na-2H]- 
[M+Cl]- 
[M+Cl]- 
[M+Na-2H]- 
[M+K-2H]- 
239.935521 
225.940767 
225.940728 
239.935446 
223.961502 
-0.11 
-0.03 
0.12 
0.17 
0.2 
0.039 
300.87702 
(>5) 
56083.1 C3H9NO4P2SCu 
C2H4N6CaFe 
C11H2O2S3Ca 
C3H5N6PFe2 
C2H2N6O2S5 
[M+Na-2H]- 
[M+(37Cl)]- 
[M-H]- 
[M+(37Cl)]
-
 
[M-H]
-
 
279.902356 
263.91057 
301.884287 
263.910556 
301.884284 
-0.02 
-0.01 
0.03 
0.04 
0.04 
0.039 
308.04202 
(>5) 
17231.2 C14H15NO3S2 
C7H18N3O4PS 
C6H16N3O7P 
C4H14N5O2PFe 
C6H18N5O4PFe 
[M-H]- 
[M+(37Cl)]- 
[M+Cl]
-
 
[M+Hac-H]- 
[M-H]- 
309.049338 
271.075567 
273.07259 
249.028125 
309.049255 
-0.14 
0 
0.09 
0.13 
0.13 
0.031 
313.1192 21179.7 C15H14N2O2 [M+Hac-H]
- 254.105528 -0.58 0.031 
318.95697 
(>5) 
12170.8 C4H11N4O3PS 
C16H8OS2Ca 
C7H8N6OS4 
C16H8N2Fe 
C4H13N6PSFe 
[M+Cl]- 
[M-H]- 
[M-H]- 
[M+K-2H]- 
[M-H]
-
 
283.987574 
319.96425 
319.964247 
282.00836 
319.964239 
-0.02 
-0.01 
0 
0.01 
0.02 
0.047 
328.0777 36607.2 C19H17NOS [M+Na-2H]
- 307.103086 -0.17 0.016 
340.97869 
(>5) 
13369.9 C11H16N2O2Ca2Fe 
C4H6N2O10Ca 
C6H10N2O12Ca 
C10H13N5CaCu 
C14H14O2S 
[M-H]- 
[M+Hac-H]- 
[M-H]
-
 
[M+Cl]- 
[M+K-2H]- 
341.985972 
281.964839 
341.985969 
306.009285 
304.030075 
-0.02 
-0.01 
-0.01 
0.01 
0.02 
0.031 
344.01870 21325.2 C14H17N3S2Fe [M-H]
- 345.026003 -0.08 0.039 
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(>5) C9H21N3O2S2Ca 
C11H22NP5 
C15H17NO2S2 
C7H18NO9PS 
[M+K-2H]- 
[M+Na-2H]- 
[M+K-2H]- 
[M+Na-2H]- 
307.070112 
323.044039 
307.070073 
323.043994 
-0.05 
-0.02 
0.06 
0.11 
359.03107 
(>5) 
11267.5 C7H10N6O2S 
C9H14N6O4S 
C9H16N8OSFe 
C5H19N6O6PS 
C5H12N6O4Ca2 
[M+Hac-H]- 
[M-H]- 
[M+Na-2H]- 
[M+K-2H]- 
[M+Hac-H]- 
300.017219 
360.038349 
338.056391 
322.082444 
300.017186 
-0.01 
-0.01 
0.03 
0.05 
0.08 
0.031 
375.13835 
(>5) 
16998.8 C17H31O3PCa 
C16H24N6Ca 
C4H23N15O2Cu 
C7H24N12S2 
C9H16N8O5 
[M+Na-2H]- 
[M+Cl]- 
[M-H]- 
[M+Cl]- 
[M+Hac-H]- 
354.163674 
340.168835 
376.145514 
340.168832 
316.124367 
0.02 
0.3 
0.3 
0.31 
0.34 
0.031 
376.82742 
(>5) 
35000.4 C2H2N7O4PCu 
C7HN6P5Fe 
C11H4NO2PCa2Cu 
C2H4N7O2PS2CaCu 
C3H3N5O5P2S2Cu 
[M+K-2H]- 
[M-H]- 
[M+Na-2H]- 
[M+Na-2H]- 
[M-H]
-
 
339.878813 
377.834696 
355.852748 
355.852745 
377.834689 
0 
0 
0.01 
0.02 
0.02 
0.016 
386.76257 
(>5) 
16740.9 C2H2P2S5Ca2 
C4H6O2P2S5Ca2 
C4H6N2OP2S3CaFe 
C6HO4PS2Ca3 
C5H2N4Ca3Fe 
[M+Hac-H]- 
[M-H]- 
[M+K-2H]- 
[M+Cl]
-
 
[M+K-2H]- 
327.748718 
387.769848 
349.813958 
351.793165 
349.813954 
0 
0 
0.01 
0.01 
0.02 
0.008 
390.75670 
(>5) 
16341.7 C7H5O3P3Fe3 
C3H2N5OPS3CaCu 
C11HPCaFe2 
C2HN6PS2Fe2 
C12H2P2Fe3 
[M-H]- 
[M+K-2H]- 
[M+Na-2H]- 
[M+Na-2H]- 
[M+Na-2H]- 
391.763995 
353.808104 
369.782026 
369.782023 
369.782012 
-0.05 
-0.03 
0.01 
0.02 
0.05 
0.008 
398.87473 
(>5) 
66915.9 C4H4N4OP2S3 
C5H9N6PS3Ca 
C6H8N4O3P2S3 
C8H3N4O5PCa 
C8H15NOS5Cu 
[M+Hac-H]- 
[M+Na-2H]
-
 
[M-H]- 
[M+Cl]
-
 
[M+Cl]- 
339.860876 
377.900062 
399.882006 
363.905323 
363.905323 
0 
0 
0 
0.01 
0.01 
0.023 
401.1877 
(>5) 
17192.2 C15H28N4OP2 
C16H33N6PCa 
C17H32N4O3P2 
C22H29N4P 
C8H18N14O2 
[M+Hac-H]- 
[M+Na-2H]- 
[M-H]- 
[M+Na-2H]- 
[M+Hac-H]
-
 
342.173837 
380.213023 
402.194967 
380.212984 
342.173716 
0.02 
0.02 
0.02 
0.12 
0.33 
0.016 
401.97727 
(>5) 
16684.3 C7H11N7S3Fe 
C13H9NO12S 
C9H15N7O2S3Fe 
C13H19NO4SCa2 
C17H12N4SCu 
[M+Hac-H]- 
[M-H]- 
[M-H]- 
[M+K-2H]- 
[M+Cl]- 
342.963421 
402.984551 
402.984551 
365.028663 
367.007867 
-0.01 
-0.01 
-0.01 
0 
0 
0.008 
410.74153 
(>5) 
28381.6 C2H4N4P2S3Ca2Fe 
C4H3O7P3S2Fe 
C2HN5O2P2S2Cu 
C5HN2O4PSCa3Fe 
C2H3N5P2S4CaCu 
[M+Cl]- 
[M+K-2H]- 
[M+K-2H]- 
[M+Na-2H]- 
[M+Na-2H]- 
375.772132 
373.792925 
373.792917 
389.766853 
389.766849 
-0.01 
0 
0.02 
0.02 
0.03 
0.039 
418.0237 
(>5) 
11843.2 C11H23N3O2P2S 
C7H22N9O2PSFe 
C9H17N7O5Ca2 
C16H15N5O2SCa 
C4H14N15P3S 
[M+(37Cl)]
-
 
[M+K-2H]- 
[M+Cl]- 
[M+(37Cl)]- 
[M+Na-2H]- 
381.057248 
381.075093 
383.0543 
381.057238 
397.049021 
0 
0 
0 
0.02 
0.02 
0.016 
447.31151 23549.5 C25H40O3 [M+Hac-H]
- 388.297745 -0.2 0.023 
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(>5) C19H47N6P 
C27H44O5 
C20H47N7Cu 
C22H41N8P 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
448.318605 
448.318875 
448.318892 
448.31918 
0.41 
-0.2 
-0.24 
-0.88 
456.76783 
(>5) 
14255.4 C8H7N3OSFe2Cu 
C4HN6O4PS4Ca2 
C8H7OPSFe4 
C6H12N3OPCu3 
C4H6N2O10SFe3 
[M+Cl]- 
[M+Na-2H]- 
[M+Hac-H]- 
[M+K-2H]- 
[M+Na-2H]- 
421.79843 
435.793162 
397.753973 
419.81922 
435.793156 
0 
0 
0.01 
0.01 
0.01 
0.039 
461.98275 
(>5) 
11919.9 C4H13N9O4SCa3 
C6H21N7O4P6 
C21H16NO2PS3 
C6H17N9O6SCa3 
C12H7N7O2S2 
[M+Hac-H]- 
[M+Na-2H]- 
[M+Na-2H]- 
[M-H]- 
[M+Hac-H]- 
402.968896 
441.008081 
441.008083 
462.990026 
402.96889 
0 
0 
0 
0 
0.01 
0.023 
468.70015 
(>5) 
23371.6 C4H5O5P3S4CaFe 
C3H2N2O2S3Fe4 
C5HN2O4PSCa3Fe 
C9HO5P3CaCu2 
C5H6N2O4S3Fe4 
[M+Na-2H]- 
[M+Hac-H]- 
[M+Na-2H]- 
[M+Na-2H]- 
[M-H]
-
 
447.72548 
409.686292 
447.725476 
447.725478 
469.707422 
0 
0.01 
0.01 
0.01 
0.01 
0.023 
470.68774 
(>5) 
8967.5 C4HNO6P2CaFeCu 
C4H4O4P6Ca2Fe 
C3H5N2OP5Ca3Fe 
C8H4P2S8Fe 
C2H2N3O6PS3Ca2Cu 
[M+Cl]- 
[M+Cl]- 
[M-H]- 
[M-H]
-
 
[M+K-2H]- 
435.71834 
435.718332 
471.695011 
471.695014 
433.739122 
0 
0.01 
0.01 
0.01 
0.02 
0.016 
486.68900 
(>5) 
13096 C9HO4PS4Ca2Fe 
C6H3N3P2S7Cu 
C6H4N2P6S5 
C6H6O3P2SCa2Fe2 
C5H4O2P6SCa2 
[M+Na-2H]- 
[M+Na-2H]- 
[M+K-2H]- 
[M+Na-2H]- 
[M+Cl]- 
465.71433 
465.714326 
449.740386 
465.714322 
451.719585 
0 
0.01 
0.02 
0.02 
0.03 
0.016 
497.21858 
(>5) 
34640.9 C13H30N12O9 
C31H35N2PS 
C24H30N8O2 
C22H41P3Ca 
C24H45O2P3Ca 
[M-H]- 
[M-H]
-
 
[M+Cl]- 
[M+Hac-H]
-
 
[M-H]- 
498.225873 
498.225858 
462.249172 
438.204705 
498.225835 
-0.03 
0 
0.01 
0.04 
0.04 
0.023 
510.7335 
(>5) 
19159.5 C5H4N4P2S2Ca2Cu2 
C11H12OP2S2Ca2Fe2 
C9H3N6OPSCaFe3 
C9HN2O5P5S2Ca 
C17HNOCa2FeCu 
[M+Hac-H]- 
[M+K-2H]- 
[M+Cl]- 
[M+Cl]- 
[M+Na-2H]
-
 
451.719646 
473.784891 
475.764096 
475.764098 
489.75883 
0 
0 
0 
0 
0 
0.008 
(>5); indicates more than five possible empirical formulae. 
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Table ‎I.4 Empirical formulae ascribed to the non-polar metabolic features detected in positive 
and negative ionisation mode which were significantly altered (p<0.05) between haemolysed 
and clean cord blood serum pairs, for which a putative annotation could not be ascribed.(See 
Chapter 7) 
m/z Intensity Empirical formula Ion 
Theoretical 
mass 
Mass 
error p- 
value 
(Da) (ppm) 
Negative ionisation mode 
229.06623 9988.2 C10H15N2P 
C6H17N4PS 
C17H10O 
C11H14N2OCa 
C9H16N2OP2 
[M+Cl]- 
[M+Na-2H]- 
[M-H]- 
[M-H]- 
[M-H]- 
194.097286 
208.091156 
230.073165 
230.073204 
230.073789 
-2 
1.77 
1.49 
1.32 
-1.23 
0.016 
253.21977 53795.1 - - - - 0.017 
254.22298 12429.3 - - - - 0.016 
279.16025 11482.4 C14H20O2 
C13H27N2OP 
C16H24O4 
[M+Hac-H]
-
 
[M+Na-2H]- 
[M-H]- 
220.14633 
258.186101 
280.16746 
0.24 
-1.86 
0.24 
0.047 
368.26771 338622.3 C15H38N7P 
C21H37N3O 
C11H35N11OS 
[M+Na-2H]- 
[M+Na-2H]- 
[M-H]- 
347.292631 
347.293662 
369.274676 
1.11 
-1.69 
0.84 
0.008 
370.26811 31665.5 C13H29N9 
C10H33N13 
C17H39N3O4 
C9H34N13OP 
C15H33N9O2 
[M+Hac-H]- 
[M+Cl]- 
[M+Na-2H]- 
[M-H]- 
[M-H]- 
311.254591 
335.298187 
349.294057 
371.27469 
371.275721 
-0.9 
1.41 
-1.66 
1.88 
-0.9 
0.023 
422.22657 
(>5) 
30167.6 C8H33N15P2 
C15H33N5OS2 
C17H37N5O3S2 
C21H40NO2PS 
C12H31N7O2 
[M+Na-2H]- 
[M+Hac-H]- 
[M-H]
-
 
[M+Na-2H]
-
 
[M+Hac-H]
-
 
401.251861 
363.212654 
423.233784 
401.251739 
363.212546 
0.1 
0.15 
0.15 
0.38 
0.4 
0.047 
446.37217 54829.6 C25H51N3O2 
C23H45N9 
[M+Na-2H]- 
[M-H]- 
425.398127 
447.379791 
-1.4 
-0.77 
0.016 
522.46071 30153.6 C29H63N3O3 
C21H58N13P 
C27H57N9O 
[M+Na-2H]- 
[M-H]- 
[M-H]- 
501.486942 
523.467575 
523.468606 
-1.72 
0.79 
-1.19 
0.008 
538.38279 
(>5) 
32777.4 C27H59N3OP2 
C28H61N3P2 
C27H54N7PS 
C20H49N13O2 
C24H56N3P3 
[M+Cl]- 
[M+K-2H]- 
[M-H]
-
 
[M+Cl]- 
[M+Hac-H]- 
503.413338 
501.434073 
539.389903 
503.413217 
479.368711 
0.09 
0.21 
0.3 
0.32 
0.42 
0.008 
669.45846 
(>5) 
25629 C4H3N2OPS7Fe3Cu 
C4H5O4P7CaFe2Cu3 
C5H4O4P2S5CaFeCu3 
C7H5OP3S2Fe3Cu3 
[M+K-2H]- 
[M-H]- 
[M+K-2H]- 
[M-H]
-
 
632.509863 
670.465738 
632.509846 
670.465729 
-0.01 
0 
0.01 
0.01 
0.016 
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C7HN2OPS6CaFe4Cu [M-H]
- 670.465721 0.02 
686.53239 
(>5) 
65380 C6H6N4OP2S8CaFeCu2 
C5HN2O9P5Ca2Fe3 
C5H7N6P7SFe3Cu2 
C4H5O10P7S3Fe3 
C9H4NO5PS5Ca3Fe2Cu 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]
-
 
687.539664 
687.539664 
687.539666 
687.539668 
687.539668 
0 
0 
0 
0 
0 
0.008 
713.56021 
(>5) 
491391.8 C2H6N5O8P7SFeCu2[NaCl] 
C7H5N6O3PS3Ca3Cu3[NaCl] 
CH6N3O14P3S2Fe4[NaCl] 
C5(13C)H2N10OP4S2Ca2Fe4 
C9H2N5O3P7S4(34S)Fe2 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
714.567486 
714.567486 
714.567486 
714.567486 
714.567486 
0 
0 
0 
0 
0 
0.0156 
775.71865 
(>5) 
7729.7 C2H32O12P7S6Ca3 
C21H2N9O3P3S8 
C6H15N8O15S3Ca2Fe3 
C2H21N14O5S5Ca2Fe4 
C25H15N2P5S3Ca3Cu 
[M-H]- 
[M-H]
-
 
[M-H]- 
[M-H]- 
[M-H]- 
776.725926 
776.725926 
776.725926 
776.725926 
776.725926 
0 
0 
0 
0 
0 
0.008 
1277.97179 
(>5) 
40384.6 C32H68N12OP4S7Ca3FeCu[NaCl] 
C25H60N13O16P5S5CaCu2 
C30H62N8O18P2S7Fe2Cu 
C28H58N14O11P5S7Ca2Fe 
C34H60N11O7P6S8CaCu 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
[M-H]- 
1278.979066 
1278.979066 
1278.979065 
1278.979064 
1278.979063 
0 
0 
0 
0 
0 
0.031 
Positive ionisation mode 
368.33950 1730.2 - - - - 0.039 
404.38893 42553.1 C27H49NO [M+H]
+ 403.3814 0.59 0.023 
405.39230 12475.6 C23H50N4 [M+Na]
+ 382.4035 -1.15 0.039 
734.58708 
(>5) 
11985.6 C2H8N4O12P5S4Fe2Cu 
C6H4N2O18PSFe4Cu 
C11H8N2O3P6S7Fe2 
C15H4O9P2S4Fe4 
C15H8O3P5S3Cu3[NaCl] 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
[M+H]+ 
733.5798 
733.5798 
733.5798 
733.5798 
733.5798 
0 
0 
0.01 
0.01 
0.01 
0.016 
800.67254 
(>5) 
57836.9 C28H6O4P4S3Ca3Fe 
C10H6N8O13P3S2Ca2FeCu 
C2H27NO17P2S3Ca2Fe3Cu 
C17H14N2O5P5S8Cu 
C31H12OPSCaFe2Cu3 
[M+H]
+
 
[M+H]+ 
[M+H]+ 
[M+H]
+
 
[M+H]+ 
799.6653 
799.6653 
799.6653 
799.6653 
799.6653 
0 
0 
0 
0 
0 
0.039 
(>5); indicates more than five possible empirical formulae. 
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